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Abstract 
 
Tissue engineering offers a potential alternative therapy to overcome the limitations 
of organ transplantation, by employing biomaterials as scaffold for cell growth. For 
example, poly-lactic-co-glycolic acid (PLGA) is a synthetic biomaterial widely used 
in tissue engineering. However, the hydrophobicity of PLGA results in scaffolds that 
are poorly wettable, and which, therefore, possess poor mass transfer properties for 
the delivery of nutrients and the removal of waste. The present work aimed to 
develop more hydrophilic PLGA scaffolds, specifically hollow fibre membranes, 
within a bioreactor system, which enables co-culture of cells in order to direct stem 
cell differentiation. Large quantities of costly growth factors are required over long 
periods for stem cell differentiation. Therefore, this project also aimed to use a cell 
line as a “factory” for the inexpensive, in situ growth factor production. Hollow 
fibres were fabricated by wet spinning and a hydrophilic polymer, polyvinyl alcohol 
(PVA), was added to the PLGA solution at three different concentrations (1.25, 2.5, 
5% w/w) in order to obtain a more hydrophilic membrane. Results indicated that 5% 
PVA-PLGA hollow fibres were the only membranes which allowed permeation of 
water, BSA and cell-secreted hepatocyte growth factor (HGF), thus indicating that 
they are the most suitable membranes for use in bioreactor devices. However, these 
membranes failed to improve cell-attachment. Cell secreted HGF was shown to be 
more stable in a dynamic culture environment than commercial HGF, thus suggesting 
its suitability for applications in bioreactor devices. However, using both commercial 
and cell-secreted HGF, mesenchymal stem cell differentiation was unsuccessful. In 
conclusion, this work has developed a hollow fibre membrane which is more 
permeable to water and proteins for a higher mass transfer of nutrients, and has 
realised a model system for the inexpensive production of growth factors for use in 
bioreactor devices and the differentiation of stem cells. 
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1.   Tissue engineering as a promising 
alternative therapy to transplantation 
 
1.1 Introduction 
 
Failure of organs is one of the main causes of death in intensive care units, and, at 
present, organ transplantation often represents the only possible treatment for end-
stage organ disease patients. However, although organ transplantation has been 
shown to be a very successful therapy for the treatment of organ failure, it presents 
several major limitations. As the demand for transplantation increases, there is 
shortage of available donors, which results in most patients dying while waiting for 
transplantation, thus suggesting that transplantation procedures alone will probably 
never be able to meet the increasing demand.  Furthermore, problems with the 
immune system lead to organ rejection, and immunosuppressive treatments can cause 
new tumour formation. It is clear that alternative strategies which could provide a 
therapy for patients without need of transplantation need to be investigated. 
Tissue engineering offers a great potential towards the development of an alternative 
therapy to transplantation. The principle of tissue engineering consists in the design 
and development of functional three-dimensional tissues by culturing cells on 
biodegradable 3D supports (scaffolds), in an in vitro environment (bioreactor) that 
resembles as closely as possible that found in vivo, prior to implantation into the 
patient. The implant will generate natural tissue and the components of the scaffold 
will be degraded. Therefore, the main issues in tissue engineering include the 
selection of the following: 
1. A suitable cell source for tissue regeneration  
2. A biocompatible and biodegradable biomaterial scaffold that will allow an 
appropriate mass transfer of nutrients and support cell growth and 
proliferation and tissue formation 
3. A bioreactor system that will recreate in vitro an environment as close as 
possible to that found in vivo by the specific tissue to be engineered.  
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This thesis investigates these three main aspects of tissue engineering by the 
development of a novel scaffold for cells, the design and characterization of a novel 
bioreactor system module, and the study of the ability of stem cells to differentiate 
into hepatocytes under opportune stimulation with liver-specific factors. 
1.2 Thesis outline 
 
This thesis is divided into 7 chapters, including this chapter, which presents the need 
for the research described in this thesis as well as a general overview of the project 
with aims and objectives. 
 
Chapter 1 reviews the literature in the field of tissue engineering, including the 
characteristics and types of biomaterials and bioreactors and the cell sources for 
tissue engineering with a special focus on stem cells.  
 
Chapter 2 gives details of the materials and experimental methods used to carried out 
the research. 
 
Chapter 3-6 are the results chapters. 
Chapter 3 focuses on the scaffold used in the project, and in particular describes the 
development and characterisation of novel PVA-PLGA hollow fibre membranes to 
be used as a scaffold for stem cells in a hollow fibre bioreactor. Chapter 4 describes 
the cell adhesion and proliferation on the novel PVA-PLGA blended membranes. 
Chapter 5 focuses on the release of the hepatocyte growth factor by cell lines and 
analyses the stability of the protein and its permeability across the PVA-PLGA 
hollow fibre membrane inside the hollow fibre bioreactor. The viability and 
metabolic activity of the cell line within the bioreactor is also analysed. Chapter 6  
focuses on mesenchymal stem cells differentiation into hepatocytes with liver-
specific growth factors and in particular with the hepatic growth factor secreted by 
the cell line. 
 
Chapter 7 provides the overall conclusions for the work and outlines the future work 
that is required both in the short and in the long term. 
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1.3  An insight into tissue engineering 
 
The term tissue engineering was defined for the first time in the mid 1980s as "an 
interdisciplinary field that applies the principles of engineering and life sciences 
toward the development of biological substitutes that restore, maintain, or improve 
tissue function or a whole organ" [1].  
Tissue engineering aims to solve the problem of shortage of donor tissues associated 
with transplantation, by engineering tissues in vitro that resemble as closely as 
possible natural tissues and that will be implanted into the body of the patient. Thus 
tissue engineering involves the design and development of functional three-
dimensional tissues by culturing cells extracted from a donor on biodegradable 3D 
supports (scaffold), in an in vitro environment (bioreactor) that resembles as closely 
as possible that found in vivo, prior to implantation (fig.1.1). The implant will 
generate natural tissue and the components of the scaffold will be degraded in a time 
scale ranging from hours to years. 
 
Fig. 1.1.The principle of tissue engineering: cells are extracted from the patient and cultured 
in vitro on biodegradable and biocompatible scaffolds that support cell growth. The scaffold 
with the cells can be cultured in bioreactors to recreate an environment as close as possible to 
that in vivo. The ultimate goal of tissue engineering is to implant the newly formed tissue 
back into the patient. From [2]. 
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However, in order to imitate natural tissues, it is necessary to understand the basic 
biology of the tissues or organs of interest. The growing interest in the fields of 
embryology and  stem cell biology have then led to a new broader term, regenerative 
medicine, to indicate either tissue engineering or repair/regeneration. In this new 
approach, by knowing the biological processes occurring in the tissue of interest, it 
will be possible to control them in order to develop strategies (e.g. the use of specific 
growth factors and cytokines to stimulate the production or the function of 
endogenous cells) either to engineer tissue substitutes or to enhance tissue repair 
or/and regeneration [3, 4]. 
The greatest successes of tissue engineering to date can be found in the engineering 
of relatively simple tissues, e.g. skin and cartilage, with Dermagraft (Smith & 
Nephew), Apligraf (Organogenesis) and Epicel (Genzyme) being among the 
approved bioengineered skin products and Carticel (Genzyme) a bioengineered 
cartilage product [4]. However, several limitations still have to be overcome, 
especially in the recreation of more complex structures such as liver, kidney and 
heart. A major challenge is represented by the oxygen and nutrient delivery to neo-
tissues both in vitro and post implantation, especially for highly metabolic tissues 
like liver, kidney and pancreas. Furthermore, the design of bioreactors able to 
maintain large masses of viable cells in vitro presents an additional challenge [3]. 
Finally, further issues are represented by the integration of the engineered tissue into 
the living system. There is a lack of appropriate animal models for the evaluation of 
the integration of the engineered implant. Immunoacceptance is probably the most 
challenging issue related to transplantation, especially in the case of non autologous 
cells. Also, once the tissue has been implanted into the patient, it might not grow at 
the same rate of the other tissues [3]. These are some of the most important 
challenges that tissue engineering has to face at present for the reconstruction of 
tissues/organs that resemble natural ones. Below the three key aspects of engineering 
tissues will be discussed further: the selection of the appropriate cell types to give 
rise to the required tissue, the design of an appropriate scaffold to support cell 
adhesion and growth and, finally, the creation of a controlled environment to allow 
the cells to proliferate and create tissue structures. 
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1.4    Cell sources for tissue engineering 
 
The first step of any attempt to engineer a tissue or organ substitute is to decide 
whether the source to be employed is given by autologous, allogenic or xenogenic 
cells. An autologous source is represented by the patient’s own cells, so there are no 
problems associated with immune rejection or disease transmission. The use of 
autologous cells, although overcoming the immunologic barrier, presents some 
problems. Autologous approaches require obtaining the patient's own cells, 
expanding them in vitro in large quantities over several weeks, and reintroducing the 
cells in a site-specific manner. Thus, each treatment is an individualized and non-
scalable process which is subject to individualised culture, quality control testing and 
preparation for delivery to the patient [4, 5]. Furthermore, providing the patient with 
their own cells is quite a difficult and expensive procedure, therefore allogenic (cells 
from other human sources) and xenogenic (cells from different species) cell sources 
have been considered. Allogenic therapies have the aim to deliver functional cells 
“ready to use”, providing more immediate clinical benefit to the patient. Allogenic 
cell preparation would allow culturing of one batch of cells to treat multiple patients 
and multiple diseases, thus reducing the expense [4]. However, allogenic and 
xenogenic sources present some problems, in primis the risk of immunorejection. 
With xenogenic sources there are also problems associated with animal virus 
transmission [3]. Furthermore, the use of primary cells from donated organs and 
tissues is often limited by the scarcity of donors.  
 
1.5     Types of cells that can be used in tissue engineering 
 
Cells with different differentiation potential have been used for tissue engineering 
purposes. Cells can be classified as totipotent, pluripotent, multipotent or 
differentiated, depending on their source and differentiation capacity (fig. 1.2),  
Totipotent cells are cells found in the zygote that have the ability to produce any cell 
type in the embryo, including the extraembryonic tissue. Pluripotent cells can 
differentiate into any of the cells in the three germ layers (endoderm, mesoderm, 
ectoderm) and therefore into any type of tissue in the body but cannot produce 
extraembryonic tissue. Multipotent cells have the potential to differentiate into 
16 
 
multiple but limited number of cell types while differentiated cells have reached the 
final stage of development and have a specific function in a specific tissue. 
 
Fig. 1.2: Differentiation capacity of cells. According to their source and differentiation 
potential cells can be classified as embryonic stem cell, adult stem cells, progenitor cells and 
differentiated cells.  
 
1.5.1 Primary cells 
 
Primary cells are mature cells that are harvested from a specific tissue removed by 
surgical procedure. An example is given by primary human osteoblasts harvested 
from the femoral heads removed during total hip replacement operations [6]. Primary 
cells do not present immunological issues if they are harvested from the same patient, 
but they tend to proliferate slowly and to de-differentiate when cultured in vitro [6]. 
These limitations have stimulated researchers to find alternative cell types for tissue 
engineering strategies. 
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1.5.2 Cell lines 
 
Cell lines are immortalised cells that have been artificially modified (e.g. through 
random mutation or artificial expression of the telomerase gene) in order to acquire 
the ability to proliferate indefinitely in culture. Different cell lines have been the most 
popular alternative to primary cells so far, but there is concern about metastasis of 
tumour-derived cell lines and the transmission of uncharacterized infectious agents 
from tumour or animal-derived cells to the patient [3]. However cell lines are useful 
for non-clinical experiments given the ease of culture and the high proliferation in 
vitro. 
1.5.3 Stem cells  
 
A promising cell source for tissue engineering strategies is at present represented by 
stem cells, for their potential to differentiate into mature cell types that may have 
therapeutic benefit in the support, repair and regeneration of damaged tissues [7]. 
Depending to the clinical application, stem cells can be from either an allogenic or 
autologous cell source, added exogenously or recruited from the host, and then 
expanded in vitro. 
Stem cells are undifferentiated, “blank” cells that do not yet have a specific function. 
They are characterised by the capacity to maintain an undifferentiated status in vitro 
(self-renewal) and the ability to differentiate under appropriate conditions into 
specialised cell types and form specialised tissues and organs (plasticity) [8]. They 
can also give rise to progenitor cells, which can differentiate into tissue-specific cell 
types. Depending on their source, two types of stem cells exist: embryonic stem cells 
(pluripotent) and adult stem cells (can be multipotent or unipotent).  
1.5.3.1 Embryonic stem cells (ESCs) 
 
Embryonic stem cells are cells isolated from the inner cell mass of the blastocyst, an 
early (4-5 days) stage of the embryo. They have the ability to proliferate in vitro for 
extended periods of time in an undifferentiated state (self-renewal capacity) and they 
are pluripotent, i.e. they have the potential to differentiate into any of the three germ 
layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), 
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mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and 
nervous system) but cannot become an entire human being because they lack the 
potential to contribute to extraembryonic tissue, such as the placenta (fig. 1.3). This 
degree of plasticity represents at the same time a strong advantage and a major 
limitation in the use of ESCs for tissue engineering purposes: the same plasticity that 
permits ESCs to differentiate into so many cell types makes difficult to maintain a 
large number of ESCs in an undifferentiated state and subsequently direct their 
differentiation to a desired lineage with high efficiency [9]. To induce differentiation 
in vitro ESCs usually form aggregates called embryoid bodies (EBs), where later cell 
types of many different lineages will be generated. EBs mimic the structure of the 
developing embryo and therefore create better conditions for the differentiation of 
cells into the three germ layers compared to cells cultured in 2D monolayers [3].The 
formation of embryoid bodies has been used to produce neural cells [10], 
cardiomyocytes [11] hematopoietic precursors [12], β-like cells [13], hepatocytes 
[14] and germ cells [15]. 
  
Fig. 1.3: Pluripotency of embryonic stem cells. Adapted from [16], with permission from the 
author. 
However, the ESCs differentiation processes are in general characterised by quite 
low efficiency and are not syncronised among the cells [4]. The selection of specific 
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lineages requires sequential exposure to several inducing factors but most cells do not 
progress to a full terminally differentiated phenotype or often they differentiate 
incontrollably into undesired cell phenotypes [4]. Methods to obtain a more 
controlled differentiation of ESCs to specific lineages include co-culture with 
differentiated cells [17, 18] or differentiation in presence of specific growth factors 
[19, 20]. Furthermore, ESCs present safety issues as they have the potential to form 
tumours once transplanted in vivo: if ESCs remain undifferentiated after implantation 
in the body, they will spontaneously differentiate into multiple cell types and form a 
type of tumour derived from all three germ layers and called teratoma [21].Therefore 
ESCs should be guided to differentiate into a specific lineage before implantation in 
order to avoid teratoma formation. 
 
Another issue arising with transplantation of ESCs is immune rejection: there is clear 
evidence that once the differentiated ESCs are transplanted, they express high levels 
of major histocompatibility complex (MHC) class I antigens and any allogenic ES-
cell based construct would be rejected [22]. This problem could be solved by 
therapeutic cloning or somatic cell nuclear transfer, which consists in the transfer of 
the nucleus of a somatic cell into an enucleated oocyte, generating a blastocyst, and 
then culturing the inner mass to obtain an ES cell line with identical MHC to that of 
the host tissue [23]. However, the reliability and efficiency of the process has to be 
improved. A further immunological issue is related to the fact that human ESCs have 
been typically cultured in medium containing animal sera and/or with mouse feeder 
layers, which may induce an immuno-response or transfer cross-species pathogens. 
Therefore, these human ES cell lines grown with xenogenic components are very 
unlikely to be ever used in clinical applications. Progress has been made in the 
derivation and expansion of cells with human feeder cells [24] or, better, feeder-free 
[25]. Another option is offered by tissue engineering: ESCs can be cultured on 
polymer scaffolds, instead of using the feeder layer. Both natural and synthetic 
scaffold have been shown to support ESCs growth and differentiation into different 
lineages [26-29]. 
Finally, one of the most debated arguments about the use of embryonic stem cells 
regards the ethical issues which arise from the isolation of these cells from an 
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embryo. ESC isolation from the inner cell mass of the blastocyst results in the 
destruction of the pre-implantation embryo, which would otherwise form a living 
human being. Some approaches have  tried to circumvent the ethical problem, like 
Chung and colleagues for example, who have shown that a single cell embryo biopsy 
could be used to generate an ES cell line, without the destruction of the embryo [30].  
1.5.3.2 Adult stem cells 
 
At present, a very promising stem cell type for tissue engineering is represented by 
adult stem cells. Adult stem cells are undifferentiated cells found in specific organs, 
where their primary role is to maintain and repair the tissue in which they are found 
[31]. These cells have a capacity for self-renewal in culture and are multipotent, since 
they have more limited differentiation potential than ESCs, although researchers have 
recently started reviewing this definition. Initially it was thought that adult stem cells 
could only be found in a limited selection of tissues and could differentiate only in 
those lineages from the originating tissues. Recent studies have demonstrated that 
adult stem cells can be derived from bone marrow [32], blood [33], brain [34], fat 
[35], liver [36], muscle [37], pancreas [38], and umbilical cord blood [39] and also 
that some adult stem cells have a greater plasticity and they are able to generate other 
cell types from the same embryonic germ layer or even cells of other germ layers 
[40] (fig. 1.4). Hematopoietic stem cells, for example, are adult stem cells found in 
the bone marrow which give raise mainly to blood cells, but they also can 
differentiate into other cell types from the mesoderm (skeletal and cardiac muscle, 
endothelium) [41-43] or even into different cell types of the endoderm (lung 
epithelium, intestinal epithelium, kidney epithelium, pancreas, liver, bile ducts) [44-
49] and of ectoderm (epidermis and neural cells) [50, 51]. There is also evidence that 
hepatic stem cells may be able to generate different cells from the endodermal 
lineage, like pancreas cells [52, 53]. Another example is offered by mesenchymal 
stem cells (MSCs), particularly abundant in the bone marrow and adipose tissue, 
which can differentiate into osteoblasts, chondrocytes and adipocytes, but can also 
give rise to cells of cardicac tissue and vascular system, skeletal muscle, nerve, liver 
and pancreas [4, 54] (fig. 1.4). An explanation of the plasticity of adult stem cells 
could be cell fusion between the stem cells and some host cells [4] or that there might 
be stem cells with more pluripotent characteristics that persist into adulthood or that 
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adult stem cells could be reprogrammed via a process of de-differentiation and then 
re-differentiation to another lineage via trans-differentiation [4]. 
 
 
Fig. 1.4: Plasticity of adult stem cells. Bone marrow stem cells can differentiate into bone 
cells but also into completely different tissues like liver, skeletal muscle, neural cells under 
opportune stimulation with cytokines and growth factors. From [55], with permission from 
the author. 
MSCs are among the most characterised adult stem cells, as they can be easily 
expanded in culture and, as mentioned above, they can differentiate into multiple 
lineages. Also, MSCs from bone marrow and adipose tissue have been shown to be 
non-immunogenic [56]: they express very low levels of MHC class I molecules on 
their cell surface and they lack MHC class II expression [4], a characteristic which 
makes them very attractive for clinical applications as they would not cause rejection 
when implanted into the body of the patient. Furthermore, MSC differentiation can 
be more easily predicted and controlled compared to ESCs. For these reasons MSCs 
at present are more suited than ESCs for tissue engineering applications. MSCs can 
also be derived from umbilical cord blood, which offers an abundant source of stem 
cells with large proliferation capacity in vitro, thus an attractive resource for 
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regenerative medicine applications [57]. Other abundant sources of MSCs are 
placenta and amniotic fluid. In’t Anker et al reported that MSCs derived from these 
two sources exhibited a phenotype and multilineage differentiation potential similar 
to that of bone marrow-derived MSCs [58].  However, large interest is focused on fat 
as an alternative to bone marrow as an autologous MSC source: lipoaspirates have 
been shown to provide an abundant, easy and accessible source of these cells with 
less discomfort for the patient compared to the painful and risky MSCs extraction 
from bone marrow. Furthermore, lipoaspirate-derived MSCs have the ability to 
differentiate into multiple phenotypes [59-61] which makes them an attractive 
alternative to bone-marrow MSCs. 
In addition, in a recent study conducted at Imperial College, London, researchers 
were able to mobilize mesenchymal stem cells from bone marrow into the 
bloodstream by treating healthy mice with VEGF followed by a new drug called 
Mozobil [62]. This work could lead to new treatments which work by mobilising a 
person’s own stem cells into the blood circulation and it is potentially very important 
for tissue engineering purposes as a simple blood drawing from the patient could 
provide a population of mesenchymal stem cells to be used for regeneration of the 
damaged tissue to be re-implanted back into the same patient without any risk of 
rejection. 
Adult stem cells are at present more suited than embryonic stem cells for tissue 
engineering purposes because their use would not raise ethical issues, as they are not 
derived from an embryo. Furthermore, they would be more committed to a specific 
lineage, non-tumourigenic and non-immunogenic, therefore they could be 
transplanted into the patient without problems of rejection. Regenerative medicine 
approaches using stem cells for the regeneration of functional tissue could be: 1) 
transplants of stem cells or their derivatives; 2) use of stem cells or their derivatives 
to construct bioartificial tissues (tissue engineering) for implantation into the body; 
and 3) induction or enhancement in vivo of resident stem cell proliferation and 
differentiation to regenerate tissues at the site of damage [3]. Adult stem cells, and in 
particular mesenchymal stem cells, have been used for clinical applications, 
especially in orthopaedical applications [63-65]. In 2008 the first full transplant of a 
human trachea grown from adult stem cells was carried out at the Hospital Clínic 
of Barcelona. Researchers harvested a section of trachea and removed all the cells 
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thus leaving a non-immunogenic acellular scaffold. The section was then seeded with 
stem cells taken from the patient’s bone marrow and a new section of trachea was 
grown in the laboratory over four days. The new section of trachea was then 
transplanted into the left main bronchus of the patient. Because the stem cells were 
harvested from the patient's own bone marrow, the patient's immune system did not 
show signs of rejecting the transplant [66]. 
Despite these promising results, the use of adult stem cells is not free from obstacles: 
their availability decreases with age in most tissues and also, once extracted and 
cultured in vitro, they tend to grow slowly. To be useful for transplant purposes, stem 
cells must proliferate extensively and generate sufficient quantities of tissue, 
differentiate into the desired cell type(s), survive in the recipient after transplant, 
integrate into the surrounding tissue after transplant, function appropriately for the 
duration of the recipient's life, and avoid harming the recipient in any way [67]. 
Furthermore, in order to take full advantage of stem cell technology for tissue 
engineering applications, it is necessary to acquire a better understanding of stem cell 
biology, and in particular of their response not only to biological factors and 
scaffolds, but also to the microenvironment (niche) in which they must survive and 
function. In addition, the isolation techniques must be improved in order to obtain a 
pure stem cell population.  
1.5.3.3  Induced pluripotent stem cells (iPSCs) 
 
A recent discovery could bring the focus of researchers to a new, pluripotent stem 
cell type. In August 2006 Takahashi and Yamanaka announced that somatic cells can 
be reprogrammed to a pluripotent state by the viral transfection of four transcription 
factors (Oct4, Sox2, Klf4 and c-myc) into mouse fibroblasts [68]. They called these 
cells “induced pluripotent stem cells” (iPSCs), as they have the ability to differentiate 
into virtually all types of cells like ESCs. One year later they also reported the 
generation of human iPSCs (fig 1.5). In 2008 Nakagawa et al showed that iPSCs can 
be generated with only three factors [69], and Huangfu et al later demonstrated that 
just two factors (Oct4 and Sox2) in combination with a valproic acid (VPA), are 
sufficient to reprogram fibroblasts to an embryonic state [70]. In the same year, Aoi 
et al showed that iPSCs can be generated not only from fibroblasts but also from 
adult mouse hepatocytes and gastric epithelial cells [71]. In 2009 Kim et al. reported 
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that Oct4 alone is sufficient to reprogram adult mouse neural stem cells into iPSCs 
[72]. 
 
Fig. 1.5: Induced pluripotent stem cells (iPS) can be generated by introducing genes 
encoding four transcription factors (Oct4, Sox2, Klf4 and c-myc) into fibroblasts. From [73]. 
 
iPSCs would solve two main problems associated with ESCs, in primis the ethical 
issues as they do not require the destruction of an embryo instead being isolated from 
somatic cells, and secondly they don’t cause immune rejection when transplanted 
into the patient [73]. For these reasons iPSCs research has become one of the hottest 
areas in life sciences, as these cells are expected to be used for generating disease 
models, drug screening, toxicology and regenerative medicine (fig. 1.6). At the same 
time the technology is still at the beginning, and there are many challenges to be 
overcome before iPSCs can be applied into clinics. One main challenge is that the 
reprogramming methods involve the expression of oncogenes by retroviral vectors, 
which may cause cancer by integrating into the genome [74]. A few alternative 
reprogramming methods have been developed to avoid genome integration by 
retroviral vectors: Stadtfeld et al, for example, generated iPSCs from mouse 
hepatocytes through an adenoviral vector, which does not integrate into the host 
genome. However, the efficiency of reprogramming was much lower than that 
obtained by retroviral infection [75]. Simple transfection, another alternative method 
developed by Okita et al [76], also resulted in low reprogramming efficiency, while a 
third strategy which employs small molecules that can replace the reprogramming 
transgenes, like VPA instead of klf4, has been shown to dramatically increase the 
efficiency of reprogramming in both human and mouse cells [70]. From these 
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examples it is clear that, although the potential of iPSCs in medicine, drug discovery 
and toxicology is immense, long-term studies must still be carried out in order to 
fully characterise them and eliminate any potential safety concern about their use. 
 
Fig. 1.6: Possible applications of iPS cells. iPS cells could be used in vivo for regenerative 
medicine applications, as well as in vitro for toxicology, disease models,  and for drug 
screening. From [73]. 
 
However, in 2010 Vierbuchen et al identified three neuron-specific transcription 
factors (Ascl1, Brn2 and Myt1l) that were sufficient to directly convert mouse 
fibroblasts into functional neurons in vitro [77]. From this finding it appears to be 
possible to directly covert one differentiated cell type into another differentiated one 
with no more need of the induced pluripotent stem cells intermediate step. This 
strategy would eliminate the safety risks associated with pluripotent stem cells, and 
possibly open a new era of investigation which would provide advances not only in 
cellular and molecular biology, but also in drug discovery and regenerative medicine. 
1.6 Biomaterials as scaffolds for cells 
 
With the selection of a source of cell, the next challenge in tissue engineering is the 
development of an organised three-dimensional support or delivery vector for the 
cells. Tissue engineering involves the use of biomaterials as scaffolds to support and 
induce tissue formation in vitro and in vivo. According to the definition proposed at 
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the Consensus Conference of the European Society for Biomaterials, Chester, 
England, March 1986, biomaterials are "any substance, other than a drug, or 
combination of   substances, synthetic or natural in origin, which can be used for any 
period of time, as a whole or as a part of a system which treats, augments, or 
replaces any tissue, organ, or function of the body." [78]. 
Biomaterials have been employed in tissue engineering as scaffolds to support cell 
growth and proliferation. The properties that need to be considered when designing a 
scaffold for tissue engineering will be discussed in the following section. 
 
1.6.1 Scaffold design properties 
 
A scaffold is defined as “the support, delivery vehicle, or matrix for facilitating the 
migration, binding, or transport of cells or bioactive molecules used to replace, 
repair or regenerate tissues” [79]. Unlike permanent implants, tissue-engineered 
scaffolds serve as temporary devices to facilitate the tissue repair and regeneration 
process [3]. The scaffolds employed in tissue engineering must be capable of 
promoting cell-biomaterial interactions, cell adhesion and extracellular matrix 
deposition, allowing sufficient transport of gases, nutrients and regulatory factors in 
order to permit cell survival, proliferation and differentiation, of provoking a minimal 
degree of inflammation toxicity when implanted in vivo (biocompatible) and of 
biodegrading at a controllable rate close to that of tissue regeneration, assuring in this 
way the complete integration of the engineered construct (biodegradable). Also, in 
the design of a scaffold it is important to consider a cell’s microenvironment since 
the cell in vivo is exposed to a series of signals (mechanical signals, signals from the 
extracellular matrix and from the neighbouring cells) that direct its function, and 
therefore the scaffold has to reproduce as close as possible the characteristics of the 
tissue where the cell is found. For this scope at present several scaffolds incorporate 
into the biomaterial bioactive molecules such as growth factors, anti-inflammatory 
drugs or gene delivery vectors to elicit the same cellular responses occurring in vivo 
[3]. Finally, adequate mechanical properties such as strength and stiffness, 
sterilizability, long-term storage, manufacturability and appropriate engineering 
design are also to be considered in the development of a scaffold for tissue 
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engineering [80]. Below are described some of the fundamental parameters to be 
considered during scaffold design. 
1.6.1.1 Scaffold structure 
 
At the macroscopic level, scaffolds can be formed into a number of different 
geometries which try to mimic the tissue/organ anatomical features (fig. 1.7). For 
example, hollow fibres have been employed for liver regeneration purposes as they 
resemble the liver lobule [81], while nanofibres have been employed as artificial 
nerve guidance channels for nerve regeneration [82, 83]. Fibres are attractive for 
tissue engineering as they provide a large surface area to volume ratio for large cell 
attachment and also they allow the rapid diffusion of nutrients to cells and waste 
products from cells [84]. Hydrogels are another macro-structure type of scaffold used 
especially for cell encapsulation and drug delivery for their capacity of absorbing a 
high amount of water, thus creating an ideal aqueous environment [85-88]. They are 
easy to inject, and in situ forming hydrogels that solidify on external stimuli have 
been designed as injectable scaffolds for minimally invasive cell and biomolecule 
transplantation [89]. However, they showed weak mechanical properties and they are 
difficult to sterilise. Highly porous foam and sponge scaffolds provide a template for 
cells to form into a 3D tissue structure and they can be processed with different 
techniques in order to obtain porous constructs. Macroporous scaffolds prepared with 
gas foaming method, for example, exhibited a porosity of over 90% and pore size of 
about 200 µm, thus allowing cell infiltration into the pores [90]. 
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Fig. 1.7: Different scaffold macro-structures: A) composite  hydrogel [88], B) gelatine foam 
[91], D) PLGA hollow fibre [92], C) nanofibres  [93]. 
 
1.6.1.2 Mass transport and scaffold micro-structure 
 
Mass transport is the movement of fluids, solutes and cells through a tissue construct 
and it is one of the most significant challenges in tissue engineering. Cells located 
further than 200 μm from a blood supply are exposed to low oxygen tension and as a 
result they become either metabolically inactive or necrotic [94]. The mass transport 
in a scaffold is related to the scaffold’s chemical composition and the structural 
characteristic of its pores, defined mainly by pore size, porosity, pore 
interconnectivity/tortuosity, and surface area. These scaffold characteristics can 
affect the diffusion or convection of nutrients, growth factors and cytokines through 
the engineered tissue [3]. Once cells are seeded on the scaffold, the distribution and 
density of cells on the scaffold highly influence the distribution and availability of 
nutrients to the cells within the scaffold interior, thus affecting mass transport [95]. 
Since most cells are anchorage dependent, the scaffold should possess properties that 
facilitate cells’ growth and attachment [96, 97]. One main parameter affecting the 
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initial cell attachment and distribution is the pore size of the scaffold. Optimal 
scaffold pore sizes have been shown to positively affect tissue regeneration in vivo 
[98-100]. 
In addition to pore size, other parameters that influence cell attachment and mass 
transport are porosity, pore interconnectivity and available surface area. Highly 
porous scaffolds allow a greater number of cells to infiltrate the scaffold’s void space 
and also an easy diffusion of nutrients to and waste products from the implant, which 
is a major requirement for the regeneration of highly metabolic organs like pancreas 
and liver. Also, the continuity of the pores is important for an adequate transport of 
nutrients and cell migration. It is also an advantage for a scaffold to possess a large 
surface area to volume ratio, in order to achieve an optimal cell density on the 
scaffold. This ratio depends on the density and average diameter of the pores [84]. 
However, while high porosities can improve the mass transport capabilities of a 
scaffold, they can also compromise the mechanical integrity of the scaffold. 
Therefore, the challenge in the design of an optimal tissue engineered scaffold is to 
find the right balance between the scaffold’s surface area, void space and mechanical 
strength [101]. 
1.6.1.3 Mechanical strength 
 
Since tissues are subjected to mechanical forces, the mechanical properties of the 
engineered construct have to be taken into account during the scaffold design, 
especially for weight-bearing tissues like bone. In these tissues the scaffold must be 
capable of sustaining the forces applied to it and to the surrounding tissues. 
Mechanical properties of scaffolds should resemble those of the native tissues. For 
bone regeneration, for example, mechanically stiff biomaterials are required to 
support cell expansion and the production of bone matrix [102], while soft 
biomaterials such as hydrogels are suitable for soft tissue engineering for their 
similarity to native soft tissues like muscle, nerves, blood vessels, fat and connective 
tissue [103]. Furthermore, the scaffold should be able to retain its mechanical 
properties until the new tissue is engineered completely [3, 101]. The mechanical 
properties of the scaffold are determined in part by the bulk properties of their 
constituent materials (e.g. Young’s modulus, degradation rate). For example, 
hydrophobic polymers tend to resist water adsorption and therefore exhibit a higher 
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mechanical strength than hydrophilic polymers or hydrogels. Because of the high 
porosity and of the consequent low material content, the mechanical properties of the 
scaffold are often determined by the structural arrangement of their constituent 
materials (e.g. pore size, fibre diameter and orientation).  
1.6.1.4 Surface properties 
 
The chemical and topographical features of the surface are the ones that determine 
the interaction between the scaffold and the cells. The surface chemistry refers to the 
chemical environment that the scaffold surface presents to the cells. To tailor the 
scaffold chemical properties, the interactions of the scaffolds with different factors, 
such as protein adsorption from biological fluids to the scaffold surface, need to be 
considered. Studies have been carried out to understand how the adsorption and 
denaturation of proteins can lead to different cellular responses at the material surface 
[104], such as cell adhesion. Scaffolds that are derived from natural materials, such 
as collagen, fibrin, hyaluronic acid, already contain innate biological molecules to aid 
cell attachment and proliferation, while the surface chemistry of synthetic scaffolds 
has often been modified in order to improve cell attachment either by direct surface 
treatment/modification or by incorporating bioactive molecules into the scaffold 
bulk. For example, hydrophobic polymers such as polylactic acid (PLA) and 
polylactic-co-glycolic acid (PLGA) can be wet by two-step immersion in ethanol and 
water in order to facilitate the entry of water into the pores thus promoting cell 
attachment [105]. Another strategy of surface modification consists in coating the 
scaffold surfaces with specific extracellular matrix-derived adhesion proteins. For 
example, PLGA scaffolds and polyvinyl alcohol (PVA) hydrogels have been coated 
with fibronectin in order to improve cell adhesion and proliferation [26, 106]. 
Finally, an alternative strategy for improving cell attachment consists of using 
electrically charged surfaces in order to improve adsorption of specific adhesive 
proteins that promote cell adhesion. This can be achieved by modulating the 
isoelectric point of the surface or of the adhesive protein, i.e., the pH at which a 
protein or surface carries no net electrical charge. A protein/surface can then exhibit 
different charges according to the pH of the surrounding environment: at pH values 
above the isoelectric point the surface/protein will be negatively charged, while at pH 
values below the isoelectric point the surface/protein will be positively charged. 
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Surface charge plays an important role in cell adhesion: the surface charge of a 
polymer affects protein adsorption to its surface, which is thought to improve cell 
attachment. Many proteins have a net negative surface charge, which promote their 
adsorption to a positively charged surface, while negatively charged surfaces will 
promote adsorption of positively charged proteins [4]. The other major strategy of 
surface chemistry modification consists in incorporating into the scaffold pepetide 
ligands derived from the active domains of ECM adhesion proteins. For example, the 
incorporation the peptide Arg-Gly-Asp (RGD) into the scaffold, is a common 
technique to enhance cell adhesion [107]. 
Surface topographical features include pores, nodes, ridges, steps, grooves and have 
been shown to be responsible for changes in cell morphology, cell activities, and with 
the production of autocrine/paracrine regulatory factors compared to smooth surfaces 
[108]. In general surface roughness increases cell adhesion, migration and the 
production of ECM. Therefore, many fabrication and surface modification techniques 
aim to generate different topographical surfaces to improve cell attachment. For 
example, nanostructured PLGA scaffolds treated with sodium hydroxide have shown 
to increase the chondrocyte adhesion, proliferation and ECM production, due to 
increased porosity and nanoscale roughness [109]. At present, there is a growing 
interest in the fabrication of nanostructured scaffolds and in particular in developing 
synthetic nanofibrous scaffolds, with nanofibres of diameters ranging from a few to 
hundreds nanometers as the differential topography created by the nanofibres has 
been shown to support cell and tissue growth [110, 111]. 
1.6.1.5 Biodegradability 
 
As opposed to permanent implants, tissue engineered scaffolds are designed to 
provide temporary support for the cells in order to facilitate tissue engineering 
processes. Therefore, tissue engineered scaffolds have to be biodegradable and the 
degradation rate of the scaffold should ideally correspond to the rate of new tissue 
formation. However, it is difficult to match the degradation rate with the wound 
healing and new tissue regeneration rate, which may vary between different patients. 
Therefore, designing scaffolds with appropriate degradation properties, especially 
combining the properties of the scaffold with the aspects of a specific tissue 
formation still remains a challenge.  For example, scaffolds used for bone implants 
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need to support mechanical forces and at the same time allow new bone formation 
[112]. In order to tailor the degradation of the scaffolds, wound healing and tissue-
regeneration mechanisms have to be further explored. Many factors can influence the 
degradation profile of scaffolds in vitro such as the polymer molecular weight, 
polydispersity, crystallinity, glass transition temperature, scaffold porosity, pH of 
medium, and in vivo, such as presence of enzymes or proteins, cellular activity and 
cell-induced pH changes [113]. There are two types of scaffold degradation: surface 
and bulk degradation. Surface degradation is characterised by a gradual decrease in 
the dimensions of the scaffold with no changes in its mechanical properties. Bulk 
degradation is characterised by loss of material throughout the scaffold’s volume 
with loss of mechanical strength while maintaining an intact surface. Therefore bulk 
degrading scaffolds might allow a better cell attachment than surface eroding 
scaffolds [101]. Many polyester scaffolds made of lactic and glycolic acid, e.g. 
PLGA and hydrophilic scaffolds like hydrogels, undergo bulk degradation. However, 
in bulk degradation, the accumulation of degradation products may have negative 
effects on the tissue, e.g. the release of acidic products from PLGA degradation. 
 
Once described the main properties of the scaffolds, the main classes of biomaterials 
will be now discussed, with a particular focus on polymers. 
 
1.6.2 Biomaterials classification 
 
Biomaterials can be classified into five groups (table 1) [114]: 
1) metals 
2) ceramics 
3) glasses 
4) polymers (natural and synthetic) 
5) composites  
 
In the past century metals and ceramics have contributed to major advances in 
medicine, especially in orthopedic tissue replacement. However, they have two major 
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disadvantages for tissue engineering applications:  they are not biodegradable (except 
biodegradable ceramics such as tricalcium phosphate) and their processability is very 
limited. For these reasons polymeric materials have received an increasing attention 
over recent years [84]. 
 
Table 1: Characteristics of the three major groups of biomaterials: polymers, metals, 
ceramics. Adapted from [80]. 
Biomaterials Examples Advantages Disadvantages 
 
Metals (Ti, Co-Cr, 
stainless steels, Au, 
Ag, Pt etc.) 
 
Joint replacements, 
bone plates and 
screws, dental root 
implants  
 
strong, tough, ductile 
 
may corrode: 
biocompatibility 
issue, difficult to 
process, not 
biodegradable 
Ceramics  
(aluminum oxide, 
calcium phosphates 
including 
hydroxyapatite, 
carbon) 
Glasses (phosphate 
based glasses, 
silicate based 
glasses, bioactive 
glasses) 
Dental implants, 
femoral head or hip 
replacement, coating 
of dental and 
orthopedic implants 
 
Orthopaedic 
implants 
 
very biocompatible, 
inert, strong in 
compression 
 
 
 
biocompatible, 
biodegradable, 
bioactive 
 
Brittle, difficult to 
process, not resilient, 
not biodegradable 
 
 
Brittle, difficult to 
process, limited 
solubility 
Polymers (collagen, 
fibrin, chitosan, 
alginate, PLA, PGA, 
PLGA....) 
Sutures, blood 
vessels, soft tissues 
easy to fabricate, can 
be tailored to suit 
specific functions, 
resilient 
not strong, deform 
with time, might 
degrade into acidic 
products 
 
1.6.2.1 Polymeric biomaterials  
 
The main advantages of polymeric biomaterials compared to metal or ceramic 
materials are the ease of manufacturability to produce various shapes (films, sheets, 
fibres etc), biodegradability, reasonable cost and availability with desired physical 
and mechanical properties.  
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Polymeric materials used in tissue engineering applications can be divided into two 
main classes:             
1) Natural: those most employed are usually from proteic (e.g. collagen, fibrin, 
gelatin, silk) or polysaccaridic (e.g. alginate, hyaluronic acid, chitosan) 
origin. Natural materials are usually biocompatible and enzymatically 
biodegradable. They have the advantage of possessing bio-functional 
molecules that aid the attachment, proliferation and differentiation of cells. 
However, these scaffolds present some drawbacks: the degradation rate 
might not be easily controlled, as it would be different according to the host, 
and therefore the lifespan of these materials would vary in vivo. Also, 
natural materials possess weak mechanical properties [101] and batch to 
batch variations. 
2) Synthetic: they present many advantages over natural polymers, e.g. they 
are available in unlimited quantities, they can be prepared with controlled 
physical and chemical properties and the degradation rate and mechanical 
properties can be chemically modified. A disadvantage is that some of them 
degrade into acid products which might increase the local acidity and this 
might result in adverse responses such as inflammation. The most common 
synthetic polymers are polyesters such as polyglycolic acid (PGA), 
polylactic acid (PLA) and and their copolymer polylactic-co-glycolic acid 
(PLGA), or polycaprolactones. Other types include polyanhydrides, 
polycarbonates and polyphosphazenes [101]. 
Since a synthetic polymer, PLGA, has been used in this project as scaffold for cells, 
the group of poly(α-hydroxy acids), to which PLGA belongs to, will be discussed in 
more detail in the next section. 
1.6.2.1.1 Poly(α-hydroxy acids)  
 
Polylactic (PLA), polyglycolic (PLGA) and poly(lactic-co-glycolic) (PLGA) acids 
are bioresorbable polyesters belonging to the group of poly-α-hydroxy acids. They 
have been extensively used for over 30 years in a wide range of biomedical 
applications and especially in surgical sutures thanks to their biocompatibility, 
biodegradability and processability, characteristics with which they received 
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approval from the Food and Drug Administration (FDA) for clinical use [80]. These 
polymers degrade by non-specific hydrolysis of their ester bonds, which results in a 
decrease in the polymer molecular weight [115]. The degradation rate of these 
polymers is determined by initial molecular weight, exposed surface area, 
crystallinity and, in the case of co-polymers, by the ratio of the monomers. The 
degradation of these polymers is also thought to be linked to macrophage/material 
interactions that stimulate macrophage activation which, in turn, leads to the 
macrophage production of the growth factors required to initiate tissue regeneration 
[80]. Within this family of polyesters, PGA has the simplest structure (fig. 1.8). 
Because it is a highly crystalline polymer, it has a high melting point and low 
solubility in organic solvents. Due to its hydrophilicity, PGA tends to degrade and 
therefore to lose its mechanical properties usually between two to four weeks post 
implantation [116]. 
 
Fig. 1.8: Chemical structure of polyglycolic acid (PGA).  
Due to the presence of an extra methyl group on the α-carbon, PLA is a chiral 
molecule and thus D (fig. 1.9 a), L (fig. 1.9 b) and D,L (fig. 1.9 c) isomers are 
possible. The polymers derived from the optically active D and L monomers are 
semicrystalline and relatively hard materials with extremely slow biodegradation 
rate, therefore they are employed in applications where high mechanical strength is 
required, such as sutures and orthopaedic devices [117], while the optically inactive 
D,L-PLA is always amorphous, with a faster degradation rate compared to the 
optically active isomers, and therefore is preferred for drug delivery applications, 
where a homogeneous dispersion of the active species within a monophasic matrix is 
required [3]. Because of its methyl group, PLA is more hydrophobic than PGA, and 
this results in a lower hydrolysis rate than PGA. Also, PLA is more soluble in 
organic solvents than PGA. 
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         a)  L-PLA                   b) D-PLA                         c) D,L-PLA 
Fig. 1.9: Chemical structure of polylactic acid isomers: L- PLA, D-PLA, and D,L-PLA. 
Although these polymers have been considered biocompatible and safe and therefore 
FDA approved, a delayed inflammatory reaction has been observed in orthopaedic 
implants made from PGA and/or PLA, which is probably due to the acidic products 
(glycolic acid for PGA and lactic acid for PLA) released by the polymer during 
degradation [118], that have the potential to significantly lower the pH of the local 
environment and this leads to an accelerated acid-catalysed hydrolysis in the tissue 
surrounding of the implant. This, in turn, could cause a faster loss of mechanical 
properties. A controlled slow release of degradation products in a manner that the 
surrounding area could metabolise them could be a solution to the acidity problem.  
 
PLGA is the co-polymer of glycolic acid and lactic acid (fig. 1.10), synthesized by 
means of random ring-opening co-polymerization of lactide and glycolide. During 
polymerisation, successive monomeric units of glycolic or lactic acid are linked 
together by ester linkages, leading to a linear aliphatic polyester.  
 
 
Fig. 1.10: Structure of polylactic-co-glycolic acid and its decomposition in lactic and 
glycolic acid. From [4]. 
 
PLGA degrades by hydrolysis or enzyme catalysed hydrolysis in four steps: 1) water 
penetrates the amorphous region and disrupts the secondary forces; 2) cleavage of the 
37 
 
covalent bonds in the polymer back-bone by hydrolysis; 3) significant mass loss 
begins to occur by massive cleavage of the backbone covalent bonds; 4) erosion: 
polymer weight loss [119]. Degradation rates of PLGA differ according to the 
proportion of lactic versus glycolic acid content (fig. 1.11): the higher the proportion 
of the more hydrophilic glycolic acid, the faster the degradation time of PLGA. For 
example, over 4 weeks time PLGA 85:15 was found to lose 10% of its mass, 
compared to 50% for PLGA 75:25 and 70%  for PLGA 50:50 [120]. Furthermore, the 
degradation of PLGA is affected by the polymer crystallinity, and by significant 
changes in temperature and pH [121]. 
 
Fig. 1.11: Half-life of PLA and PLGA homopolymers and copolymers. From [122]. 
 
Several processing methods can be used to produce PLGA tissue scaffolds, e.g. 
solvent casting/particulate leaching technique, phase separation, emulsion freeze-
drying, gas foaming, electrospinning and 3D printing [123] (fig. 1.12). PLGA is used 
for the fabrication of different forms of scaffolds, such as fibres, mesh, membranes, 
sponges. 
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Fig. 1.12: Morphology of PLGA scaffolds prepared with different processing methods: A) 
gas foaming/salt leaching for cartilage regeneration [124], B) thermally induced phase 
separation for mesenchymal stem cell culture [4], C) electrospinning for nerve regeneration 
[4], D) solvent casting for in vitro and in vivo degradation studies [125], E) emulsion freeze 
drying  for smooth muscle reconstruction [126], F) 3D printing for bone reconstruction [127]. 
 
Hollow fibre PLGA membranes have proved to be a good scaffold for cells, 
especially bone and cartilage derived cells, because they offer a large surface area to 
volume ratio in order to obtain large cell numbers when incorporated into a hollow 
fibre perfusion bioreactor [92]. High cell seeding and cell affinity are important 
factors to be considered in the fabrication of a scaffold.  One of the major limitations 
in the use of PLGA for tissue engineering scaffolds is its hydrophobic character, 
resulting in sub-optimal adhesion, spreading and growth of cells on the surface of the 
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material [128], and also resulting in low hydraulic permeability through the scaffold. 
Hydraulic permeability is important for mass transfer studies as cell culture medium 
contains proteins which support the growth of cells (albumin, transferrin, fibronectin, 
fetuin), but also growth factors and proteins released by the cells themselves. Some 
techniques to make membranes more hydrophilic include pre-wetting the material 
with ethanol before cell seeding [105], hydrolysis with NaOH [129], protein-coating 
[130] and plasma treatment [131]. Blending with hydrophilic polymers is another 
way of improving the properties of polymeric membranes, especially their 
permeability and hydrophilicity [132-135]. Water-soluble porogens such as 
poly(ethyleneglycol) (PEG) [136, 137], polyvinylpyrrolidone (PVP) [138-142] and 
polyvinylalcohol (PVA) [139, 143-146] have been reported to improve the 
permeability of membranes. PVA is a water-soluble polyhydroxy polymer formed by 
hydrolysis of polyvinyl acetate [147] and degrades mostly by oxidative or thermal 
degradation (pyrolysis) [148], but also by photodegradation [149]. The degradation 
of PVA is pH dependent: alkaline hydrogen peroxide solutions, for example, can 
cause complete dissolution of PVA in 10 minutes at 95º C. Thanks to its 
hydrophilicity, excellent chemical resistance (e.g. long term temperature and pH 
stability), non-toxicity and biodegradability, PVA has been used in various 
pharmaceutical, medical, cosmetic and food products [150-152]. For the same 
reasons PVA is an attractive polymer for tissue engineering applications. For 
example, Oh et al have demonstrated how blended PVA-PLGA blend scaffolds made 
by the particulate-leaching method improved porosity, hydrophilicity and wettability 
of the material resulting in better cell adhesion and growth [147].  
 
1.7  Bioreactors for tissue engineering    
       
With the selection of the appropriate cell source and scaffold, the third challenge in 
tissue engineering is the ability to recreate an environment in vitro which mimics as 
closely as possible the environment that the cells experience in vivo, in order to allow 
their growth and expansion. In order to achieve this goal, bioreactors, i.e. systems for 
the cultivation of cells by controlling supplies of nutrients and gases, have been 
applied in tissue engineering. A bioreactor is a simulator, a device that should ideally 
create an environment that allows the cells to proliferate and differentiate as in vivo, 
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establish uniform cell distribution on 3D scaffolds, maximise the mass transfer of 
nutrients and oxygen to the tissue, and expose the tissues to physical stimuli, if 
required. The aim of the most recent bioreactors is then to mimic the cell’s 
microenvironment in a living organism while allowing for a strict control over the 
cell environment and a real-time insight into cellular events, such as cell proliferation 
and differentiation [153].                                                    
                                                                                  
1.7.1 Bioreactors employed in tissue engineering 
 
Several types of bioreactor have been applied so far in tissue engineering. The choice 
of the bioreactor depends on the tissue to be engineered and its functional 
biomechanical environment. Below are described some of the most common 
bioreactors used in tissue engineering. 
1.7.1.1 Spinner flask 
 
The spinner flask (fig. 1.13) represents one of the first bioreactor models. Scaffolds 
seeded with cells are attached to needles hanging from the cover of the flask and 
medium is added in order to cover the scaffolds. A magnetic stirrer bar at the bottom 
of the flask continuously mixes the media thus providing the cells with a 
homogeneous distribution of oxygen and nutrients [154]. Spinner flasks have been 
shown to increase the efficiency of scaffold cell seeding and survival compared to 
static culture [155]. Cartilage constructs have been grown in these devices with good 
results, however the thickness of the tissue was found to be far thinner than native 
one, probably due to the poor mass transfer capacity of the reactor [156]. Another 
issue related to spinner flasks is that the fluid flow is turbulent and characterised by 
relatively high shear forces that could cause damage to the cells. Furthermore, the 
non uniformity of the shear forces may negatively influence the homogeneity of cell 
distribution on the scaffold [101]. 
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Fig. 1.13: The spinner flask, one of the first bioreactor models. From [156]. 
 
1.7.1.2  Rotating-wall vessel bioreactor (RWV) 
 
Since high shear stresses can cause cell damage, bioreactors with low shear stresses 
have been developed. The most common system that operates at low shear stress is 
the rotating-wall vessel (RWV), where the cells are grown in a microgravity 
environment [157]. This device, first introduced by NASA, consists of two 
concentric cylinders whose annular space contains the cell culture medium (fig. 
1.14). The inner cylinder is static and permeable to allow gas exchange for oxygen 
supply. The outer cylinder is impermeable and rotates horizontally at a speed that 
causes centrifugal forces that balance the gravitational forces thus generating a 
microgravity environment. In contrast to the spinner flask, the fluid flow is laminar 
and the shear stresses generated by the flow decrease in the direction of the flow 
[101]. The efficacy of RWV bioreactors has been demonstrated for cartilaginous 
[158] osteogenic [159], neuroendocrine [160], hepatic [161], adipose [162], vascular 
[163] and cardiac tissues [164]: tissues grown for a few weeks in the RWV showed 
characteristics very close to those of native tissue and were structurally and 
functionally superior compared to those cultured in static conditions or spinner 
flasks. One disadvantage of the RWV system is that the growth of the tissue is 
usually not uniform: the centrifugal force causes the scaffold to frequently collide 
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with the bioreactor wall, thus inducing cell damage and disrupting cell attachment 
[165]. 
 
Fig. 1.14: Schematic draw (A) and picture (B) of the rotating wall vessel bioreactor. From 
[166].  
 
1.7.1.3    Flow perfusion bioreactor 
 
Flow perfusion bioreactors offer enhanced transport of nutrients to the interior of the 
scaffold and also a more uniform cell distribution compared to static culture and 
spinner flasks as they allow medium to be transported throughout the entire structure 
(external and internal) of the material (fig. 1.15), reducing in this way both external 
and internal diffusional limitations of 3D-scaffolds. In these systems a pump is used 
to perfuse medium continuously through the interconnected pores of the scaffold, 
thus maximising the mass transfer of nutrients. Furthermore, they expose the cells to 
mechanical forces by fluid shear stress, which can be varied by simply changing the 
flow rates in the system [154]. Perfusion bioreactors are the ideal culture systems for 
highly metabolic cells, e.g. hepatocytes, thanks to the increased mass transport of 
oxygen and nutrients to the cells [167]. 
Perfusion bioreactors can be used for seeding and/or culturing three-dimensional 
constructs. During seeding, cells are transported directly into the scaffold pores, 
while during culture, medium flows continuously through the internal pores thus 
enhancing the mass transfer of nutrients though the whole construct [168]. Perfusion 
bioreactors have been designed in different configuration, e.g. column, hollow fibre 
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and microfluidic bioreactors. For the purposes of this thesis, only hollow fibre 
bioreactors will be described.  
 
 
Fig. 1.15: Flow perfusion system: the culture medium is forced through the internal porous 
network of the scaffold, enhancing in this way nutrient delivery to and waste removal from 
the cells [154]. 
 
1.7.1.3.1 Hollow fibre bioreactor 
 
A hollow fibre bioreactor consists of a bundle of hollow fibres encased in a 
cylindrical shell with ports for flow of media around the fibres. It is a two 
compartment module with an intracapillary and an extracapillary space (fig. 1.16). 
The fibres are fabricated from a porous material that permits the passage of nutrients 
and low molecular weight species but excludes cells and high molecular weight 
cellular products such as antibodies. Cells can be seeded either on the outer or in the 
inner surface of the fibre, with intracapillary or extracapillary media perfusion, 
respectively.  
 
Cell culture 
medium 
scaffold pore 
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Fig. 1.16: Lateral and front view of a hollow fiber bioreactor. Adapted from  [169, 170]. 
 
Flow inside the lumen of the fibre has a parabolic velocity profile, so that the cells 
grown on the inner surface of the fibre are subjected to a uniform shear stress which 
is directly proportional to the intracapillary flow rate [155]. The hollow fibres, by 
providing nutrients to the cells and eliminating their waste, mimic in vivo blood 
vessels. The main advantage of using this type of bioreactor is that it provides 
nutrients at the centre of the growing tissues, while oxygen delivery is the main 
factor limiting cell growth in hollow fibre bioreactors, as cell distributions and 
morphologies were found to vary with the distance from the oxygen supply. Hollow 
fibre systems have been employed for cell expansion [171], gene transfer [172], 
production of recombinant protein and viruses [173, 174], dialysis [175] and 
extracorporeal hepatic devices [176]. The most widespread use of hollow fibre for 
biomedical application is renal dialysis, where blood is passed through the 
intracapillary space of a hollow fibre membrane dialyser with a low molecular weight 
cut-off (< 10 kDa).      
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1.8 Co-cultures, scaffolds, growth factors and bioreactors to direct 
stem cell differentiation: potentials and limitations 
 
As discussed in the previous sections, cells with different differentiation potential 
have been employed for tissue engineering purposes. For their ability of self-renewal 
and differentiation into different mature cell types, stem cells are becoming one of 
the most promising cell sources for tissue engineering strategies. For their capacity of 
differentiation toward different lineages, stem cells have been employed in this 
project, and this section will discuss the different strategies that researchers have 
explored in order to direct stem cell fate. 
Soluble factors, cell-cell and cell-matrix interactions and cell microenvironment can 
be considered the most important effectors of stem cell fate (fig. 1.17) [177]. The 
following paragraph will discuss in more depth these four effectors with a focus on 
tissue engineering applications. 
 
 
Fig. 1.17: Stem cell fate is influenced by interaction of soluble factors, extracellular matrix 
and signals from neighbouring cells. From [177]. 
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1.8.1 Cell-cell interactions 
 
Cell-cell interactions consist of specific binding of signalling molecules to cell-
surface receptors (cadherins, cell adhesion molecules) which induces specific 
signalling pathways affecting gene expression, self-renewal and differentiation [177]. 
Cell-cell contact based signalling provides in fact important cues for development, 
morphogenesis and phenotypic stabilisation of stem cells [178]. Furthermore, cell-
cell interactions have been shown to play a critical role in tissue regeneration in vitro 
[179]. For example, high mesenchymal stem cell densities have been shown to 
induce higher chondrogenic differentiation rates due to soluble factors and to signals 
from the neighbouring cells [180, 181]. 
Numerous studies have also shown that tissue specific cells may promote and 
enhance differentiation of stem cells towards a specific lineage by promoting 
dynamic cell-cell interactions. Therefore several studies focused on co-cultures 
systems, where stem cells were cultured in direct or indirect contact with tissue 
specific cells. For example, co-culture of hepatocytes with embryonic stem cells or 
mesenchymal stem cells was shown to enhance stem cell proliferation and 
differentiation towards the hepatic lineage [182-184]. Similarly, Csaki et al 
demonstrated that primary osteoblasts co-cultured with MSCs actively made cell-cell 
contacts, which strongly promoted the proliferation of MSCs and their differentiation 
into osteoblasts [185]. This was further confirmed by the observation that high-
density co-cultures of primary osteoblasts and MSCs increased the MSC 
differentiation rate [185]. In high density co-culture systems, the expression of 
integrins (adhesion molecules that mediate cell-cell and cell-matrix interactions) is 
high, thus confirming the cell-cell communications that are taking place [185]. 
Another example is given by differentiation into neural lineage by co-culture with 
stromal cell lines or cerebellar neurons or astrocytes [186-191]. Despite co-culture 
systems have shown a great potential for the differentiation of stem cells, they still 
produce a heterogeneous population of cells, which raises the issue of the retrieval of 
the differentiated stem cells from the culture. Furthermore, they fail to induce 
terminal differentiation, suggesting that co-cultures alone might lack factors which 
are required to induce complete differentiation and therefore they are not sufficient to 
adequately replicate the complexity of the in vivo environment [192]. 
47 
 
1.8.2 Cell-matrix interactions 
 
Cell-matrix interactions also play an important role in regulating stem cell 
differentiation. Components of the ECM, such as collagen, laminin and fibronectin, 
are recognised by the transmembrane integrin receptors, and induce specific 
signalling pathways, which lead to changes in gene expression, cell growth and 
differentiation [177] (fig. 1.17). 
Biomaterials have been the most important tool so far to recreate in vitro the 
extracellular matrix and they can provide signals to the cells that are missing in 2D 
cultures. Biomaterials can provide both chemical and physical stimuli that can 
influence stem cells fates. In particular, it was found that scaffolds can promote 
embryonic and adult stem cell self-renewal [29, 193], proliferation [194] and 
differentiation [26]. MSCs cultured on agarose gels with different stiffness, for 
example, differentiated into neural, muscle, or bone lineage according to the stiffness 
of the scaffold, which closely resembled that of brain, muscle or bone respectively 
[193]. Both biologically derived and synthetic biomaterials have been investigated as 
an extracellular matrix (ECM) in regenerative medicine and tissue engineering. In 
general materials from natural sources are advantageous for stem cells adhesion and 
differentiation because of the presence of specific ECM biofunctional molecules  
recognisable by the cells [177]. Fibrin scaffolds, for example, have been shown to 
significantly improve neural and chondrogenic differentiation of ESCs [195, 196]; 
hyaluronic acid hydrogels have been shown to maintain the pluripotency and 
undifferentiated state of human ESCs and to direct their differentiation towards 
specific lineages when soluble growth factors were added [27]; alginate, a natural 
polysaccharide derived from algae walls, has also been used for stem cell culture: 
Maguire and colleagues, for example, reported that mouse ESCs encapsulated in 
alginate poly-L-lysine supported cell proliferation and differentiation into 
hepatocytes [28]; collagen has been shown to direct chondrogenesis from human 
MSCs and to sustain umbilical cord stem cells expansion, viability and hematopoietic 
function [197]; silk has also been used to differentiate MSCs into bone and cartilage 
[198]. However, issues related to natural materials, e.g. purification, immunogenicity 
and pathogen transmission have driven the design of synthetic biomaterials which 
mimic the ECM, which have gained particular interest due to their excellent 
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mechanical properties, processability and low cost [177]. The development of 
artificial ECM should enable more efficient and scalable culture of stem cells, as well 
as greater control over stem cells behaviour [177]. 
Among synthetic materials, PGA, PLA and PLGA have been shown to support ESCs 
growth and differentiation [26]. Taqvi et al have also demonstrated that mESCs 
differentiation into the hematopoietic lineage was increased by decreasing PLA 
scaffold pore size and increasing the polymer concentration [199]. Nanofibrous 
scaffolds from poly(ε-caprolactone) (PCL) have also been found to enhance both 
MSCs and ESCs proliferation and adipogenic, chondrogenic and osteogenic 
differentiation [200, 201]. Finally, poly(ethylene glycol) (PEG) hydrogels have been 
studied as scaffolds for both MSC and ESCs cultures and have been shown to 
promote chondrogenic differentiation of mESCs [202]. 
Scaffold materials have also been chemically modified in order to improve adhesion, 
proliferation and differentiation of stem cells. Incorporation or deposition of simple 
chemical modifications within/on a material offers a great potential to control stem 
cell differentiation. Scaffolds modified with methyl, amino, hydroxy and carboxy 
groups, for example, have been shown to trigger differentiation of MSCs into 
chondrocytes and osteoblasts when cultured in the appropriate medium [203]. 
However, these modifications only directed the differentiation of a limited number of 
stem cells. Emerging technologies associated with nanotopography, e.g. 
nanopatterned chemically modified surfaces, have shown promising results in terms 
of controlling initial cell responses and offer a great potential for the induction and 
control of cell functionality [203]. 
 
1.8.3 Growth factors 
 
The third type of effector on stem cell differentiation is represented by soluble factors 
(growth factors, cytokines, chemokines), which, by binding to specific cell receptors, 
can induce intracellular signalling pathways which can cause stem cells to 
differentiate into specific lineages. Different factors have been reported for their 
capacity to induce stem cell differentiation into specific lineages. The transforming 
growth factor β (TGF-β), for example, is a multifunctional growth factor involved in 
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tissue development and repair. It exists in three different isoforms (TGF-β1, 2, 3) and 
belongs to a superfamily of proteins called TGF-β superfamily. Among the proteins 
of the TGF-β superfamily, TGF-β1 and bone morphogenetic protein (BMP) are 
considered two key factors in chondrogenic differentiation [181]. It has in fact been 
reported that TGF-β1 and BMP proteins induce mesenchymal stem cells towards 
chondroblastic and osteoblastic differentiation [181, 204]. Weiss et al demonstrated 
that TGF-β1 alone can induce chondrogenesis, thus highlighting the pivotal role of 
this protein in chondrogenic differentiation, and the supportive role of other factors 
(BMPs, insulin-like growth factor 1 (IGF-1) and fibroblast growth factor (FGF)), 
which act synergistically with TGF-β in the differentiation of stem cells towards the 
chondrogenic lineage [205]. BMPs, FGFs and TGF-β are also involved in liver 
differentiation [206]. In particular, FGFs and BMPs are essential for selective 
differentiation in hepatic cells from definitive endoderm [207], and Touboul et al 
reported the induction of definitive endoderm by adding activin A, FGF-2 and BMP-
4 to cell culture medium, while the subsequent addition of FGF-10 induced the 
differentiation of the cells of the definitive endoderm into the hepatic progenitor cells 
[208]. FGF proteins have also a key role in neural differentiation [209], and this is 
confirmed by the fact that when FGF activity is disrupted, neural induction is 
inhibited [210]. The multifunctional growth factor TGF-β is also implicated in neural 
differentiation, and in particular in the development of dopaminergic neurons [211, 
212]. 
From these examples it is clear that some factors are involved in several signalling 
pathways that lead to the differentiation of stem cells into different lineages, 
therefore the accurate programming of stem cells toward a specific lineage might 
require not only the activation of some specific pathways but also the inhibition of 
other signalling pathways. Therefore there is a need for a better understanding of 
which factors maintain or induce stem cell differentiation toward a specific lineage 
during development, and in what time sequence. Indeed it was reported that when 
growth factors were delivered to the cells in a time sequence that resembled that 
occurring during the specific tissue development, the differentiation rate was higher 
compared to that of cells treated with simultaneous delivery of the same growth 
factors [181, 204, 206-208, 213]. Snykers et al. for example, reported that 
mesenchymal stem cells differentiated toward the hepatic lineage with a higher 
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efficiency when cells were exposed to liver-specific factors in a time-sequence that 
mimicked the in vivo liver embryogenesis (FGF-4 to induce endoderm, followed by 
hepatocyte growth factor (HGF), insulin-transferrin-selenium, dexamethasone and 
trichostatin A to induce liver specification), compared to those treated with a 
“cocktail” of the all factors at the same time-points [213], while  Touboul et al 
differentiated hESCs into hepatocytes using a differentiation protocol that followed 
the key stages of liver development and showed that the cells expressed some liver 
markers and displayed hepatic functions [208]. Similarly, Raiche et al. showed that 
the sequential delivery of IGF-1 and BMP to MSC cells resulted in a even more 
increased alkaline phosphatase activity and bone formation compared to 
simultaneous release [214], while Yilgor et al found a higher chondrogenic 
differentiation rate by means of sequential delivery of BMP-2 and BMP-7 to MSCs 
compared to simultaneous or individual release [215]. The sequential exposure of 
cells to growth factors seems therefore to be a successful approach for differentiation 
of stem cells as it mimics more closely the gradual and sequential process of tissue 
development that is found in nature.   
1.8.3.1 Growth factor delivery systems 
 
Once identified which growth factors are needed for directing the fate of stem cells 
toward a specific lineage, and with which time sequence, another issue arising is 
represented by the mean of delivery of the growth factors.  In most current 
differentiation protocols growth factors are supplemented directly into the cell culture 
medium at regular intervals. However, cells often need a prolonged exposure to 
growth factors in order to achieve terminal differentiation and maintain in vitro the 
specific functions of differentiated cells. Therefore other systems for growth factor 
delivery have been employed. Recent advances in tissue engineering have led to the 
development of new systems of growth factor delivery: the growth factor can be 
incorporated into the biomaterial, thus creating a scaffold releasing growth factors 
that elicit specific cellular responses, such as differentiation (fig. 1.18). Park et al, for 
example, developed a hyaluronic acid-based hydrogel scaffold containing brain-
derived neurotropic factor. The controlled delivery of the factor from the hydrogel 
facilitated the differentiation into neural lineages of mesenchymal stem cells that had 
been incorporated into the material [216]. However, hydrogel-based scaffolds have 
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limitations such as cell death in the depths of the scaffolds as well as poor 
mechanical properties [217]. For these reasons more solid scaffolds such as PLGA 
have been preferred for growth factor delivery. Sahoo et al, for example, developed 
PLGA nanofibers capable of continuous release of bFGF to direct the differentiation 
of MSCs towards the fibroblastic lineage [217]. The growth factors can also be 
encapsulated into biodegradable nano/microparticles which release them in a time-
controlled manner. PLGA nano/microparticles releasing BMP have, for example, 
been shown to enhance bone formation [218, 219]. The particles can be then 
incorporated into the biomaterial, thus creating a scaffold releasing growth factors. 
 
  
 
Fig. 1.18: Different biomaterials for growth factor delivery. A: PLGA nanoparticles 
releasing BMP  [204]; B: poly-L-lysine PEG hydrogel for neurotropic factor delivery [220]; 
C: PLGA nanofibres delivering bFGF [217]. 
 
Although these three strategies allow for the prolonged delivery of growth factors, 
biomaterials incorporate commercial growth factors, which are often expensive, 
especially if the cells need to be exposed to them for a sustained period of time. Stem 
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cells differentiated into hepatocytes, for example, started losing their characteristic 
morphology and expression of liver-specific markers after a few days [221]. 
Similarly, a loss of chondrogenic phenotypes at late stages of differentiation was 
observed [222], indicating that cells needed to be treated with the specific growth 
factors for a longer period of time. 
Furthermore, current differentiation protocols do not lead to enough cells 
differentiated: most cells are still critically limited by insufficient differentiation and 
only exhibit a progenitor phenotype [206, 207, 222]. If embryonic stem cells are 
used, there are also safety issues as they can give rise to tumors known as teratomas. 
Hence, it is critical for any therapeutic strategy employing a stem cell–based 
approach to ensure complete and irreversible differentiation of stem cells into the 
desired terminal target cell type. This could be achieved for example by extending 
the timing of differentiation protocols in order to allow a greater mass of 
differentiated cells to be produced. In contrast to artificial release of growth factors 
from biomaterials, co-culture systems would make the protein continuously available 
for the stem cells for extended periods of time and at no additional costs. The 
neighbouring cells might also provide, through cell-cell contacts, additional signals 
required for differentiation that would not occur with the delivery of exogenous 
synthetic growth factors. The co-culture system would be the strategy that mimics 
more closely nature. Co-culture systems and biomaterials-systems might lead to 
different degrees of differentiation, e.g. different phenotypes and different markers 
expression. The factors and signalling pathways regulating tissue development still 
have not been completely clarified and therefore there is a need for a deeper 
understanding of the mechanisms of tissue specification in the embryo in order to 
reproduce in vitro the steps of stem cells differentiation that occur in nature.  
 
1.8.4 Bioreactors for stem cells expansion and differentiation 
 
Another issue related to stem cell differentiation is that the number of cells that need 
to be expanded in vitro and then differentiated for clinical use is still a limitation, 
and, as a consequence, current differentiation protocols do not lead to enough cells 
for clinical use [206, 207]. This suggests that there is a need for systems that are able 
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to expand progenitor cells in order to obtain large yields of more differentiated cells 
which can remain more stable for longer periods of time. Traditional static cell 
culture systems like flasks and multi-well plates are not ideal for stem cell expansion 
as they do not provide adequate nutrient and oxygen distribution [223], and it is 
difficult to control some of the key regulatory factors of stem cells, especially shear 
stress and oxygen levels [3], which have been found to play an important role in stem 
cell proliferation and differentiation [224, 225]. In addition, static 2D systems cannot 
provide large volumes of media required for stem cells expansion.  Furthermore, 
these systems fail to reproduce in vitro the dynamic environment experienced by the 
cells in vivo. Therefore dynamic cell cultures systems need to be designed and tested 
for the in vitro expansion and maintenance of stem cells. The use of bioreactors that 
create a shear stress and provide continuous oxygenation in the culture medium 
represents an advance from static flasks as they enable a precise control of the 
cellular microenvironment. MSCs subjected to fluid perfusion, for example, showed 
an increased cell density and more uniform distribution [226] and those subjected to 
compression differentiated towards the chondrogenic lineage [61] compared to static 
cultures. Some fluid shear stress-based bioreactors have been also used with ESCs to 
study the embryoid body model and to promote differentiation toward a specific 
lineage [227-229]. 
As can be seen from these examples, substantial progress has been made in directing 
differentiation of stem cells toward lineage-specific cells. However, in order to bring 
these findings to clinical applications, large-scale robust and totally controlled culture 
systems capable of expanding and differentiating stem cells, as fast and pure as 
possible, are needed [230, 231]. Stirred suspension bioreactors have gained special 
interest for stem cell expansion, as they have been shown good results in the 
expansion of different types of stem cells and in their differentiation into pancreatic 
and neural lineages [231, 232]. However researchers have to face many challenges in 
scaling-up stem cell cultures. For example, if cells are cultured in suspension, they 
might aggregate and this would result in a limited diffusion of nutrients, growth 
factors, and gases within the aggregates [230]. Another problem is the heterogeneity 
in the culture environment due to gradients in dissolved oxygen and metabolites. 
Thus it is important to ensure that the culture is adequately mixed while limiting 
shear forces that could damage the cells [230]. The maintenance of embryonic stem 
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cells in the self-renewal state presents a further problem, as it requires growth factors 
and extracellular matrices that are very expensive. Another issue related to ESCs is 
related to the potential genetic instability of these cells through many divisions, 
which might present safety issues for clinical applications [230]. Finally, since the 
current systems to differentiate stem cells do not produce a completely homogeneous 
population of differentiated cells, monitoring the differentiation status of the cells 
during the scale-up process is another challenge, and selection processes might be 
needed in order to select the differentiated cells from the immature ones [230]. 
Ultimately, each clinical application will require a bioreactor with different 
properties in order to recreate the most suitable environment for the differentiation of 
the stem cells into a specific lineage. 
1.9 Conclusions 
 
Stem cell differentiation is a complex process that still has not been fully understood. 
The result obtained by several studies indicate soluble factors, cell-cell and cell-
matrix interactions as the most important effectors of stem cell fate. Advances in 
tissue engineering have allowed the fabrication of different scaffolds that mimic the 
natural extracellular matrix, thus allowing cell growth and proliferation, and in some 
cases, directing stem cell differentiation. Cell-cell interactions play an important role 
in stem cells differentiation and different co-culture systems have been employed to 
direct the stem cell fate toward the desired lineage. Soluble cytokines and growth 
factors have also been shown to be required for stem cell differentiation, and 
different systems of delivery to the cells have been investigated. However, for 
clinical applications, large numbers of differentiated cells are needed over time, 
requiring large amounts of costy growth factors and rising the issue of high costs. 
Finally, a dynamic microenvironment that mimics as closely as possible that found in 
vivo needs to be recreated in vitro in order to promote stem cell growth, proliferation 
and differentiation. To achieve this, different bioreactor designs have been realised, 
for the expansion and differentiation of stem cells in vitro. Although each of these 
factors have been shown to induce some degree of stem cells differentiation, the 
appropriate combination of all of them might be required in order to achieve an 
adequate stem cell expansion and a terminally differentiated cell stem cell-derived 
phenotype, for clinical applications. 
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Therefore this project aims to combine the development of a suitable bioreactor, and 
scaffold for stem cells growth and of co-culture systems for the cheap production of 
growth factors for stem cell differentiation. The next paragraph will describe in 
further details the aims and objectives of the project. 
 
1.10   Aims and objectives  
 
The major aim of this project is to develop a suitable bioreactor to enable the co-
culture of cells in order to direct stem cell differentiation. Several aspects of the 
system need to be considered in order to achieve the goals of the project. In the first 
place, the type of bioreactor that will be used for the optimal growth of stem cells and 
the appropriate mass transfer of nutrients must be selected. It is known that hollow 
fibres offer a greater surface area to volume ratio for the culture of higher cell 
numbers compared to flat sheets and also act as a barrier between the cells and the 
medium that flows inside the lumen of the fibre, thus allowing high flow rates with 
no risk of cell damage due to mechanical forces caused by the flow [92]. Therefore 
the hollow fibre bioreactor was selected for the purposes of this project. The system 
that this project aims to realise is represented in fig. 1.19.  Stem cells are seeded on 
the outer surface of the hollow fibre, and medium containing growth factors is 
continuously circulated inside the lumen of the fibre. Because the fibre is porous, the 
growth factors can permeate through the pores of the membrane and differentiate the 
stem cells. 
 
                     
Fig. 1.19: Schematic representation of the system that this project aims to realise: stem cells 
are seeded on the outer surface of a PLGA hollow fibre membrane and medium containing 
specific growth factors is continuosly circulated inside the lumen of the fibre. Growth factors 
permeate across the pores of the fibre thus reaching the stem cells and causing their 
differentiation. 
Stem cells Differentiated cells 
Medium with 
growth 
factors 
Medium out 
Hollow fibre 
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When considering this system, the next aspect that should be investigated concerns 
the choice of the material from which to fabricate hollow fibres. The synthetic 
polymer PLGA has been widely used in tissue engineering as it is biocompatible, 
biodegradable and FDA approved [80]. For these reasons, PLGA was selected for 
this project. However, despite these advantages, PLGA presents a major issue: its 
hydrophobic character makes the membrane poorly wettable by water and aqueous 
solutions e.g.. cell culture medium, thus reducing cell adhesion and transfer of 
nutrients across the membrane, which is extremely important for appropriate in vitro 
tissue reconstruction [128]. Therefore strategies to improve hydrophilicity of PLGA 
need to be investigated.  
The last part of the project will focus on the differentiation of stem cells by means of 
growth factors and co-culture systems. Growth factors are among the most important 
effectors in stem cell differentiation. However, the use of commercial growth factors 
would imply high costs as large quantities of protein would be required for the 
differentiation of the stem cells and for the maintenance of their differentiated state. 
Therefore, a system for the continuous and inexpensive production of growth factors 
needs to be investigated. Cells can release proteins into the cell culture medium, 
either spontaneously or when engineered to do so. Therefore a cell line capable of 
releasing one or more growth factors at the concentrations needed for stem cell 
differentiation and that is stable in dynamic culture systems must be selected. In this 
way, a growth factor-secreting “cell factory” would be developed, which would 
continuously provide the growth factors to the cells within the system, thus reducing 
the cost of the experiment.  
Finally, In order to explore a clinically relevant application of the system, the 
differentiation of stem cells into one specific cell type must be investigated. Liver 
disease is one of the big killers in the world and tissue engineering might offer a valid 
therapy to overcome the issues related to liver transplantation. Therefore the hollow 
fibre bioreactor system will be tested for a potential application in liver tissue 
engineering. A cell line capable of releasing liver specific growth factors that can 
permeate across the pores of the hollow fibre membranes and differentiate the stem 
cells into hepatocytes needs to be selected.  
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In summary, this research aims to: 
 
 Improve the hydrophilicity of PLGA 
 Develop a bioreactor system that allows optimal stem cell growth and transfer 
of nutrients 
 Develop a system for the continuous and inexpensive production of growth 
factors 
 Develop a system for the differentiation of stem cells by means of growth 
factors and co-cultures 
 Differentiate stem cells into hepatocytes by means of liver-specific growth 
factors and co-culture systems as a potential application 
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2. Materials and methods 
2.1     Materials 
 
All materials were purchased from Sigma Aldrich, except from those listed in the 
following table: 
MATERIAL COMPANY 
PLGA, Resomer RG 756S Boehringer Ingelheim 
NMP Acros Organics 
Compressed nitrogen gas BOC Gases 
HL60 cells ECACC 
Vybrant CFDA SE Cell Tracer Kit Invitrogen 
Quant-iT™ Pico Green dsDNA quantitation assay kit Invitrogen 
HGF ELISA Development system kit R&D Systems 
Sodium Pyruvate Gibco 
FGF-4 Peprotech 
HGF R&D Systems 
Blocking reagent for immunostaining Roche 
Goat anti-rat transferrin antibody Insight Biotechnology 
Sheep anti-rat albumin antibody AbD Serotech 
Sheep anti-rat UGT antibody Cypex 
Fluorescein anti-sheep IgG Vector Laboratories 
Fluorescein anti-goat IgG Vector Laboratories 
99% Isopropanol Fisher Scientific 
Haematoxylin stain Fisher Scientific 
 
 
59 
 
2.2      Membrane preparation  
 
The polymer used to fabricate the membranes was poly (lactic-co-glycolic) acid 
(PLGA) with 75:25 lactide-glycolide ratio. 
The process of membrane preparation can be divided into two steps: 1) polymer 
solution preparation and 2) membrane fabrication. 
2.2.1 Polymer solution preparation 
 
Polymer solutions were prepared from PLGA blended with polyvinyl alcohol (PVA) 
(0, 1.25, 2.5, 5% w/w) by dissolution in N-methyl-2-pyrrolidinone at a total polymer 
concentration of 20% w/w. The mixture was placed on a roller mixer (SRT9D, Bibby 
Stuart, UK) and left under ambient conditions (8-20°C) overnight, to ensure complete 
dissolution. 
2.2.2 Flat sheet fabrication 
 
Flat sheet membranes were fabricated by the phase inversion method. 2-3 ml of 
polymer solution were cast over the surface of a flat glass plate (10 cm x 15 cm) with 
a 1 cm diameter glass pipette kept at a height of 200 μm from the plate using 200 μm 
wire wrapped around it. The plate was then submerged in deionised water (non-
solvent) at 10-20º C for a few minutes to allow the phase-inversion process to take 
place. The resulting membrane could then be peeled from the surface of the plate and 
was soaked in water for 3 days. The water was changed twice a day for solvent 
removal. The membranes were then left to dry in ambient conditions for at least 24 h 
prior to use. 
2.2.3 Hollow fibre fabrication 
 
Polymer solutions were degassed under a vacuum for 1 hour to remove air bubbles 
and then extruded through a double-orifice spinneret to produce hollow fibre 
membranes through a process called wet-spinning, using the method optimised by 
Shearer [233]. A schematic representation of the spinneret and of the spinning 
apparatus used to fabricate the fibres can be seen in fig 2.1 and 2.2, respectively. It 
consists of a spinneret, three water tanks and motorized rollers. The first two tanks 
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(coagulation bath and wash bath) were filled with tap water (non-solvent) and the 
temperature of the coagulation bath set at 25º C. After setting up the spinning rig, the 
polymer solution was pumped through the spinneret outer annulus (1.0 mm outer 
diameter, bore 0.7 mm inner diameter) while distilled water was extruded through the 
inner orifice (inner diameter 0.4 mm) at a flow rate of 200 ml/h. As soon as the 
polymer solution contacted the water from the spinneret it precipitated forming a 
fibre. The newly formed hollow fibre was collected by a roller located at the bottom 
of the first tank (the coagulation bath) to ensure that the fibre dropped vertically. The 
fibre was fed through the other rollers and washed in the second tank and finally 
collected in the last tank, where it was left for 24h before drying in ambient 
conditions (10-20°C).  
 
 
Fig. 2.1: Picture and schematic representation of the double orifice spinneret. Adapted from 
Shearer H., 2007 [233]. 
Flow of water 
Flow of polymer 
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Fig. 2.2: Representation of the spinning apparatus. Distilled water and polymer solution were 
pumped by means of two different syringe pumps through the orifice of a spinneret. The 
hollow fibre formed by precipitation was collected in the first tank and then transferred by 
means of motorised rollers to a second tank and finally collected in a third tank and left for 
24 h prior to drying. From Shearer H., 2007 [233]. 
 
2.3 Treatment of hollow fibre membranes with sodium 
hypochlorite 
 
Fibres were incubated for 24 hours in 5% v/v sodium hypochlorite (NaOCl) or in 
distilled water at 37° C in order to study the effect of NaOCl on the morphology, 
hydrophilicity, permeability and mechanical properties of the fibres. After 24 hrs the 
fibres were washed for one hour with distilled water to remove any residual NaOCl. 
2.4 Membrane characterization 
2.4.1  Morphological analysis 
 
Morphological analysis of the membranes was conducted using scanning electron 
microscopy (SEM). Hollow fibres were cut into pieces of approximately 5 mm in 
length. The membranes were sputter coated with gold (Edwards Sputter Coater 
5150B) and subsequently analyzed by SEM (JEOL JSM-6480LV) with an 
acceleration voltage of 15 kV at the Centre for Electron Optical Studies (CEOS), 
University of Bath. Images of the inner and outer surfaces and of cross-sections of 
hollow fibre membranes were obtained.  
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2.4.2 Mean pore size and porosity  
 
Mean pore size and overall porosity of hollow fibre membranes were determined by 
gas permeation using a single-fibre dead-end module with purified nitrogen (BOC, 
UK) as the test gas. A schematic representation of the gas permeation module and 
apparatus used can be seen in fig. 2.3.  A 12 cm long hollow fibre was glued into a 10 
cm x 6 mm stainless-steel tube with epoxy resin. The excess length was trimmed, and 
at one end the lumen of the fibre was sealed while at the other end the shell side was 
sealed. The module was connected to a bubble-meter and nitrogen gas was passed 
into the module through the lumen, exiting through the fibre wall at a range of flow 
rates between 2 l/min and 6 l/min and the corresponding air pressures measured. The 
time required by the soap bubble inside the bubble-meter to reach 100 ml was 
recorded and the volumetric flow rate of gas flowing through the fibre calculated 
with equation 2.1:  
                                                       
t
V
Q                                              (2.1) 
where Q = volumetric gas flow rate (m
3
s
-1
), V= volume of gas timed (0.1 m
3
), t = 
time taken (s).  
The volumetric gas flow rate was then converted into molar gas flow rate with 
equation 2.2:  
                                             
RT
QP
N out                                         (2.2) 
Where N= molar gas flow rate (mol s
-1
), Pout is the atmospheric pressure (1 x 10
5 
Pa), 
R the molar gas constant (8.31 J mol
-1
 k
-1
), T = temperature (298 K). 
The gas permeability was then calculated using equation 2.3: 
                                                  
inAP
N
J                                        (2.3) 
Where J = gas permeability (mol s
-1 
Pa
-1
m
-2
), A = membrane surface area (m
2
), Pin = 
pressure inside the fibre (Pa). 
Also, the mean pressure across the fibre P was calculated as: 
                                          
2
outin PPP

                                    (2.4) 
The gas permeability J values were then plotted against mean pressures P values 
across the fibre, thus obtaining the equation y = P0x + K0. The values of P0 and K0 
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obtained from the equation, were used to calculate the mean pore diameter using the 
method described by Li et al. [234] with the mean pore radius being calculated using 
equation 2.5:  

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where r = pore radius (m), P0 = gradient of flux versus mean pressure plot (mol m
−2
 
Pa
−1
 s
−1
), K0= intercept of flux versus mean pressure plot (mol m
−2
 s
−1
), R = 
Universal Gas Constant (8.314 JK
−1
 mol
−1
), MN2= molar mass of nitrogen (kg mol
−1
) 
and μ = viscosity of nitrogen (Pa s). 
Overall porosity was calculated with the following formula (equation 2.6): 
       

p 1
 polymer
 fibre
                                            (2.6) 
where εp = porosity, ν polymer = specific volume of the polymer, (m
3
 kg
−1
) and ν fibre = 
specific volume of the fibre (m
3
 kg
−1
). 
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(A) 
 
 
 
 
(B) 
 
Fig. 2.3: Schematic representation of the gas permeation module (A) and apparatus ((B) used 
to determine the mean pore size of the fibres. Nitrogen gas flowed inside the lumen of the 
hollow fibre from the sealed shell end, while the other end of the fibre was sealed so that all 
the gas collected in the bubble meter had perfused through the wall of the fibre. 
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2.4.3 Mechanical properties 
 
The mechanical properties of PLGA and PVA-PLGA hollow fibre membranes were 
tested with a mechanical test rig (Instron 3367 with 10N loadcell running Bluehill 
software). The membranes were cut in pieces of 6 cm in length and clipped into a 
grip attached to the Instron machine. A crosshead speed of 2 mm/min was set and the 
stress-strain curves were obtained from the samples. From the stress-strain curves 
Young’s modulus (E) was calculated at the elastic limit using the following formula 
(equation 2.7):  
                                    
LA
FL
E


0
0


                                             (2.7) 
where σ = stress (MPa), ε = strain, F = force applied to the membrane (N), A0 = 
cross-sectional area of the membrane (m
2
), ΔL = change in length (m) and L0 = 
original length of the sample (m). 
When a fluid was circulated inside the lumen of the hollow fibre, the membrane was 
subjected to an internal pressure, therefore the hoop stress, i.e. the stress acting in the 
circumference of the cylinder wall, should be considered in the calculation of the 
Young’s modulus. 
The hoop stress is expressed as:  
                                         
A
S
                                                      (2.8) 
where σ = hoop stress, S= circumferential hoop tension (N), A = cross sectional area 
of the membrane (m
2
). 
More specifically, the hoop stress in hollow fibre with membrane thickness  > than 
1/10
th
  of the internal radius ri is given by the equation 2.9: 
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where pi = internal pressure in the hollow fibre, po= external pressure, ri= hollow 
fibre internal radius, ro= hollow fibre external radius, r = the radial variable. 
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2.4.4 Hydrophilicity 
 
The contact angle method was used to evaluate the hydrophilicity of PLGA and 
PVA-PLGA flat sheet membranes. A schematic representation of the method is 
displayed in fig. 2.4. Drops of purified water (3 μl) were deposited onto the top side 
of 5 cm x 1 cm membranes positioned on the stage of a bench-type contact angle 
goniometer (NRL Goniometer Model 100-00), ensuring that the membrane was 
completely flat. Measurements were repeated at different positions on the flat sheet.  
Since hydrophobic materials are not easily wetted by water, in order to confirm the 
results obtained by contact angle measurements, the flat sheets were also placed in 
water to see whether they floated or sank. 
 
Fig. 2.4: Schematic representation of the contact angle method. A drop of water is deposited 
on the surface of the membrane. In a hydrophilic membrane the drop of water will easily 
spread out on the surface and the material will have a lower contact angle (θ). On the 
contrary a hydrophobic membrane is not easily wetted by water and the contact angle for that 
material will be higher, as the drop cannot easily spread out on the surface of the material. 
 
2.4.5 Hydraulic and protein permeability: the single fibre hollow 
fibre bioreactor 
 
In order to evaluate the permeability of the hollow fibre membranes to water and of 
bovine serum albumin (BSA), a single hollow fibre bioreactor module was used. 
Being an important component of serum, BSA was used as a model protein for the 
study of the permeability of the hollow fibre membranes to proteins.   
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Medium  
in 
2.4.5.1 Single fibre bioreactor setup 
 
The bioreactor consisted of a borosilicate glass tube of 10 cm in length, 4 mm outer 
diameter and 2.4 mm inner diameter, with 2 side ports at a distance of 2 cm from the 
extremes of the bioreactor. A single fibre hollow fibre membrane (10 cm length) was 
inserted into the bioreactor, glued with silicone (or epoxy resin for experiments with 
cells) at the ends and left to dry overnight, so that the working length was 6 cm. A 
schematic representation of the module used in the project can be seen in fig. 2.5. 
This system intends to reproduce the concept of the Krogh’s cylinder, which implies 
that organs are composed of many microcirculatory functional units (the Krogh’s 
cylinders) organised in parallel and perfused by capillaries with each section of a 
capillary responsible for the supply to a corresponding cylindrical section of 
surrounding tissue. When this principle is applied to hollow fibre bioreactors, the 
entire hollow fibre bundle in the bioreactor can be described by one fibre surrounded 
by an annulus representing the extracapillary space (fig. 2.6). This approach assumes 
that all the fibres are identical in terms of properties and internal flow, perfectly 
straight and equally spaced.  The interstitial spaces between adjacent Krogh’s 
cylinders are ignored.  
In the single fibre bioreactor flow was achieved using a peristaltic pump (Masterflex 
L/S™ model 7519-06) and two stop tubings (Masterflex Santoprene tubing, 2.06 mm 
internal diameter, Cole Parmer). Mean transmembrane pressure was controlled by a 
digital pressure transducer at the inlet and outlet of the bioreactor.  
 
 
Fig. 2.5: Picture of the single fibre hollow fibre bioreactor module: it consists of a 10 cm 
long borosilicate glass tube with two side ports, one inlet for the flow of the medium inside 
the device, and of one outlet for the flow of the medium outside the device. One hollow fibre 
is inserted inside and glued at the side ports. 
Media 
out 
Side 
port 
Hollow fibre 
2 cm 
2 cm 
10  cm 
Silicone 
glue  
68 
 
 
 
Fig. 2.6: The Krogh’s cylinder model: the entire bundle of fibres can be described as one 
fibre surrounded by an annulus representing the extracapillary space. 
 
2.4.5.2 Permeability experiments 
 
Hollow fibre membranes were washed with either 5% NaOCl v/v or distilled water 
prior to permeability experiments. Distilled water was circulated for 24 hours through 
the lumen of the fibre and in the extra capillary space prior to the experiments to 
ensure both the inner and outer surfaces were completely wetted. In contrast, when 
sodium hypochlorite was used to wash the membrane, 5% NaOCl v/v solution was 
circulated for one hour in the lumen of the fibre and in the extra capillary space in 
order to open the pores of the membrane and subsequently the inner and outer surface 
of the fibre were washed with distilled water for 30 minutes in order to remove any 
NaOCl residual.  
Fresh distilled water was subsequently circulated for seven hours through the lumen 
of the hollow fibre at a flow rate of 2.5 ml/min. Water permeate was collected from 
one side port (the other was closed) every hour and permeate flow rate measured, 
while retentate was collected from the lumen outlet (fig. 2.7). Permeate volume was 
used to calculate the volumetric water flux (J; equation 2.10) and the hydraulic 
permeability (LP; equation 2.11): 
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Extracapillary space 
Hollow 
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tA
V
J
P
                                     (2.10) 
                                     
P
J
Lp

                                      (2.11) 
where V= volume of permeate collected (l), t = time (h), A = membrane surface area 
(m
2
), ∆P = transmembrane pressure (Pa) 
BSA solution (100 μg/ml in PBS; MW = 66,430 Da) was pumped through the lumen 
of the fibre at a flow rate of 2.5 ml/min. The system was allowed to reach steady state 
for 2 hours and then run for a further two hours, during which time samples were 
collected every 20 minutes. Permeate samples were collected from a side port and the 
retentate was collected from the lumen outlet. Samples were also taken from the feed 
bottle. BSA concentration was determined according to the method of Bradford [235] 
with absorbance read at 595 nm using a UV plate reader (Synergy™ HT Multi-
detection Microplate reader, running Microplate Data collection and analysis 
software Gen5™). 
 
Fig. 2.7: Schematic representation of the module used in the permeation experiments. Water 
or BSA solution were pumped from a feed bottle through the lumen of the membrane inside 
the bioreactor, and collected in the permeate. The water or BSA solution that did not 
permeate through the membrane but exited the outlet of the bioreactor was collected in the 
retentate bottle. 
 
2.5 Determination of Reynolds number (Re) and shear stress 
 
Distilled water was circulated by means of a peristaltic pump (Masterflex L/S™ 
model 7519-06) inside the lumen of the hollow fibre, inserted into a single fibre 
hollow fibre bioreactor module at increasing flow rates, from 0.8 to 5 ml/min and the 
Feed bottle 
Peristaltic pump 
Pressure gauge 
Bioreactor 
Permeate 
Pressure gauge 
   retentate 
Port closed 
fibre 
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difference in pressure between inlet and outlet was measured with a digital pressure 
transducer.  
Reynolds number, which tells whether the flow is laminar (for Re < 2100) or 
turbulent (for Re > 2100), was calculated with the following formula (equation 2.12):  
                                            

vd
Re                                            (2.12) 
Shear stress (τ) at the walls of the pipe was calculated with the following formula 
(equation 2.13): 
                                               
d
v

8
                                            (2.13) 
where d = hollow fibre diameter (m), v = fluid mean velocity (m/s), ρ = fluid density 
(kg/m
3
), μ = fluid viscosity (Pa s). 
 
2.6 Static cell cultures  
 
Cell culture was performed according to good cell culture practice, under aseptic 
conditions and within a category II laminar flow containment hood (Kendro 
Laboratory Products Plc, Hertfordshire, UK). All reagents used for cell cultures were 
pre-warmed to 37° C before use. 
 
2.6.1 HL60 cell culture  
 
HL60 human promyelocytic leukemia cells were thawed and resuspended in a 25 cm
2 
flask at a density of 3-5 x 10
5
 cells/ml in RPMI-1640 medium containing 20% v/v 
foetal calf serum (FCS) and maintained in a humidified environment at 37°C and 5% 
CO2 . Cells were counted daily with a haemocytometer to check their proliferation. 
Once they had reached the appropriate cell density, cells were centrifuged at 1000 
rpm for 5 minutes, the supernatant aspirated and the pellet resuspended at a 
concentration of 3 x 10
5 
cells/ml in RPMI-1640 medium with 10% FCS v/v and 
maintained in a humidified environment at 37° C and 5% CO2. Medium was changed 
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three times a week and cells were counted twice a week to check that their number 
did not exceed 1 x 106 cells/ml, which may cause their spontaneous differentiation 
into mature myelocytes (monocytes, macrophage-like cells, eosinophils, or 
granulocytes) [236]. 
 
2.6.2 MG63 cell culture  
 
MG63 human osteosarcoma cells were thawed and resuspended in a 75 cm
2 
cell 
culture flask  at a density of 1 x 10
4
 cells/cm
2
 in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% v/v foetal calf serum (FCS), 1% v/v sodium 
pyruvate, 1% v/v non essential amino acids and 1% v/v antibiotic-antimicotic 
solution. Cells were maintained in a humidified environment at 37° C and 5% CO2 
and medium was replaced every 2-3 days. When cells reached confluence, they were 
washed with 10 ml of PBS and subsequently incubated with 3 ml of 1% v/v trypsin-
EDTA at 37° C and 5% CO2 in order to release the cells from the surface. Once all 
the cells were detached from the surface (cells were examined at the microscope to 
ensure that they were all floating) 6 ml of complete medium was added in order to 
inactivate the trypsin and cells were centrifuged at 1,200 rpm for 5 minutes. The 
supernatant was discarded and the cell pellet was resuspended in 2 ml of fresh 
medium. Cells were then plated at a concentration of 1 x 10
4
 cells/cm
2
 and 
maintained at 37° C and 5% CO2.  
2.6.3 Isolation and culture of rat mesenchymal stem cells (rMSCs) 
 
Mesenchymal stem cells were isolated from the femur and tibia bone marrow of 2 
month old Wistar rats using the method described by Cho et al [237]. The femur and 
tibia were removed and skin and muscles surrounding the bones were carefully 
removed. The bones were placed in 50 ml of sterile minimum essential Eagle’s 
medium, alpha-modification (α-MEM). The epiphyses of the bones were removed, a 
hole was created in the knee joint end of each bone and a syringe full of PBS was 
used to flush out the marrow from the bones. The collected marrow was suspended in 
PBS in order to eliminate the blood and centrifuged at 400 g for 5 minutes. The 
resulting pellet was resuspended in α-MEM with 10% v/v FCS, 1% v/v antibiotic-
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antimicotic solution and 1% v/v 200 mM L-Glutamine and incubated overnight in a 
25 cm
2
 culture flask (NUNC) at 37° C with 95% humidity and 5% CO2. The 
following day the medium was removed in order to discard the non-adherent cells 
and it was replaced with fresh medium. When the cells had reached 80% confluence, 
they were washed twice with PBS and subsequently 1 ml of 0.25% v/v trypsin-EDTA 
was added and the flask was left at 37° C and 5% CO2 for about 1 minute in order to 
release the cells from the surface. Once all the cells were detached from the surface 
(cells were examined at the microscope to ensure that they were all floating) they 
were resuspended in 6 ml of complete medium in order to inactivate the trypsin and 
centrifuged at 1,200 rpm for 10 minutes. The supernatant was discarded and the cell 
pellet was resuspended in 2 ml of fresh medium. Cells were then plated at a 
concentration of 5 x 10
3
 cells/cm
2
 and maintained at 37° C and 5% CO2. Cells were 
used only at low passages, usually passage 2 or 3, in order to limit their spontaneous 
differentiation. 
 
2.7 Dynamic cell cultures  
 
2.7.1 HL60 culture in the single fibre hollow fibre bioreactor 
 
All bioreactor components were autoclaved at 1 bar and 120º C for 20 minutes. The 
75:25 PLGA hollow fibre was sterilized by soaking in penicillin-streptomycin 
solution (1% in PBS) overnight. The following day, the lumen of the fibre was 
sterilized by injecting into it the antibiotic solution with a 2 ml syringe. Inside the 
culture hood the ends of the single fibre bioreactor were glued and the antibiotic 
solution injected into the side ports of the bioreactor and left overnight in order to 
sterilize the extracapillary space of the bioreactor. The following day the antibiotic 
solution was pumped through the lumen of the hollow fibre with a peristaltic pump 
(Masterflex L/S™ model 7519-06) continuously for 24 hours at a flow rate of 2 
ml/min in the cold room. RPMI 1640 medium was then pumped for a few minutes 
through the fibre to wash away the antibiotic solution. A schematic representation of 
the system can be seen in fig. 2.8. HL60 cells were prepared as described in section 
2.6.1 and 20 ml of cells at a density of 3 x 10
5
 cells/ml were continuously circulated 
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by means of a peristaltic pump through the lumen of the fibre for 48 hours at a flow 
rate of 2 ml/min or 4 ml/min. Samples of 1 ml of cell suspension were collected 
every 24 hours from the feed bottle for analysis and compared with the results 
obtained from cultures of HL60 cells grown in static flasks for the same period of 
time (controls). 
 
Fig. 2.8: System used to culture HL60 cells in a dynamic environment. Cells were pumped 
from a feed bottle into the lumen of a PLGA hollow fibre inserted into a single fibre 
bioreactor by means of a peristaltic pump and recycled into the same bottle. 
 
2.7.2 Analysis of HL60 proliferation in the single fibre hollow fibre 
bioreactor 
 
Analysis of HL60 proliferation within the single fibre bioreactor was carried out 
using the MTT cell proliferation test [238]. Samples of 1 ml of HL60 cells in RPMI 
medium were collected from the feed bottle of the system described in fig. 2.8  and 
100 μl of HL60 cells were added in triplicate to each well of of a 96-well plate. 20 µl 
of MTT solution (2mg/ ml in PBS) were subsequently added to each well and the 
plate was incubated for 3 hours at 37°C and 5% CO2. Plates were then centrifuged, 
the supernatant removed and 100 μl of dimethyl sulfoxide were added to each well. 
The plate was shaken for 30 minutes and the absorbance was read with a UV plate 
reader (Versa Max Microplate Reader, software Soft Max Pro) at a wavelength of 
540 nm from which were subtracted the readings at 690 nm (background) for more 
accurate results. Results were compared with a standard curve of absorbance versus 
metabolically active cells and the number of metabolically active cells calculated 
(cells/ml). The absorbance measured was then divided by the viable cell number per 
well in order to obtain the absorbance per cell and have more comparable results. 
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Bioreactor 
Pressure gauge 
Port closed 
Port closed 
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The viability of the cells inside the bioreactor was assessed by the Trypan Blue 
method. 100 μl of Trypan Blue solution were added to 100 μl of cells, and 10 μl of 
this combined solution were placed into the chamber of a haemocytometer. Live 
(unstained) and dead (blue stained) cells were counted. 
2.8 Cell seeding and attachment on PLGA and 5% PVA-PLGA flat 
sheet membranes 
2.8.1 Seeding of MG63s and rMSCs  
 
Flat sheets were sterilised prior to seeding with 5% antibiotic-antimicotic solution 
overnight at 4° C. The following day the membranes were cut into small circles of 
approximately the same area of the well (culture area 1.9 cm
2
) and inserted into the 
wells of a 24 well plate. A silicon ring (1.48 cm internal diameter) was inserted on 
the top of the membrane in each well in order to keep the membrane at the bottom of 
the well. The membranes were then left in 5% antibiotic-antimicotic solution for one 
hour and subsequently washed with PBS. MG63s or rMSCs, cultured as described in 
section 2.6.3, were seeded on the top of membranes at a density of 5,000 cells/cm
2 
for 
rMSCs and 10,000 cells/cm
2 for MG63s in a volume of 500 μl. The plates were then 
incubated at 37° C and 5% CO2 for 4 days. Medium was changed at day 2 and 
samples of membranes with cells attached were removed every 24 hours for analysis. 
The analysis of cell attachment and proliferation on the two different types of 
membranes was compared with the attachment and proliferation of cells on plastic 
(control). 
 
2.8.2 Qualitative analysis of cell attachment: live staining 
 
Qualitative analysis of cell attachment was conducted by means of a live staining 
technique, using the Vybrant CFDA SE Cell Tracer kit. Carboxy-fluorescein 
diacetate, succinimidyl ester (CFDA SE) passively diffuses into the cells and its 
succinimidyl ester group reacts with intracellular amines, forming fluorescent 
conjugates. 
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Medium was removed from the wells and replaced by 500 μl of CFDA SE (5 μM 
solution in PBS). The cells were incubated at 37° C and 5% CO2 for 15 minutes and 
subsequently washed with PBS. Cells were then incubated for 30 minutes with fresh 
complete medium at 37°C and 5% CO2. Cells were then washed with PBS and fixed 
for 20 minutes with 10% v/v formalin solution. After fixation cells were washed 
twice with PBS and stored at 4° C prior to analysis. Analysis of morphology, 
attachment and distribution of the cells on the membranes was conducted using 
fluorescence microscopy (Leica DMI 4000B). 
 
2.8.3 Quantitative analysis of cell attachment: Pico Green assay 
 
A Quant-iT
™
 Pico Green
®
 dsDNA Quantitation Assay Kit was used to determine the 
number of cells on PLGA and 5% PVA-PLGA flat sheets. Pico Green
®
 dsDNA 
reagent is a fluorescent acid stain which quantifies double-stranded DNA in solution. 
Medium was removed from the wells and cells were washed with PBS then 
incubated overnight at -80° C with 1 X TE buffer (10mM Tris-HCl, 1mM EDTA; pH 
7.5) in molecular grade water in order to detach the cells from the membranes and 
lyse them. For the analysis, 100 μl of each sample were added to wells of a 96 well 
plate, three repeats being performed for each sample. In addition, DNA calibration 
was carried out using known concentrations of DNA in the range 0-2 μg/ml. 100 μl 
of Pico Green working solution diluted 200X in TE buffer was added to each well 
and the plate was read immediately with a fluorescent plate reader (Synergy™ HT 
Multi-detection Microplate reader, running Microplate Data collection and analysis 
software Gen5™, Biotek) with excitation wavelength set at 485 nm and emission 
wavelength at 530 nm.  
2.9 Secretion of Hepatocyte Growth Factor (HGF) by HL60 and 
MG63 cell lines 
 
2.9.1 Stimulation of HL60s to secrete HGF 
 
HL60s were stimulated to secrete HGF by treatment with 12-O-
tetradecanoylphorbol-13-acetate (TPA) or dibutyryl cyclic adenosine-monophosphate 
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(dbcAMP) as shown by Inaba and colleagues [239] or heparin, as shown by 
Matsumoto and colleagues [240]. 
HL60s (1 x 10
6 
cells/ml) were treated with either DMSO, TPA (1 ng/ml), dbcAMP 
(100 nM in sterile water) or heparin (1 μg/ml in sterile water) or with a combination 
of the four and incubated for four days at 37° C and 5% CO2. After this time the cells 
were centrifuged at 1000 rpm for 5 min and the supernatants collected and stored at -
80° C prior to analysis. Cells treated with the compounds were compared with 
untreated cells, to see whether the addition of the chemicals had any effect on the 
increase of the amount of HGF secreted.  
 
2.9.2 Secretion of HGF by MG63s 
 
MG63s were seeded at density of 1 x 10
4
 cells/ml in 24 well plates and incubated for 
three days at 37°C and 5% CO2. After three day incubation the supernatants were 
collected from the cells and stored at -80° C for the analysis.  
 
2.9.3 Quantification of HGF secretion by HL60 or MG63 cells 
 
HGF secreted by MG63s or HL60s was quantified using a human HGF DuoSet
®
 
ELISA (Enzyme-Linked ImmunoSorbent Assay) Development System kit. A 
polystyrene 96 immuno-microwell plate (NUNC) was coated with 100 μl per well of 
mouse anti-human HGF capture antibody at a concentration of 1 μg/ml and the plate 
was sealed and incubated overnight at room temperature. The following day the 
solution was aspirated from every well and the plate was washed three times with 
0.05% v/v Tween
®
 20 in PBS (wash buffer). 200 μl of 1% w/v BSA in PBS were 
added to each well and the plate was incubated at room temperature for one hour. 
The plate was washed three times with wash buffer, and 100 μl of samples or 
standards (serial dilutions of recombinant human HGF, 0-10 ng/ml) were added to 
each well and the plate was sealed and incubated for two hours at room temperature. 
The plate was washed three times with wash buffer, and 100 μl of biotinylated goat 
anti-human HGF detection antibody (200 ng/ml in 1% w/v BSA in PBS) were added 
to each well and the plate was sealed and incubated for two hours at room 
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temperature. The plate was washed three times with wash buffer, and 100 μl of 
Streptadividin conjugated to horseradish-peroxidase (diluted 1:200 in 1% w/v BSA in 
PBS) were added to each well and incubated for 20 minutes in the dark at room 
temperature. The plate was washed three times with wash buffer, and 100 μl of 
3,3’,5,5’ tetramethylbenzidine were added to each well and incubated for 20 minutes 
in the dark at room temperature. 100 μl of 2N H2SO4 (stop solution) were added to 
each well and the optical density was determined immediately, using a microplate 
reader (Synergy™ HT Multi-detection Microplate reader, running Microplate Data 
collection and analysis software Gen5™, Biotek) with wavelength set at 450 nm and 
wavelength correction set at 540 nm. 
 
2.9.4 Comparison of commercial and MG63s derived HGF in static 
and dynamic environment 
 
Commercial HGF (recombinant human HGF, MW= 60-70 kDa) at initial 
concentration 2 ng/ml in DMEM + 10% FCS  and HGF released by MG63 cells 
(diluted in order to obtain a concentration of 2 ng/ml) were placed in separate glass 
bottles and incubated for 3 hours at 37° C and 5% CO2. Samples were collected from 
each bottle every 30 minutes and stored at -80° C until analysis. In order to compare 
samples in a static environment to those in a dynamic environment, commercial and 
MG63-derived HGF were also circulated inside platinum-cured silicone tubing 
(internal diameter 2.4 mm, Cole Parmer) by means of a peristaltic pump in a closed 
recycling system at 37° C and 5% CO2. Samples were taken every 30 minutes from 
the feed bottle and stored at -80° C until analysis. For the analysis samples were 
thawed at 37° C and the amount of HGF present in the samples was quantified by an 
HGF ELISA kit as described in section 2.9.3. 
 
2.9.5 Permeation of MG63-derived HGF through 5% PVA-PLGA 
hollow fibre membranes 
 
In order to evaluate the permeability of the hollow fibre membranes to hHGF, a 5% 
PVA-PLGA single fibre hollow fibre bioreactor module was used. A description of 
the bioreactor system can be seen in section 2.4.5.2. HGF released by MG63 (initial 
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concentration 8 ng/ml in DMEM + 10% v/v FCS + 1% v/v sodium pyruvate + 1% 
v/v non essential aminoacids + 1% v/v antibiotic-antimycotic solution) was circulated 
through the lumen of the fibre at a flow rate of 2.5 ml/min, the system was allowed to 
reach steady state and then run for three hours, during which time samples were 
collected every 10 minutes. Permeate samples were collected from a side port and the 
retentate was collected from the lumen outlet. For a schematic representation of the 
system see fig. 2.7. Samples were also taken from the feed bottle. Samples were 
stored at -80° C until analysis. HGF concentration was determined with an ELISA kit 
as described in section 2.9.3. 
 
2.10 Hepatic differentiation of rat mesenchymal stem cells  
 
2.10.1  Analysis of stem cells markers 
 
The presence of two positive MSC surface markers (CD44 and CD90) and absence 
of a negative MSC marker (CD45) was assessed by flow cytometry in order to check 
the purity of MSCs. 
Rat MSCs were trypsinised, pelleted, resuspended in 0.1% BSA in PBS (incubation 
buffer) and divided between 1.5 ml eppendorf tubes. A minimum of 30,000 cells per 
surface marker were used for the experiment. Cells were centrifuged at 1200 rpm for 
10 minutes, the supernatant was aspirated and cells were incubated for 30 minutes in 
ice with 50 μl of primary antibody (dilution 1:5 in incubation buffer). The primary 
antibodies used for the analysis were: mouse anti-rat CD44, mouse anti-rat CD45 and 
mouse anti-rat CD90, all purchased from Immunotools. The primary antibodies were 
conjugated to a fluorophore, and more specifically CD44 and CD45 were conjugated 
to fluorescein isothiocyanate (FITC) and CD90 to phycoerythrin (PE). Mouse IgG1 
FITC-conjugated, mouse IgG1 PE-conjugated and mouse IgG2 FITC-conjugated 
were used as negative controls for the three different markers. Following incubation 
with the primary antibody, 1 ml of incubation buffer was added to each sample and 
cells were centrifuged for 10 minutes at 1200 rpm. Supernatant was discarded, pellets 
were resuspended in incubation buffer and samples centrifuged again. The procedure 
was repeated three times and subsequently 300 μl of each sample were transferred to 
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a flow cytometry tube and kept on ice until analysis. Samples were analysed within 
one hour by flow cytometry (Becton Dickinson FACSCanto I, running BD FACS 
Diva software) at the BioImaging Suite, University of Bath. 
 
2.10.2  Hepatic differentiation of MSCs 
 
Mesenchymal stem cells were differentiated into hepatocytes according to the 
protocol of Snykers et al. [213, 241]. rMSCs were plated on 24 well-plates at a 
density of 20,000 cells/cm
2 in α-MEM supplemented with 10% fetal calf serum, 2 
mM L-glutamine and 1% antibiotic-antimicotic solution (basal medium). Once cells 
reached 100% confluency they were cultured for three days in basal medium 
supplemented with 0.25 mM sodium pyruvate and 10 ng/ml of fibroblast growth 
factor 4 (FGF-4). After this first differentiation step, cells were cultured for three 
days in basal medium supplemented with 0.25 mM sodium pyruvate and 20 ng/ml 
commercial HGF or 20 ng/ml of HGF secreted by MG63s. In the following 12 days 
cells were cultured in basal medium supplemented with 0.25 mM sodium pyruvate, 
20 ng/ml commercial HGF or HGF secreted by MG63s, 1X insulin-transferrin-
sodium selenite (ITS), 20 μg/l dexamethasone and 1μM trichostatin A (TSA). 
Differentiation media were changed every three days. Cells were checked for 
changes in morphology using light microscopy. At day 18 cells were fixed for 20 
minutes at room temperature with 10% formalin solution, washed two times with 
PBS and kept at 4°C until analysis. 
 
2.10.3   Analysis of hepatic markers 
 
The presence of three hepatic markers (albumin, UGT and transferrin) was assessed 
by immonofluorescence to check the differentiation of rMSCs into hepatocytes.  
600 μl of 0.1% v/v Triton X100 in PBS were added to each well and incubated for 20 
minutes at room temperature in order to permeabilise the cells. The solution was then 
removed and replaced by 600 μl of blocking buffer: 1X blocking reagent in maleic 
acid buffer (100 mM maleic acid, 150 mM NaCl; pH 7.5). Plates were incubated for 
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one hour at room temperature. Blocking buffer was removed and 200 μl of primary 
antibody (dilution 1:100 in blocking buffer) were added to each well and plates were 
incubated overnight at 4° C. The primary antibodies used for the analysis were: goat 
anti-rat transferrin, sheep anti-rat albumin and sheep anti-rat UGT antibody. The 
following day the antibody solution was removed from the wells and plates were 
washed three times with PBS and left for 15 minutes on a shaker between every 
wash. PBS was then removed and 200 μl of secondary antibody (fluorescein anti-
sheep IgG or fluorescein anti-goat IgG) diluted 1:100 in PBS were added to each 
well.  Plates were incubated for two hours at room temperature and protected from 
light. After two hours the antibody solution was removed from the wells and plates 
were washed three times with PBS and left for 15 minutes on a rotator between every 
wash. Plates were then analysed immediately for hepatic markers using fluorescence 
microscopy (Leica  DMI 4000B). 
 
2.10.4  Staining of adipogenic cultures 
 
Oil Red O staining was performed to detect mature adipocytes in culture. Cells were 
fixed for 20 minutes at room temperature with 10% v/v formalin solution and 
subsequently washed with PBS. 300 mg of Oil Red O powder were dissolved in 100 
ml of 99% v/v isopropanol and 30 ml of this solution were mixed with 20 ml of 
distilled water. The working solution was incubated for 10 minutes at room 
temperature and filtered through a Whatman filter paper before use. 500 μl of 60% 
v/v isopropanol were added to each well and left for five minutes. The solvent was 
then removed and replaced by 500 μl of Oil Red O working solution and the plates 
were incubated at room temperature for five minutes. Oil Red O solution was 
removed and cultures were rinsed with distilled water until the water rinsed off clear. 
500 μl of haematoxylin stain were then added to each well in order to stain the nuclei 
of the cells and left for 1 minute at room temperature. Haematoxylin solution was 
removed and then cultures were rinsed with distilled water until the water rinsed off 
clear. Plates were analysed using light microscopy (Leica DMI 4000B) for the 
presence of adipocytes in cultures (red stained). 
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2.11  Statistical analysis 
 
Unless stated, data are represented as the mean value from n = 4 ± 1 standard 
deviation. Graphs were created using Graph Pad Prism Software. One-way analysis 
of variance (one-way ANOVA) was used to test significant differences between 
multiple samples. Since ANOVA does not identify which samples are different from 
one another, Tukey’s post-hoc test was used to identify significant differences 
between independent samples. When appropriate, R
2 
values are presented in graphs 
as an indication of the deviation from the trendline equation. 
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3. Characterization and improvement 
of the properties of PLGA hollow fibre 
membranes 
 
3.1    Introduction 
 
3D constructs require more efficient transport of nutrients, oxygen, growth factors, 
CO2 and metabolites to and from the cells compared to 2D culture systems. Early 
studies showed that cellular spheroids larger than 1 mm in diameter usually contain a 
hypoxic necrotic centre, surrounded by viable cells [242]. Because engineered 
constructs should be at least a few millimetres in size to serve as grafts for tissue 
replacement, mass transfer limitations represent one of the greatest challenges to be 
addressed. A challenge in mass transport is represented by oxygen mass transport 
because of its extremely low solubility in aqueous media and because limitations in 
oxygen transfer are significant when cells adopt 3D structures [168]. Oxygen is one 
of the most important nutrients for cells, as it acts in all aerobic metabolic cycles. 
However, it is the factor that often limits cell survival and tissue growth [156]. All 
reactors designed for tissue growth are considered mass transfer limited relative to 
oxygen.  Oxygen mass transfer can be described as the movement of molecules due 
to convective flow and diffusion. On the other hand, an excess of oxygen in medium 
causes the presence of free radicals, which are cytotoxic. Therefore oxygen 
concentrations are usually maintained at between 20% and 100% air saturation to 
maintain a balance between oxygen needs and tolerance of the cells to free radicals. It 
must also be taken into account that different tissue types have different oxygen 
requirements, depending on cell type, concentration and metabolic activity. For 
example the oxygen uptake of human skin fibroblasts seeded at a cell density of 10
6
 
cells/ml is 0.064 mmol O2 /l h, while it is 0.30 mmol O2/l h for human hepatocytes. It 
must be considered that oxygen has to be transferred from a gaseous phase to a liquid 
one before it can be used by the cells. While culture systems present maximal oxygen 
concentrations of 0.2 mmol O2/ l h, blood of a healthy adult man  can carry up to 9.5 
mmol O2/l h. The diffusive component will remain limited in vitro due to the small 
oxygen gradient compared to the in vivo situation. Diffusive transport will have to be 
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matched with an important convective effect to bring sufficient oxygen molecular 
flux to the growing cells. 
The rate of diffusion of nutrients and oxygen is proportional to their concentration 
gradient, where the constant of proportionality is the diffusion coefficient (D) in the 
Stokes-Einstein equation:  
r
kT
D
6

 
Where k is the Boltzmann’s constant, T is the temperature and r is the particle radius. 
Since the volume of a sphere is equal to the cube of its radius, the diffusion 
coefficient is inversely proportional to the cube root of the molecular weight. This 
means that larger molecules such as growth factors will have a lower diffusion 
coefficient. In particular, the diffusion of growth factors is limiting at low 
concentrations, especially if a high density cell culture is not supplemented with 
additional growth factors [155]. 
The mass flux is also related to the stagnant boundary layer that can be generated at 
the cell/medium interface (Fick’s law of diffusion). Mass transfer is then limited by 
the thickness of the stagnant layer and by the concentration at the boundary of the 
stagnant layer and can be increased by reducing the thickness of the stagnant 
boundary layer surrounding the cells. Therefore the role of convection generated in 
bioreactors is to reduce diffusion limitations imposed by stagnant boundary layers 
around the cells. External mass transfer (transport of molecules from medium to 
tissue surface) rates are dependent mostly on the hydrodynamic conditions in the 
bioreactor, while internal (transport through the tissue to the cells) rates may depend 
on the scaffold/tissue structure.  
Hollow fibres are attractive macrostructures for tissue engineering as they provide a 
large surface area to volume ratio for higher cell attachment compared to flat sheets 
and also because they act as a solid barrier between the cells and the media, allowing 
high media flow rates to be selected for appropriate mass transfer of nutrients and 
waste products to and from the cells, without any cellular damage.  
Despite the advantages of using PLGA hollow fibres compared to flat sheets, one of 
the major limitations in the use of PLGA as a tissue engineering scaffold in 
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bioreactor devices is its hydrophobic character, which results in low permeability of 
water and water-based solutions, such as cell culture media, through the scaffold. 
However, a modification of the chemical composition of the membrane might lead to 
a more hydrophilic fibre, which is likely to positively affect the hydraulic 
permeability and also cell adhesion. This could potentially solve the mass transfer 
limitations and allow for the employment of PLGA hollow fibres into bioreactors 
devices. 
In order to improve the hydrophilicity of membranes, some techniques have been 
attempted in the past, including pre-wetting the material with ethanol before cell 
seeding [105, 128], hydrolysis with NaOH [128, 129] protein-coating [130] and 
plasma treatment [131]. In our research group there have been attempts to improve 
the hydrophilicity and permeability of PLGA membranes by ethanol pre-wetting or 
hydrolysis with NaOH, but both the methods resulted in distortion and/or breakage of 
the fibres after a very limited period of time [128, 233]. Blending with a hydrophilic 
polymer, e.g. poly(ethyleneglycol) [136, 137], polyvinylpyrrolidone [138-142] and 
polyvinyl alcohol (PVA) [139, 143-146], is another technique that has been shown to 
successfully improve the hydrophilicity and permeability of the membranes [132-
135]. 
 
In this project, blending with the hydrophilic polymer polyvinyl alcohol (PVA) has 
been performed. Due to its hydrophilicity, excellent chemical resistance (e.g. long 
term temperature and pH stability), non-toxicity and biodegradability, PVA has been 
used in various pharmaceutical, medical, cosmetic and food products [150-152]. For 
the same reasons PVA is an attractive polymer for tissue engineering applications. 
For example, Oh et al have demonstrated that blended PVA-PLGA sponge scaffolds 
made by thermal compression molding, exhibited improved porosity, hydrophilicity 
and wettability, which resulted in better cell adhesion and growth [147]. 
In this project, blended PVA-PLGA hollow fibre membranes were fabricated by wet 
spinning in order to improve hydrophilicity, pore size and protein permeability of the 
membrane. In addition to blending PLGA with PVA, subsequent treatment of hollow 
fibres with 5% v/v sodium hypochlorite (NaOCl) for 24 hours was performed in 
order to optimise their properties, especially their permeability. NaOCl is one of the 
most popular chemical cleaning agents used to remove irreversible fouling [243] and 
the most common disinfectant for haemodialysis membranes [244]. Cleaning with 
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NaOCl has been largely employed on pure and blend polyethersulphone membranes 
in order to increase their degradation and therefore their pore size [245], their 
hydrophilicity [243, 245], their hydraulic permeability [140, 142, 243, 246-248] and 
in order to remove proteins deposited on or inside the membrane [244, 246]. 
Morphology, mechanical properties, hydrophilicity and permeability of PVA-PLGA 
blended hollow fibres untreated and treated with NaOCl were analysed. 
 
3.2    PVA-PLGA blended membranes 
 
Blended PVA-PLGA hollow fibre membranes (PVA content: 1.25%, 2.5% and 5% 
w/w) were fabricated by wet spinning as described in section 2.2.3. Morphology, 
mechanical properties, hydrophilicity and permeability of 1.25, 2.5 and 5% PVA-
PLGA blended hollow fibres were studied to determine their potential suitability for 
tissue engineering applications. 
The following results were published as: Meneghello G, Parker DJ, Ainsworth BJ, 
Perera SP, Chaudhuri JB, Ellis MJ, De Bank PA. “Fabrication and characterization 
of poly(lactic-co-glycolic acid)/polyvinyl alcohol blended hollow fibre membranes 
for tissue engineering applications” Journal of Membrane Science 344 (2009) 55-61 
[249]. 
3.2.1 Morphological analysis  
 
Fig. 3.1 illustrates the SEM images of PVA-PLGA blended membranes at three 
different concentrations of PVA: 1.25, 2.5 and 5%. The phase inversion process used 
to fabricate the fibres resulted in anisotropic membranes with skin layers on both the 
inner and outer surfaces, with large finger-like macrovoids in the sublayer, extending 
from the skin layers to the centre of the fibre wall. With increasing PVA content, the 
central core diminished and for the 5% PVA-PLGA hollow fibre membranes was 
completely replaced with macrovoids that extended over the middle half of the fibre. 
This is indicative of instantaneous demixing [250] and is a result of the change in 
thermodynamic and hydrodynamic interactions between PVA, NMP and water [251]. 
 
86 
 
   
                               
    
 
Fig. 3.1: Cross sections and surface views of PVA-PLGA hollow fibre membranes soaked in 
water for 24hrs. A-C: 1.25% PVA-PLGA HFMs; D-F: 2.5% PVA-PLGA HFMs, G-I: 
5%PVA-PLGA HFMs. Fibres present large macrovoids in the centre and skin on the outer 
surfaces. From [249]. 
 
The morphology of blended PVA-PLGA hollow fibres is very similar to that of pure 
PLGA membranes (fig. 3.2): membranes present thin outer and inner skin layers (A, 
B) supported by a porous structure, with finger-like pores and macrovoids extending 
towards the centre of the fibre wall (B). Outer surfaces present some pores as well, 
but of smaller size and not regularly distributed (C). 
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Fig. 3.2: Cross section (A, B) and outer surface (C) of 75:25 PLGA hollow fibre membranes. 
 
3.2.2 Mean pore size and overall porosity 
 
Mean pore size was obtained by gas permeation technique, as described in section 
2.4.2. The aim of the experiment was to obtain membranes with an increased pore 
size and porosity which allowed a greater transfer of nutrients while still providing a 
suitable scaffold to support cells. The mean pore size calculated was 0.54± 0.11 μm 
for PLGA hollow fibres, 0.67± 0.15 μm for 1.25% PVA-PLGA hollow fibres, 0.89± 
0.16 μm for 2.5% PVA-PLGA and 1.1± 0.1 μm for 5% PVA-PLGA hollow fibres. 
These data demonstrate an increase in pore size corresponding to an increase in PVA 
concentration (Fig. 3.3), with the coefficient of determination of 0.97 indicating an 
almost perfect linear relationship. These data indicate that the blended membranes 
are suitable as tissue engineering scaffolds as the size of the pores is big enough for 
the passage of molecules including large proteins across the scaffold, but small 
enough to prevent cells from infiltrating the fibre lumen. 
 
A B 
C 
88 
 
 
Fig. 3.3: Relationship between the PVA concentration and the pore size of PVA-PLGA 
hollow fibre membranes. Data represent the mean ± standard deviation (n= 4) and were fitted 
with linear regression using GraphPad Prism software. R
2
= 0.97; y= 0.1099x + 0.5515. From 
[249]. 
 
 
By increasing the concentration of PVA in the polymer solution, overall porosity 
increased as well, although not linearly but reached a plateau at 2.5% PVA 
concentration (fig. 3.4): the overall porosity calculated for the fibres was 
respectively, 0.46± 0.01  for PLGA hollow fibres, 0.67± 0.026 for 1.25% PVA-
PLGA, 0.76± 0.02 for 2.5% PVA-PLGA and 0.77± 0.03 for 5% PVA-PLGA fibres. 
Further studies should be performed in order to investigate the reason why the 
porosity did not increase at PVA concentrations higher than 2.5%. 
These data indicate that PVA had a positive effect on the porosity of the scaffold, as 
not only could it contribute to increasing the size of the pores thus allowing for a 
better mass transfer of larger molecules across the scaffold, but also improved the 
overall porosity of the material. An increased porosity allows for higher cell 
adhesion, migration and for an adequate transport of nutrients and waste products 
across the scaffold, which are major requirements in bioreactors design for the 
regeneration of highly metabolic tissues.  
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Fig. 3.4: Relationship between PVA concentration and porosity of PVA-PLGA hollow fibre 
membranes. Data represent the mean ± standard deviation (n= 4) and were fitted with non-
linear regression (one site competition using GraphPad Prism software).  
 
3.2.3 Mechanical properties 
 
To investigate the mechanical properties of PLGA and PVA-PLGA membranes, and 
see whether the newly fabricated membranes that exhibited an increased porosity 
could still provide a suitable scaffold for the cells, load-displacement curves were 
obtained from the analysis of five samples for each type, and Young’s modulus, 
tensile strengths at break, and yield strengths were calculated. From load 
displacement curves (Fig. 3.5), the lack of linearity suggests there is no defined 
elastic region for these membranes. The Young’s modulus calculated for the samples 
considered the original cross sectional area of the sample (A0) and the change in 
length (L – L0). However, it is worth of notice that during tensile strength the hollow 
fibres exhibited a change in length but also in cross-sectional area: when stress 
reaches the maximum value, the cross section decreases due to “necking”. Therefore 
it would be more accurate to consider the true sample cross-section in the Young’s 
modulus calculation instead of the original dimensions of the cross section before 
tensile testing. The relative reduction of area, i.e. the ratio between the decrease of 
the specimen cross-section area before its rupture and its original cross-sectional area 
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(A0) is given by:
0
min0
A
AA
A

 , where Smin is the minimum specimen cross sectional 
area.  
Furthermore from the graph it can be noticed that pure PLGA fibres beared the 
highest load (1.9 N) while the tolerable load decreased upon increasing the PVA 
concentration, with 5% PVA-PLGA fibres bearing the lowest load (0.75 N). 
 
Fig. 3.5: Load displacement curves of PLGA (A) versus 1.25% (B), 2.5% (C) and 5% (D) 
PVA-PLGA hollow fibre membranes. n=5 *** P< 0.001. From [249]. One-way analysis of 
variance (one-way ANOVA) was used to test significant differences between multiple 
samples. 
 
As shown in Table 4.1, it is clear that Young’s modulus, tensile and yield strength 
decrease with increasing PVA concentration in the polymer solution, with a loss of 
31% in Young’s modulus when 5% PVA was added to the polymer solution 
compared to pure PLGA hollow fibre membranes.  
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Table 3.1: Young’s Modulus, tensile strength at break and yield strength of PLGA and PVA-
PLGA hollow fibre membranes. Data represents the mean± standard deviation (n=5). 
**P<0.01, *** P < 0.001. From [249]. One-way analysis of variance (one-way ANOVA) was 
used to test significant differences between multiple samples. 
 
Fibre type 
Young’s 
modulus (MPa) 
Tensile strength at 
break (MPa) 
Yield strength 
(MPa) 
PVA0%  
(pure PLGA) 
109 ±2.50 3.88 ±0.36 2.58 ±0.64 
PVA1.25% 106 ±4.00 2.77 ±0.15*** 1.43 ±0.03*** 
PVA2.5% 101 ±3.40** 2.08 ±0.08*** 1.26 ±0.41*** 
PVA5% 75 ±9.50*** 1.68 ±0.09*** 1.05 ±0.03*** 
 
The loss of mechanical strength was expected since PVA, being a hydrophilic 
polymer, tends to adsorb more water and therefore exhibits a lower mechanical 
strength compared to PLGA, which is hydrophobic. Therefore, the higher the PVA 
content in the solution, the higher the content of water adsorbed and the lower the 
mechanical strength of the fibre. Furthermore, PVA, by increasing the pore size and 
the porosity of the scaffold, contributes to a decrease in the mechanical properties of 
the material. However, the reduction in mechanical strength did not affect the 
handling of the fibres and was therefore deemed to be insignificant in practical terms. 
 
3.2.4 Hydrophilicity  
 
Hydrophilicity of a membrane scaffold is likely to affect its hydraulic permeability 
and cell adhesion. To evaluate whether the addition of PVA had an effect on the 
membrane surface hydrophilicity, the water contact angle on the pure PLGA and 
blended PVA–PLGA membranes was measured as described in section 2.4.4. 
However, since hollow fibres do not provide a suitable flat surface for testing the 
hydrophilicity with the water contact angle method, flat sheets were employed for 
this experiment. The water contact angle of pure PLGA membranes was 64± 0.5º, 
which indicates that the membrane surface is hydrophobic. By increasing the PVA in 
the polymer solution, the contact angle decreased, with 5% PVA–PLGA having the 
lowest value (50± 1.7º) and therefore being the most hydrophilic (Fig. 3.6). The 
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trendline obtained from the data shows that contact angle decreased exponentially 
with increasing PVA content in the solution, with 5% PVA–PLGA membranes 
having a value very close to that of the plateau (48.5º).  
 
 
 
Fig. 3.6: Water contact angle values for PLGA and PVA-PLGA flat sheet membranes. Data 
represent the mean± SD (n= 4) and were fitted with non-linear regression (one phase 
exponential decay) using GraphPad Prism software. **P<0.01; ***P<0.001. One-way 
analysis of variance (one-way ANOVA) was used to test significant differences between 
multiple samples. From [249]. 
It was also observed that pure PLGA flat sheet membranes floated when immersed 
into water as PLGA, being a hydrophobic polymer, resists water adsorption, whereas 
5% PVA–PLGA flat sheets sank, qualitatively indicating that they are more 
hydrophilic. 
When combining this data with the mechanical properties data, it can be concluded 
that 5% is the optimal concentration of PVA to be added to PLGA in order to obtain 
the highest improvement in hydrophilicity with minor loss of mechanical properties. 
Hydrophilicity is very important when considering water flux, permeation of 
nutrients across the membrane and cell attachment [139, 145-147]. Hydrophobic 
materials are poorly wetted by cell culture medium, resulting in limited cell 
attachment to the scaffold and poor transfer of nutrients and waste products across 
the membrane. One common attempt to improve the wettability of scaffolds is pre-
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wetting with ethanol, but this method has been shown to induce structural 
deformation of the material and the fibres have a tendency to stick together do to the 
ethanol acting as a plasticizer [128]. On the contrary, the addition of PVA to the 
polymer solution allows for the fabrication of hollow fibres without need of pre-
treatment with a wetting agent. 
3.2.5 Hydraulic and protein permeability 
 
Mass transfer of nutrients through scaffolds is an important parameter in tissue 
engineering. One of the major limitations of PLGA is its hydrophobic character, 
which results in low permeability of water and water-based solutions (e.g. cell culture 
medium) through the scaffold. The addition of hydrophilic PVA to PLGA could lead 
to a more hydrophilic membrane, thus improving its permeability to water and 
nutrients. 
The hydraulic and protein permeability of pure PLGA and blended PVA-PLGA 
membranes was assessed as described in section 2.4.5.  
No pure water flux readings were obtained from PLGA membranes, confirming their 
hydrophobic character and need for a wetting agent. Interestingly, no measurable 
pure water flux readings were collected from 1.25 and 2.5% blended membranes 
during the experimental timeframe. However, a water flux of 7.0 l m
−2
 h
−1
 and a 
hydraulic permeability of 0.12 l m
−2
 h
−1
 Pa
−1
 were calculated at steady state for the 
5% PVA–PLGA membranes. The increase in water flux over time observed in 5% 
PVA-PLGA membranes is probably caused by the combination of increased pore 
size, porosity and hydrophilicity reported for these membranes (fig. 3.7). 
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Fig. 3.7: Water permeation across PLGA, 1.25 and 2.5% PVA-PLGA hollow fibre 
membranes (A) and across 5% PVA-PLGA hollow fibres (B). Data represent the mean ± SD 
(n =4) and were fitted with linear regression (polynomial) using GraphPad Prism software. 
y=1.8801x. R
2
=0.98. 
 
 
A good hydraulic permeability is an important parameter in the design of hollow 
fibres for bioreactor applications, as water-based solutions, such as cell culture 
media, need to able to move across the scaffold to ensure a continuous provision of 
nutrients to and removal of waste from the cells, which is of great importance 
especially for highly metabolic organs. From the results above, it can be then 
concluded that 5% PVA-PLGA blended hollow fibres are the only membranes 
among the three different PVA-PLGA hollow fibres that allowed for water 
permeation and therefore the most suitable membranes to be used in bioreactor 
devices. 
 
On the basis of the pure water flux findings, permeability of 5% PVA–PLGA 
membranes to BSA was assessed. This experiment was performed by D. Parker, 
undergraduate project student in the research group [249].  BSA, being an important 
component of serum, was used as a model protein for the study of the permeability of 
the hollow fibre membranes to proteins. Over a period of two hours, there was no 
significant difference in feed, permeate or retentate concentrations which all 
remained around the feed concentration of 100 µg/ml (fig. 3.8). Thus, there was no 
solute rejection nor any fouling due to protein adsorption that would reduce flux 
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[252]; the BSA flux was found to be constant with time at 0.18×10
−3
 ±1×10
−5
 kg m
−2
 
s
−1
 after the 2 h wetting period.  
 
 
 
Fig. 3.8: Permeation of 100 µg/ml BSA solution across 5% PVA-PLGA hollow fibres. 
Concentration of BSA in the feed solution (A), permeate (B) and retentate (C). Data 
represent the mean ± SD (n=4). From [249]. 
(A) 
(B)
 A  
(C)
 A  
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Previous reports suggest three mechanisms for fouling in microfiltration membranes: 
(1) internal fouling by pore narrowing, (2) blocking of pores by protein aggregates 
and (3) formation of protein deposit on the membrane surface [253]. Among these 
three, the most likely mechanism for BSA fouling is internal deposition of protein 
molecules, since the pore size is within the microfiltration range, leading to pore 
narrowing and hence flux reduction [252]. Due to the large pore size of the 5% PVA–
PLGA microfiltration membranes, multi-layered deposition of BSA would be 
required to add significant resistance to permeation for fouling to be observed; BSA 
has molecular dimensions of 14 nm × 4 nm × 4 nm [254] and the 5% PVA–PLGA 
membranes have been found to have an average pore size of 1.1 µm, two orders of 
magnitude greater than the largest dimension of the BSA molecule. Therefore, it is 
unlikely the BSA fouling will occur in 5% PVA-PLGA blended membranes. 
This result is very promising, as, although it does not give a value for the molecular 
weight cut-off (MWCO) of the PVA-PLGA hollow fibre, it can give a first indication 
of a range of molecular weights that are allowed to pass across the blended 
membrane, i.e., molecules up to 66 kDa (BSA molecular weight) can be transported 
from the extracellular space into the lumen of the fibre and vice versa. BSA, being an 
important component of cell culture medium, was a good model protein to be used 
for permeability experiments. These results indicate that 5% PVA-PLGA hollow 
fibres exhibit increased porosity, pore size and hydrophilicity not only for better cell 
adhesion and hydraulic permeability, but also for higher mass transfer of proteins and 
nutrients across the scaffold, characteristics which make them a potential good 
scaffold for organ tissue engineering applications. 
However, a problem associated with the flux of nutrients through the pores of the 
membrane is given by the convective force through the pores, which might affect cell 
adhesion on the outer surface of the fibre. The calculation of the convective force 
through a pore of diameter 1.1 µm of 5% PVA-PLGA membranes gives a value of 
84.25 pN. Taking into account that forces required to make the cells adhere to a 
surface have mean values ranging from 10 to 160 pN [255, 256] further investigation 
should be carried out in order to verify whether this force might cause detachment of 
the cells from the outer surface of the hollow fibre. 
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3.3    Treatment of membranes with sodium hypochlorite 
 
Treatment of hollow fibres with 5% sodium hypochlorite (NaOCl) for 24 hours was 
performed in an attempt to optimise their properties, especially their permeability. 
Morphology, mechanical properties, hydrophilicity and permeability of the fibres 
were studied in order to determine its effect. 
 
3.3.1 Morphology and pore size 
 
Treatment with 5% sodium hypochlorite (NaOCl) had a considerable effect on the 
morphology of the outer and inner surfaces of the PVA-PLGA fibres. After 60 
minutes incubation with NaOCl pore openings could be already observed on the 
outer and inner surfaces of 5% PVA-PLGA fibres (fig. 3.9). The effect of sodium 
hypochlorite increased with increasing treatment duration: in fact the skin layer of the 
membranes treated with sodium hypochlorite for 24 hours had disappeared and the 
surfaces appeared evenly porous, with increased pore size and porosity (fig. 3.10 A-I) 
and large macrovoids in the central core (fig. 3.10 L-N). Since the skin layer provides 
resistance to mass transfer, removal of the skin has the potential to increase the mass 
transport through the membrane, and also to unveil the porous interior, leading to a 
significant increase in surface area.  
The morphological changes observed in the fibres are probably a result of the 
oxidative degradation induced by sodium hypochlorite: sodium hypochlorite is 
known to be an oxidising agent and has been shown to induce degradation of 
polymeric membranes by oxidation of hydroxyl and ether functions and C-H bonds 
of polymers. Furthermore, oxidation of alcohols by NaOCl has been previously 
reported [257]. Therefore OH groups of PVA are oxidised by NaOCl to carbonyl 
groups, and this oxidation results in the degradation of the outer and inner membrane 
surfaces, thus leaving a highly porous surface and larger pores. These data confirm 
previous experiments on polyethersulphone membranes that showed how 
hypochlorite treatment affected performance and surface properties of the membrane 
as it led to a significant degradation of the membrane surface leaving bigger pores 
[245]. 
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Fig. 3.9: Cross section (A), inner (B) and outer (C, D) surfaces of 5% PVA-PLGA hollow 
fibres treated for 60 minutes with 5% NaOCl. 
 
 
Surprisingly, treatment of pure PLGA fibres with NaOCl did not have the same effect 
than that on blended fibres, as after 24 hours the skin was still not removed (fig. 3.11 
D, E) and only a few cracks could be noticed on the outer surface (fig 3.11.F). Also, 
in the central core, finger-like pores were observed (fig. 3.11 A-C), compared to the 
large macrovoids present in PVA-PLGA membranes. It can be hypothesized that the 
addition of PVA allows for more oxidation sites by NaOCl and therefore to a more 
rapid action, or that the phenomena is enhanced by the thermodynamic changes 
occurring after the addition of PVA. It can be concluded that the mild oxidising 
properties of NaOCl are enhanced when PVA is present. 
The exact value of pore size of NaOCl treated fibres could not be obtained by gas 
permeation analysis because the fibres split as a result of the flow of nitrogen gas 
inside the lumen at increasing pressures. 
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Fig. 3.10: Outer surface (A-I) and cross-section (L-N) of 1.25, 2.5 and 5% PVA-PLGA 
blended membranes treated for 24 hrs with 5% NaOCl. 
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Fig. 3.11: Cross  section (A-C), and outer surface (D-F) of PLGA fibres treated with NaOCl 
for 24 hrs.   
 
3.3.2 Mechanical properties  
 
The addition of PVA in the polymer solution led to a decrease in mechanical strength 
of the fibres correspondent with the increase of PVA content. When fibres were 
subsequently treated with sodium hypochlorite, a further decrease was observed (fig. 
3.13, table 3.2). These results correspond with the removal of the skin and the 
increased porosity of the membranes caused by the oxidation with NaOCl. There are 
no examples in literature of PLGA scaffolds treated with NaOCl, since it has been 
mostly used in chemical engineering applications rather than tissue engineering. 
However, from previous studies, it could be hypothesised that NaOCl helps the 
A B 
C D 
E F 
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complete removal of the remaining PVA in the membrane, leading to a further 
increase in pore size and therefore to a further decrease in the mechanical properties 
of the fibres [248]. 
  
Fig. 3.12: Load displacement curves of 1.25% (A’), 2.5% (B’) and 5% (C’) PVA-PLGA 
hollow fibre membranes treated with 5% NaOCl for 24 hours compared to untreated 1.25% 
(A), 2.5% (B) and 5% (C) PVA-PLGA hollow fibres. **P<0.01, *** P<0.001. One-way 
analysis of variance (one-way ANOVA) was used to test significant differences between 
multiple samples. 
 
 
 
 
 
 
 
 
 
 
 
** 
*** 
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Table 3.2 Young’s Modulus, tensile strength at break and yield strength of NaOCl treated 
PVA-PLGA fibres compared to untreated fibres. Data represents the mean ± standard 
deviation (n= 4) *P<0.05, *** P < 0.001. One-way analysis of variance (one-way ANOVA) 
was used to test significant differences between multiple samples. 
Fibre type 
Young’s 
modulus (MPa) 
Tensile strength 
at break (MPa) 
Yield strength 
(MPa) 
PVA1.25%+NaOCl 88 ±5.20*** 1.78 ±0.04*** 1.39 ±0.01 
PVA 2.5%+ NaOCl 68 ±5.06*** 0.98 ±0.22*** 0.82 ±0.30* 
PVA 5% + NaOCl    58 ±0.93*** 0.95 ±0.21*** 0.82 ±0.12 
(PVA1.25%)      106 ±4.00 2.77 ±0.15    1.43±0.03 
(PVA2.5%)      101 ±3.40 2.08 ±0.08    1.2±0.41 
(PVA5%)      75 ±9.50 1.68 ±0.09    1.05±0.03 
 
3.3.3 Hydrophilicity and hydraulic permeability 
 
Blending of PLGA with PVA showed an increase in hydrophilicity and hydraulic 
permeability of PLGA hollow fibres. PVA-PLGA blended fibres subsequently 
treated with NaOCl showed an even lower contact angle (down to 37° ± 1.7 for 5% 
PVA-PLGA membranes) (fig. 3.13), decreasing linearly with the increase of PVA 
concentration, suggesting that NaOCl may also contribute to improve the 
hydrophilicity of the membranes. A decrease in contact angle was also observed by 
Susanto and colleagues after treatment of polyethersulphone membranes with NaOCl 
[243, 245]. However, the increase of the hydrophilicity of PVA-PLGA after 
treatment with NaOCl requires further investigation, since the pores of the treated 
membranes are significantly bigger, and the water drop might infiltrate into the fibres 
giving unreliable results.  
Treatment of polyethersulphone membranes with NaOCl has recently been shown to 
increase permeability and water flux across the membrane, a phenomena which is 
much more evident when the membrane is blended with a hydrophilic additive, as the 
additive is decomposed by NaOCl [243, 246]. Furthermore, the capacity of NaOCl to 
remove proteins deposited on or inside the membrane as shown by previous works 
[243, 244, 246] would be very important to solve mass transfer issues, still crucial for 
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tissue engineering applications. However, despite an initial significant increase in 
water flux across NaOCl-treated fibres, NaOCl treatment resulted in a significant 
reduction in mechanical strength with the treated fibres splitting after only 2-3 hours 
with water flow inside the lumen. This was probably caused by the increased porosity 
and pore size resulting from the skin removal from the outer surface, which were 
detrimental for the mechanical integrity of the fibres. Therefore treatment of PLGA 
membranes with NaOCl is not suited for tissue engineering applications and was no 
longer considered in this project. 
 
 
Fig. 3.13: Water contact angle values for PVA-PLGA flat sheet membranes treated with 5% 
NaOCl for 24 hours. Data represent the mean ± SD (n=4) and were fitted with linear 
regression using GraphPad Prism software. y= -2.186x + 48.38. R
2
 = 0.9847   **P< 0.0.1. 
One-way analysis of variance (one-way ANOVA) was used to test significant differences 
between multiple samples. 
 
3.4   Conclusions 
 
One of the major limitations in the use of PLGA as tissue engineering scaffolds in 
bioreactor devices is its hydrophobic character, which results in low wettability and 
permeability of water and protein through the scaffold. In this project, blended PVA-
PLGA hollow fibre membranes were fabricated to allow wetting without the use of a 
wetting agent, and to improve protein permeation. 
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The addition of PVA to PLGA spinning dopes resulted in asymmetric porous hollow 
fibre membranes with mean pore sizes increasing linearly from 0.54 µm for PLGA to 
1.1 µm for 5% PVA–PLGA, and porosity increasing from 0.46 to 0.77. An 
exponential decrease in water contact angle from 64º to 50º indicates that PVA 
improves hydrophilicity of PLGA hollow fibre membranes. Pure water flux was only 
obtained with 5% PVA–PLGA fibres, and these fibres were shown to be permeable 
to BSA, with no solute rejection or reduced flux or pore size due to fouling. A 
decrease in mechanical strength from 109 to 75 MPa was seen, however this did not 
prove detrimental in handling the fibres.  
 
Pure PLGA and blended PVA-PLGA hollow fibres were also treated with sodium 
hypochlorite in order to improve the properties of the membranes. NaOCl caused the 
removal of the skin from the inner and outer surface of the fibre, increased pore size, 
and possibly increased hydrophilicity. However, this proved to be detrimental for the 
mechanical integrity of the fibres.  
It can be concluded that the addition of 5% PVA to PLGA spinning dopes improves 
the PLGA hollow fibre membrane scaffold properties because it allows for wetting 
without an additional wetting agent and is necessary for pure water flux and protein 
permeation, while treatment of hollow fibres with NaOCl negatively affects the 
mechanical integrity of the fibres, making them not suitable for tissue engineering 
applications.  
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4.  Cell adhesion and proliferation on 
PVA-PLGA blended membranes 
 
4.1   Introduction 
  
It has been demonstrated that cell adhesion, spreading and proliferation on 
biomaterial surface are determined by many material properties, including surface 
roughness and topography, chemical composition, wettability, surface charge and 
surface treatments [258]. These parameters have to be considered in the design and 
fabrication of a scaffold. 
The source of the adhesive force at the interface cell-surface is given by the ligand-
receptor bonds (typically protein-protein or protein-carbohydrate non-covalent 
interactions). However, the flow of medium exerts a disruptive (counteradhesive) 
force on the cells. For the cells to be adhesive to the surface this disrupting force 
must be balanced by the opposite adhesive force applied by the cells, i.e. the sum of 
the forces must be zero (Σ ǀFǀ = 0) . It is thought that about 10-20 ligand-receptor 
bonds are enough to encounter the disruptive force. The relative strength of these 
competing forces (the disruptive hydrodynamic force and the adhesive force) dictates 
the adhesion strength of the cells to the surface [259]. 
 
The results presented in chapter 3 showed that 5% PVA-PLGA blended membranes 
exhibited increased porosity, pore size, hydrophilicity, hydraulic and protein 
permeability compared to pure PLGA scaffolds. Blended membranes exhibited a 
moderate hydrophilic character, with a contact angle of 50 degrees, compared to the 
more hydrophobic pure PLGA membranes, for which an angle of 64 degrees was 
measured. The increased hydrophilicity of the blended membrane was shown to 
allow for higher mass transfer of nutrients compared to PLGA, which in contrast did 
not allow for adequate hydraulic and protein permeation across the membrane. PVA-
PLGA membranes, being more hydrophilic, tend to be more easily wetted by 
aqueous solutions, and to exhibit a lower protein adsorption, compared to 
hydrophobic PLGA (see section 3.2.5), thus allowing for a higher permeation of 
nutrients across the scaffold. The improved wettability of PVA-PLGA membrane 
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should be also favorable for cell adhesion and for their even distribution on the 
membrane compared to the hydrophobic PLGA. Hydrophobic surfaces in fact 
possess high interfacial free energy in aqueous solutions, which tend to unfavourably 
influence the initial stage of cell contact with the biomaterial. However, in contrast, 
some other studies have shown that hydrophobic materials, by adsorbing adhesive 
proteins present in the serum (e.g. fibronectin and vitronectin) of cell culture 
medium, would facilitate the adhesion and proliferation of the cells on the scaffold 
[260]. 
 
Therefore, to examine cell attachment and proliferation on the novel membranes, rat 
mesenchymal stem cells (MSCs) and human osteosarcoma cell line (MG63s) were 
seeded on pure PLGA and blended PVA-PLGA membranes. Tissue culture plastic 
was used as control. PLGA and PVA-PLGA flat sheets were used for the tests 
instead of hollow fibres for the ease of membrane seeding and observation with the 
microscope. Medium was changed every 48 hours and samples of cells seeded on 
both pure PLGA and blended PVA-PLGA flat sheet membranes were collected every 
24 hours in a 96 hour time period and analysed qualitatively with fluorescence 
microscopy and quantitatively with the Pico Green dsDNA quantitation assay. 
 
4.2 Adhesion and proliferation of MSCs to PLGA and to 5% PVA-
PLGA flat sheets 
 
4.2.1 Qualitative analysis 
 
Figures 4.1-4.7 show the live staining of rat MSCs attached to pure PLGA and to 5% 
PVA-PLGA blended flat sheet membranes after 24, 48, 72 and 96 hours seeding. 
Tissue culture plastic was used as control. Fig. 4.1 shows the seeding of cells on 
tissue culture plastic. 24 hours after seeding several cells appeared to have adhered to 
the surface of the well but they are not homogeneously distributed (fig. 4.1 A). The 
cells presented a rounded morphology, indicating that there is not a particularly high 
affinity between the cells and the surface of the well. At 48 hours after seeding most 
cells still presented a rounded morphology (fig. 4.1 B) but after 72 hours they spread 
on the surface of the flat sheet with many of them exhibiting a flat large morphology 
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with some spindle-like cells and some polygonal cells. At 96 hours the surface was 
mostly covered with cells (fig. 4.1 D) except from some empty areas, and the cells 
exhibited both spindle like and polygonal morphology (fig. 4.2 A, B). MSCs usually 
have a more spindle like morphology when they retain a high differentiation 
capacity, with a polygonal shape when they are losing their ability to differentiate. 
Mesenchymal stem cells are defined as fibroblast-like cells with regard to their 
morphology, and in fact their morphology is so similar to that of fibroblasts that it is 
impossible to distinguish these two cell types by morphological analysis [261, 262]. 
Fig. 4.3 A shows a picture of mesenchymal stem cells and fig. 4.3 B one of 
fibroblasts. From the two pictures it can be observed how similar is the morphology 
of the two cell types. However, the cells exhibiting a more polygonal morphology 
might also be stem cells spontaneously differentiating in osteoblasts. In fact, as can 
be seen in fig. 4.3 C, osteoblasts have a polygonal morphology, and it would not be 
surprising the presence of some osteoblasts within the stem cells as mesenchymal 
stem cells can spontaneously differentiate into osteoblasts, especially when cultured 
at high densities [263]. 
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Fig. 4.1: 5X magnification of rat MSCs on tissue culture plastic at 24 (A), 48 (B), 72 (C) and 
96 (D) hours after cell seeding. Cells were stained with Vybrant CFDA SE Cell Tracer kit 
and analysed by fluorescence microscopy. Scale bar: 500 µm. 
 
 
                    
 Fig. 4.2: 10 X (A, scale bar: 200 µm) and 20X (B, scale bar: 100 µm) magnification of  
rMSCs on tissue culture plastic 96 hours after cell seeding. Cells were stained with Vybrant 
CFDA SE Cell Tracer kit and analysed by fluorescence microscopy.               
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Fig. 4.3: Typical morphology of bone marrow mesenchymal stem cells (A, from [264], with 
permission from the author), of fibroblasts (B, from [265]),  and osteoblasts (C, from [266], 
with permission from the author). 
 
When the rMSCs were seeded on pure PLGA flat sheets, it was observed that after 24 
hours cells had attached in clumps to the material (fig. 4.4 A) and, in contrast to 
tissue culture plastic  had already started spreading on its surface (fig. 4.4 B, 4.5A) 
indicating high affinity between the cells and the scaffold. After 48 hours cells 
appeared to have covered most of the material surface (fig. 4.4 C), probably thanks to 
its porosity, indicated by the black circles, which might have facilitated cell adhesion 
to the flat sheet. Cells continued spreading, showing their mesenchymal stem cell 
morphology (fig. 4.5 B). This is visible as well after 72 hours (fig. 4.4 E- F, fig. 4.5 
C), while at 96 hours a very dense cell layer was observed (fig. 4.4 G, H). When 
comparing the attachment of the cells to tissue culture plastic, it can be noticed that 
MSCs seem to exhibit a higher affinity to PLGA than tissue culture plastic, as can be 
observed at 48 and 72 hours. 
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Fig. 4.4: 5X (scale bar: 500 µm) and 10X (scale bar: 200 µm) magnification of rMSCs   
proliferation on PLGA flat sheets at 24, 48, 72 and 96 hours after cell seeding.  Cells were 
stained with Vybrant CFDA SE Cell Tracer kit and analysed by fluorescence microscopy.     
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 Fig. 4.5: 20X magnification (scale bar: 100 µm) of rMSCs attachment and proliferation on 
PLGA flat sheets at 24 (A), 48 (B), 72 (C) and 96 (D) hours after cell seeding. Cells were 
stained with Vybrant CFDA SE Cell Tracer kit and analysed by fluorescence microscopy. 
     
On the contrary, when mesenchymal stem cells were seeded on 5% PVA-PLGA flat 
sheets, they showed much lower affinity to the material compared to pure PLGA. In 
fact after 24 hours very few cells attached to the surface of the scaffold and exhibited 
a rounded morphology, indicating a low affinity to the material (fig. 4.6 A). After 48 
hours they started spreading (fig. 4.6 B) and after 72 and 96 hours the surface of the 
flat sheet still appeared mostly empty with some areas with cell clusters that had 
continued spreading (fig. 4.6 B and C, and fig. 4.7 A and B). 
This result was not expected, since the improved hydrophilicity obtained with the 
addition of PVA to PLGA should have facilitated cell adhesion to the material, as 
described by the previous study from Oh SH et al [147]. However, there are two 
conflicting theories about whether it is more appropriate to use hydrophilic or 
hydrophobic materials to increase cell attachment. Some studies have shown that 
hydrophilic materials, being more wettable by aqueous cell culture media, increased 
the affinity of cells and therefore facilitated the adhesion of the cells to the surface of 
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the scaffold [123, 267-270]. In contrast, other studies have shown that hydrophobic 
materials, by enhancing adsorption of adhesive proteins through hydrophobic 
interactions, could improve cell adhesion [260, 271, 272]. It was found that 
hydrophobic materials adsorbed more fibronectin, collagen I and vitronectin than 
hydrophilic materials, thus increasing cell affinity to the scaffold [260]. More 
specifically, there are conflicting results regarding mesenchymal stem cells 
attachment on hydrophilic and hydrophobic materials. Several studies have shown 
that highly hydrophilic materials enhance MSC adhesion and proliferation compared 
to hydrophobic ones [267, 268, 273-276], while other studies reported a better MSC 
attachment on hydrophobic or even super-hydrophobic surfaces [260, 271]. From 
these examples it is clear that it is still not well understood whether mesenchymal 
stem cells prefer hydrophobic or hydrophilic materials. 
 
    
    
Fig. 4.6: 10X magnification (scale bar: 200 µm) of rMSCs attachment and proliferation on 
5% PVA-PLGA flat sheets at 24 (A), 48 (B), 72 (C) and 96 (D) hours after cell seeding. 
Cells were stained with Vybrant CFDA SE Cell Tracer kit and analysed by fluorescence 
microscopy.     
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Fig. 4.7: 5X magnification (scale bar: 500 µm) of rMSCs attachment and proliferation on 5% 
PVA-PLGA flat sheets at 72 (A) and 96 (B) hours after cell seeding. Cells were stained with 
Vybrant CFDA SE Cell Tracer kit and analysed by fluorescence microscopy. 
     
The latter theory could explain the data obtained in this experiment. The serum 
present in cell culture medium contains some adhesive proteins such as vitronectin 
and fibronectin, which contain the RGD sequence recognised by cell-surface integrin 
receptors. The binding of these adhesive proteins to integrins  facilitates cell adhesion 
to the surface and is followed by a series of structural changes in the cells, such as 
cell spreading and cytoskeletal reorganisation. PLGA, being a hydrophobic material, 
might have enhanced the adsorption of these adhesive serum proteins and therefore 
mesenchymal stem cell attachment [277]. Furthermore, vitronectin provides factors 
that help the cells to spread out, and this might explain why cells had spread on 
PLGA surfaces after 24 hours. On the contrary, the more hydrophilic PVA-PLGA 
membranes are less likely to adsorb proteins. For example, in section 3.2.5 it was 
shown that BSA could pass through the pores of the membrane without being 
adsorbed on the material surface. PVA-PLGA might also have reduced vitronectin 
and fibronectin adsorption, thus reducing cell adhesion and spreading to the 
membrane surface. 
 
However, since the use of pure PLGA was shown to be unsuitable for bioreactor 
applications because of its hydrophobic character (section 3.2.5), further strategies, 
such as immobilising adhesive proteins e.g. fibronectin, collagen, vitronectin, or 
peptide ligands ( e.g. the RGD sequence) on the surface of PVA-PLGA blended 
membranes or blending the polymer solution with ECM proteins (e.g. collagen) 
could be attempted in order to allow the use of PVA-PLGA hollow fibres as 
  A 
A 
  B 
A 
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membranes that would accomplish the dual task of supporting the adhesion and 
proliferation of MSCs and, at the same time, of ensuring a good mass transfer of 
nutrients to and waste from the cells. 
 
4.2.2 Quantitative analysis  
 
To quantify the mesenchymal stem cell attachment and proliferation on PLGA and 
PVA-PLGA flat sheets, the Pico Green assay was performed, which measured the  
number of stem cells present on tissue culture plastic, PLGA and 5% PLGA-PVA 
over 96 hours, following seeding at a density of 10,000 cells/well.  
A mass balance equation to describe cell growth limited by nutrients depletion is 
given by the Monod model [278, 279]: 
)( DN
dt
dN
   
where N is the number of cells in the system, D the death or dilution rate, µ the 
steady state growth rate, assuming that the growth of the cells follow the Michaelis-
Menten saturation curve:  








Rk
R
R
max  
where R is the nutrient concentration, µmax is the maximum growth rate and kR is the 
half-saturation constant. 
As can be seen from fig. 4.8, a higher cell number on PLGA and tissue culture plastic 
was observed after 24 hour seeding compared to PVA-PLGA, with around 15,000 ± 
4597 cells attached to plastic wells and around 16,500 ± 3670 to PLGA, while around 
8,500 ± 4857 to 5% PVA-PLGA. These first data indicate that MSCs have adhered 
on tissue culture plastic and PLGA membranes but not on 5% PVA-PLGA 
membranes since the number of cells measured after 24 hours was lower than the 
seeding density (10,000 cells/well). When these data are compared with the 
qualitative analysis of the live cell staining, an even lower number of attached cells 
would probably be expected, since the majority of the membrane was without cells, 
with very few MSCs attached. This discrepancy between the qualitative and 
quantitative analysis might be due to the fact that Pico Green measures the DNA of 
every cell, while live staining only stains live cells. Therefore there may have been 
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8,500 cells attached to the membrane, but many of them were dead after 24 hours, 
and not detected by live staining. 
 
Beyond 24 hours, while cells continued to proliferate on tissue culture plastic and on 
PLGA membranes, there was very little proliferation on 5% PVA-PLGA membranes, 
with around 13,500 ± 4782 cells measured at 48 h and a decrease down to 12,000± 
4818 cells at 96 hours. These data confirm the qualitative analysis since very few 
cells were observed on 5% PVA-PLGA membranes at all the time points while cell 
proliferation was clearly visible for cells seeded on PLGA and on plastic wells. 
Also, while the number of MSCs measured is very similar for PLGA and controls up 
to 48 hours, at 72 hours more cells had proliferated on PLGA (around 50,000 cells ± 
416) than on controls (around 39,000 ± 2041 cells), further increasing after 96 hours. 
In fact the MSCs number had nearly doubled on PLGA flat sheets after 96 hours, 
with about 93,000 ± 8235 cells against about 53,000 ± 2835 cells on tissue culture 
plastic. 
 
These data confirm the high affinity of mesenchymal stem cells to PLGA and 
reinforce the hypothesis that MSCs prefer hydrophobic environments to hydrophilic 
ones, as shown by the low adhesion and proliferation of cells on 5% PVA-PLGA flat 
sheets. 
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Fig. 4.8: Pico Green quantitative analysis of MSCs proliferation on tissue culture plastic (●), 
PLGA (■) and 5% PVA-PLGA (▲) flat sheet membranes. Data represent the mean ± SD (n 
= 3). 
 
 
4.3 Adhesion and proliferation of MG63 cells to PLGA and to 
5%PVA-PLGA flat sheets 
 
4.3.1 Qualitative analysis 
 
In order to investigate the suitability of 5% PVA-PLGA membranes as a scaffold for 
other cell types, MG63 osteosarcoma cells were seeded and their morphology 
compared to cells seeded on PLGA and on tissue culture plastic (controls). Fig.4.9 
demonstrates that after 24 hour seeding, cells had adhered on plastic (A) and already 
started spreading (B). After 48 and 72 hours cells continued proliferating as can be 
observed in fig. 4.9 C- F where most of the well area is covered by cells. Cells 
exhibited a spindle-like morphology, indicating that the cells had spread on the 
surface of tissue culture plastic. At 96 hours cells had proliferated to a degree that a 
dense layer of cells had nearly entirely covered the well (fig. 4.9 G). 
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In contrast, few cells adhered to PLGA membranes after 24 hour seeding and they 
still presented a rounded morphology (fig. 4.10 A, B), indicating low affinity of 
MG63s for PLGA. At 48 and 72 hours after seeding, the few cells that were observed 
on the surface of the membrane still presented a rounded morphology (fig. 4.10 C- 
F). At 96 hours the cells did not evenly cover the membrane surface growing in 
clumps, and leaving many areas without cells. They still had not spread and 
presented a rounded morphology (fig. 4.10 G, H). 
 
In contrast, after 24 hour seeding on 5% PVA-PLGA flat sheets, cells adhering to the 
membrane looked more evenly distributed compared to PLGA (fig. 4.11 A, B). They 
still presented a rounded morphology, but they appeared more spread at 48 hours 
(fig. 4.11 C, D). At 72 hours cells continued spreading (fig. 4.11 E, F), and the 
elongated morphology is more evident at 96 hours (fig. 4.11 H), although few live 
cells were observed on the membrane (fig. 4.11 G). It can be seen that MG63s 
behaved quite differently from MSCs on these surfaces, as the stem cells showed 
higher affinity to PLGA compared to tissue culture plastic and to PVA-PLGA, while 
MG63s seem to have a higher affinity to tissue culture plastic than to pure or blended 
PLGA membranes. But, most importantly, MG63s started spreading after 48 hours 
and appeared to be more evenly distributed on blended membranes compared to pure 
PLGA ones, while very few MSCs adhered in clumps to PVA-PLGA membranes 
maintaining a round shape even after 96 hours. The reason for the better spreading 
and distribution of MG63s on 5% PVA-PLGA membranes compared to MSCs might 
be due to the fact that MG63s have a higher affinity to hydrophilic environments and 
therefore they are more likely to adhere to hydrophilic materials rather than 
hydrophobic ones, such as PLGA. This is confirmed by recent studies that showed 
how osteoblastic-like cells, including MG63s, formed a homogeneous layer on super-
hydrophilic materials, while grew in clumps on super-hydrophobic ones [280]. 
Further studies on MG63s indicated a lower proliferation and higher apoptosis of 
cells on hydrophobic surfaces compared to hydrophilic ones [281]. 
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Fig. 4.9: 5X (scale bar: 500 µm) and 20X (scale bar: 100 µm) magnification of MG63 cells 
on tissue culture plastic at 24, 48, 72 and 96 hours after cell seeding. Cells were stained with 
Vybrant CFDA SE Cell Tracer kit and analysed by fluorescence microscopy.      
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Fig. 4.10: 5X (scale bar: 500 µm) and 20X (scale bar: 100 µm) magnification of MG63   
cells on PLGA flat sheets at 24, 48, 72 and 96 hours after cell seeding. Cells were stained 
with Vybrant CFDA SE Cell Tracer kit and analysed by fluorescence microscopy.         
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Fig. 4.11: 5X (scale bar: 500 µm) and 20X (scale bar: 100 µm) magnification of MG63 on 
5% PVA-PLGA flat sheets at 24, 48, 72 and 96 hours after cell seeding. Cells were stained 
with Vybrant CFDA SE Cell Tracer kit and analysed by fluorescence microscopy.         
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4.3.2 Quantitative analysis  
 
In fig. 4.12 the number of MG63s that have adhered and proliferated on tissue culture 
plastic, PLGA and 5% PVA-PLGA membranes is shown. It can be seen that after 24 
hours the number of cells present in plastic wells is already three times higher 
(around 69,000 ± 7221 cells per well) than the seeding density (26,690 cells per 
well), while the number measured for both the membranes is very similar with 
around 42,000 cells per well. Beyond 24 hours, a continuous increase in the number 
of cells on plastic wells was observed, with around 300,000 ± 27146 cells per well 
present in tissue culture plastic after 96 hours. These results confirm the visual 
observation of cell adhesion, spreading and proliferation obtained by fluorescence 
microscopy, where MG63s seemed to have a high affinity to tissue culture plastic, 
appearing spread 24 hours after seeding and proliferating until confluent.  
 
As with the qualitative analysis, the quantitative analysis shows that MG63s adhered 
and proliferated on both PLGA and PVA-PLGA to a minor degree. However, after 
72 hours, only about 63,000 cells per well were measured on PLGA flat sheets and 
57,000 ± 6108 on 5% PVA-PLGA, while the images obtained from live staining  
suggested a higher proliferation of cells on blended membranes than on pure PLGA 
membranes after this time. At 96 hours the number of cells measured on PLGA is 
lower than that on PVA-PLGA flat sheets, with about 80,000 cells compared to 
94,000 on blended membranes, as expected from the trend of results obtained with 
live staining. However, the high error bar observed for the PVA-PLGA 
measurements suggests that there is no significant difference in cell adhesion and 
proliferation on pure PLGA and PVA-PLGA membranes. 
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Fig. 4.12: Pico Green quantitative analysis of MG63s adhesion and proliferation on tissue 
culture plastic, (●), PLGA (■) and 5% PVA-PLGA (▲) flat sheet membranes. Data represent 
the mean ± SD (n = 3). 
 
4.4  Conclusions 
 
5% PVA-PLGA flat sheet membranes have been tested for cell attachment and 
proliferation of rat MSCs and MG63 cells in comparison to pure PLGA membranes 
and tissue culture plastic. The results obtained in these experiments indicate a 
different affinity of the two cell types to the different materials. Qualitative and 
quantitative analysis of rat mesenchymal stem cell attachment and proliferation 
indicated that MSCs adhered, spread and proliferated more on hydrophobic PLGA 
membranes compared to hydrophilic blended PVA-PLGA membranes and to tissue 
culture plastic.  In contrast, MG63s adhered, spread and proliferated better on tissue 
culture plastic than on the two membrane types. However, although there is no 
significant difference between the number of MG63s that adhered to pure PLGA and 
to blended PVA-PLGA membranes, MG63s appeared to be more spread and more 
evenly distributed on the hydrophilic blended membranes than on pure PLGA ones, 
suggesting that MG63s might have higher affinity for hydrophilic environments. 
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Despite a higher mesenchymal cell affinity for PLGA compared to PVA-PLGA,  
PLGA is not suitable for employment in hollow fibre bioreactor devices as its 
hydrophobicity does not allow an appropriate mass transfer of nutrients across the 
membrane, which is extremely important especially for the in vitro reconstruction of 
highly metabolic organs. In contrast, PVA-PLGA hollow fibre membranes are 
suitable for employment in bioreactors thanks to their hydrophilic character which 
allows a higher wettability and therefore a higher permeability of nutrients across the 
membranes. Hence further strategies should be investigated in order to improve cell 
attachment on blended membranes, such as modifying the scaffolds with adhesive 
proteins or peptide ligands (e.g. RGD sequence), or blending the polymer solution 
with ECM adhesive proteins thus possibly obtaining a membrane which would 
accomplish the double function of being a good scaffold for cells and at the same 
time allowing the passage of molecules across the pores without adsorbing them at 
the material surface. 
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5.  Human hepatocyte growth factor 
release by cell lines and its application 
in a 5% PVA-PLGA hollow fibre 
bioreactor 
 
5.1      Introduction 
In chapter 3 a 5% PVA-PLGA hollow fibre bioreactor was shown to allow BSA 
permeation across the fibre membrane without protein adsorption. In order to 
demonstrate the applicability of this novel system to tissue engineering, it was 
necessary to show that functionally relevant proteins could also permeate across the 
pores of the 5% PVA-PLGA hollow fibres. More specifically, the permeation of 
hepatocyte growth factor (HGF), an important growth factor involved in liver 
development and regeneration, was analysed in order to test the system for a potential 
application in liver tissue engineering. 
5.1.1 The liver and liver tissue engineering 
Liver is the largest organ of the human body and can be considered a large scale 
biochemical reactor, as it plays a central role in the metabolism, i.e., the sum of the 
physical and chemical processes through which living matter is produced, maintained 
and destroyed, and where energy is produced for liver and all other organs [101]. At 
a macroscopic level it consists of two main lobes, left and right. Each lobe contains 
many thousands of units called hepatic lobules that are the structural and functional 
units of the liver. Each lobule  has a central terminal hepatic venule (central vein), 
and at each corner of the lobule there is a portal triad which contain branches of the 
hepatic artery, tributaries of the hepatic portal vein and the bile collector ducts [101] 
[4](fig. 5.1).  Incoming blood flows into the liver via the portal triads, passes across 
the plates of liver cells extending between the portal triads and the central vein, and 
leaves the liver via the central vein [4]. The intrahepatic circulation consists of 
sinusoids, which are small capillaries with walls lined by layers of endothelial cells 
that are not continuous but perforated by small holes (fenestrae) [101] and separated 
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from the hepatocyte compartment by a thin extracellular matrix region called the 
space of Disse [3]. 
 
Fig. 5.1: Structure of liver and cell types that constitute it. Adapted from: [282] with 
permission from the author. 
Five different cell types occupy nearly the 80% of the liver volume, whereas the 
remaining 20% is occupied by ECM components and by extracellular space, e.g. 
space of Disse. Hepatocytes represent the 65% of the liver cells and accomplish the 
majority of specific hepatic functions: 
 Formation of glycogen 
 Transformation of lipids in carbohydrates 
 Removal of hormones and toxins 
 Iron deposit 
 Formation of red blood cells and heparin 
 Drugs metabolism  
 Synthesis of plasma proteins, e.g. albumin 
 Synthesis of all 12 non-essential amino-acids  
 Urea and bile production  
 
By convenction liver is divided into three zones: zone 1 (periportal), zone 2 
(midacinar) and zone 3 (pericentral) [4]. Hepatocytes have subsequently 
Right 
lobe 
Left 
lobe 
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morphological and functional variations according to the zone in which they are 
found (zonation).[3]: the smallest cells are located in zone 1 and the largest cells are 
located in zone 3, cell division potential is maximal periportally and negligible 
pericentrally and specific genes are expressed in specific zones. Therefore a precise 
microarchitecture allows the liver to carry out its many different functions [3]. The 
wall of sinusoids consists mainly of a single layer of endothelial cells, which regulate 
the hepatic circulation by means of synthesis and release of cytokines. Other cells of 
the sinusoids are pit cells, Kupffer cells and stellate cells. Pit cells are lymphoid cells 
attached to the luminal surface and are liver-specific natural killer cells. Kupffer cells 
form part of the sinusoid lining and are the hepatic macrophages as they can 
phagocitate bacteria and other materials present in the blood. Stellate cells reside in 
the space of Disse and are mainly responsible for the production and secretion of 
extracellular matrix proteins [283, 284]. 
Although the liver is an organ with an incredible regeneration capacity after acute 
injury (it can regenerate from as little as 25% of its tissue), when the normal 
regeneration process is compromised, the damaged liver is unable to perform its 
normal physiological roles due to irreversible and irreparable damage. This condition 
is called liver failure [285]. According to the British Liver Trust, liver disease is the 
5
th
 “big killer” in the UK, with more than 15,000 deaths in 2007, and a death rate 
increasing year by year, with a death rate doubled since 1991. There is no cure for 
liver failure at present, and orthotopic liver transplantation is the only clinically 
proven effective treatment for patients with endstage liver disease [286]. As the 
demand for liver transplantation increases, there is an increasing divergence between 
the number of patients waiting for transplantation and the number of available 
organs. This scarcity of donor organs results in most patients dying while waiting for 
a transplantation [286], therefore suggesting that liver transplantation procedures 
alone will probably never be able to meet the increasing demand [3]. Furthermore, 
liver transplantation is one of the most expensive surgical procedures, with costs 
increasing year by year. It is clear that alternative therapy strategies are needed and 
tissue engineering could provide a therapy for patients without need of liver 
transplantation.  
One of the first aspects that need to be considered for the in vitro reconstruction of 
liver is represented by the delivery of the hepatocyte growth factor (HGF) to the 
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cells. Experiments conducted in the past on mice lacking of HGF proved that the 
hepatocyte growth factor is essential for liver development: embryos lacking of HGF 
presented livers severely reduced in size compared to wild type embryos, with 
hepatocytes abnormal in morphology, reduced in number, and with frequent signs of 
apoptosis [287, 288]. Similarly to liver development, HGF is among the most 
important growth factors involved in liver regeneration, being a strong mitogen for 
hepatocytes. It is present in large quantities in the matrix of liver, lungs, spleen, 
placenta, brain [289] and in liver is mostly produced by the stellate cells and also by 
endothelial cells. HGF acts by binding with high affinity to tyrosine kinase receptor 
c-met and activates MAP kinases, leading to the expression of regeneration genes 
[290]. The fact that HGF is involved in liver regeneration is confirmed by many 
factors: HGF levels in plasma increase after partial hepatectomy, it causes a strong 
mitogenic response of hepatocytes in culture, HGF injection in portal vein of normal 
rats and mice causes proliferation of hepatocytes and enlargement of the liver, its 
receptor c-met is activated after partial hepatectomy, and the knock-out of the 
receptor is associated with lower or no regeneration. For its important role during 
liver specification, HGF is widely employed to differentiate stem cells into 
hepatocytes [213, 291-293], and was used for the same purpose in this project. 
5.1.2 Introduction to the experimental work 
Fig. 5.2 represents an overview of the system employed to achieve the aim of this 
project: medium with liver-specific factors flows inside the lumen of the fibre, and 
these factors permeate across the pores of the membrane, thus reaching the stem cells 
on the outside of the fibre and differentiating them into hepatocytes. 
 
 
Fig. 5.2: Schematic representation of the system employed to achieve the aims of the 
project. 
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For the reasons outlined above, HGF was chosen as the liver-specific factor to be 
analysed for this project. However, due to the high cost of  commercial HGF, an 
inexpensive system to generate a continuous supply of HGF was investigated.  
It is known from the literature that some cell lines have the capacity to secrete HGF 
into the cell culture medium: the human leukaemia cell line HL60 as stated by 
Nishino et al [294], Matsumoto et al [240], Inaba et al [239] and the human 
osteosarcoma cell line MG63, as described by Taichman et al [295]. According to 
Inaba and colleagues, HL60 releases HGF in cell culture medium under stimulation 
by 12-O-tetradecanoylphorbol (TPA) and/or dibutyryl cyclic adenosine-
monophosphate (dbcAMP), while Matsumoto and colleagues found that heparin 
induces the release of HGF from HL60s. According to Taichman, MG63 cells 
spontaneously secreted HGF without the need of any external stimulation. The use of 
a cell line secreting HGF would allow for the realization of a “cell factory” 
continuously “producing” the growth factor into the medium. The use of HL60s as 
cell factory was attractive as, being non-adherent cells, they would allow the 
realisation of a system consisting of a hollow fibre bioreactor where stem cells were 
seeded on the outer surface of the membrane and HL60s flowed inside the lumen of 
the fibre, continuously releasing the HGF into the culture medium. The hollow fibre 
membrane would therefore constitute a selective barrier which would maintain the 
two cell types separate, but would allow the continuous passage of HGF from the 
lumen of the membrane to the outer surface, where mesenchymal stem cells had been 
seeded. 
 
On the basis of these findings, HL60s and MG63s were tested for their capacity to 
secrete the HGF in cell culture medium. HL60 cells were also analysed for their 
viability and metabolic activity when pumped inside the lumen of the bioreactor at 
two different flow rates: 2 ml/min and 4 ml/min, in order to see whether an 
increasing shear stress had any negative effect on the cells. 
Cell-secreted HGF was then circulated inside the lumen of the 5% PVA-PLGA 
hollow fibre bioreactor in order to verify the permeability of the novel membrane to 
the protein and the stability of the growth factor in dynamic environment. 
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5.2  Proliferation and metabolic activity of HL60s in the single fibre 
hollow fibre bioreactor 
 
Before testing the capacity of HL60s to secrete HGF when circulated within the 
hollow fibre bioreactor, the cells were stained with trypan blue and analysed with a 
MTT assay in order to see whether the shear stress caused by the flow inside the 
lumen of the hollow fibre might affect their viability and metabolic activity, as this 
could affect also their efficiency in the secretion of HGF. The single fibre hollow 
fibre bioreactor was therefore tested to see whether it could recreate a suitable 
dynamic environment for the HL60 cell line. The hollow fibre in fact would 
reproduce a blood vessel in the lumen of which blood cells, included HL60s, could 
circulate, thus reproducing an in vitro environment closer to that in vivo compared to 
the static tissue culture flask.  
The value of Reynolds number (a dimensionless number that gives a measure of the 
ratio of intertial forces to viscous forces in a given flow condition, and is used to 
determine whether the flow will be laminar or turbulent) calculated at the flow rate of 
5ml/min inside the hollow fibre is 189, which indicates that the flow inside the 
hollow fibre is laminar. Laminar flow actually occurs at low Reynolds numbers (< 
2100), and is characterized by smooth, constant fluid motion, low flow velocity and 
high viscosity, while at values > 2100 the flow is turbulent, characterised by high 
flow velocities and low viscosities, and dominated by inertial forces, which tend to 
produce random eddies and vortices, which are deleterious for cell integrity.  The 
calculation of the shear stress at the wall at a volumetric flow rate of 5 ml/min, i.e. a 
mean axial velocity of 0.165 m/s gave a value of 1.165 Pa, which is within a 
physiological range in blood vessels (0.1-1.2 Pa is the physiological range of shear 
stress experienced by vascular cells) [296-298].  
Given the high cell volumes that would have been required for the experiment, flow 
rates higher than 5 ml/min were not considered.  
Fig. 5.3 and 5.4 show the metabolic activity per cell when HL60s were pumped 
inside the lumen of the hollow fibre in the single fibre bioreactor for 24 and 48 hours, 
at flow rates of 2 ml/min and 4 ml/min. From the graphs it can be noticed that the 
metabolic activity per cell was between 1.1 and 1.3 times higher in the samples 
cultured in the bioreactors at both flow rates rather than in a static environment. This 
was particularly evident when cells were pumped at a flow rate of 2 ml/min for 48 
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hours (fig. 5.3 B), where the cells cultured inside the bioreactor showed an 
absorbance/cell of 9x10
-6
 compared to 7x10
6 
of controls. Also their viability in the 
bioreactor was excellent, with 99% of cells viable except for those kept at 4 ml/min 
after 48 hours, which showed a survival rate of 84%. These preliminary results 
suggested that the shear stress created by the flow seemed to have a positive 
influence on HL60s’ metabolic activity and confirm the findings of McDowell and 
Papoutsakis, who reported 85% or higher viability of HL60s cultured in a stirred tank 
bioreactor and an increase in the cell line metabolic activity [299]. The results 
obtained with this experiment confirm that the shear stress induced by the laminar 
flow did not cause cell death and, on the contrary, stimulated HL60s metabolic 
activity compared to static culture systems.  
However, in the system used for the experiment the sample of cells extracted for the 
analysis might not give an accurate indication of the number and proliferation of the 
cells, as some cells might have accumulated in some parts of the system, e.g. inside 
the connections at the inlet or outlet of the bioreactor, or those at the inlet or outlet of 
the reservoir. Furthermore, another aspect of the experiment that might have caused 
inaccuracies in the results is given by the fact that the cells, being more dense than 
the medium, might have settled on the bottom of the feed bottle. As a consequence 
the cells analysed might not be representative of all the cells inside the system, 
especially after 48 hour, and therefore this aspect should be improved. For example, a 
magnetic stirrer could be inserted in the feed bottle in order to continuously mix the 
cells inside the reservoir. Also, in order to obtain more accurate results on the cell 
density and metabolic parameters, inline probes could be used which would allow the 
real time monitoring of cell density and metabolic activity without the need for 
sampling. For example, real time sensors for oxygen, glucose or lactate could give 
accurate online values for the metabolism of cells, while laser turbidity probes, light 
based probes or radio-frequency impedance probes would allow the real time 
measurement of cell density over time. 
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Fig. 5.3: Metabolic activity per cell shown as function of absorbance in the MTT assay for 
HL60 cells pumped into the hollow fibre for 24 (A) and 48 hours (B) at a flow rate of 2 
ml/min (bioreactor), compared to cells grown in static flasks (control). Data represent the 
mean ± SD (n= 4). ** P < 0.01. 
 
 
Fig. 5.4: Metabolic activity per cell shown as function of absorbance in the MTT assay for 
HL60 cells pumped into the hollow fibre for 24 (A) and 48 hours (B) at a flow rate of 4 
ml/min, compared to cells grown in static flasks (control). Data represent the mean ± SD (n= 
4). 
 
In addition to the shear stress caused by the flow of cells inside the hollow fibre, the 
shear stress caused by the pulsatile flow of the peristaltic pump should be considered 
when checking the integrity, viability and metabolic activity of HL60 cells circulated 
inside the hollow fibre bioreactor. Peristaltic pumps produce alternatively high and 
low fluid flow rates, and this might be negatively affecting the viability of cells. 
However, the pulsatile nature of blood flow through the vascular network generates 
wall shear stress and therefore the peristaltic pump is a valid tool to simulate the fluid 
shear stress found in vivo, provided that the shear stress generated is within 
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(A) (B) 
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physiological range [300]. Therefore the peristaltic pump used in this project was a 
useful tool for the circulation of human leukaemia cells (HL60s) inside the hollow 
fibre membrane, thus simulating circulation occurring in vivo. 
 
5.3   Secretion of HGF by the HL60 cell line 
 
Following the confirmation of the suitability of the single fibre bioreactor for HL60 
culture, the cell line was tested to verify the release of HGF when stimulated with 
some specific inducers, more specifically TPA, cAMP and heparin as described by 
Nishino et al [294], Matsumoto et al [240], Inaba et al [239].  They reported about 16 
ng/ml of HGF secreted in the medium, and 20 ng/ml are needed for the 
differentiation of MSCs into hepatocytes, according to the protocol of Snykers et al 
[213]. A two-fold concentrator could be used in order to obtain the concentration of 
HGF required for the differentiation of stem cells. Since TPA was prepared in 
DMSO, cells were also treated with DMSO to check whether the compound had any 
effect on the release of HGF. The concentration of HGF secreted in the cell culture 
medium was measured by ELISA. 
As can be seen in fig. 5.5, in contrast with the findings in the literature, neither 
inducers alone nor the combination of them gave a significant amount of HGF 
released in medium. However, there are differences between the different treatments, 
with TPA being the most effective inducer of HGF release with 0.227± 0.59 ng/ml, 
followed by DMSO with 0.078± 0.2 ng/ml. In addition, the HGF levels found in cell 
culture medium after stimulation of HL60s with TPA or with dbcAMP were 
significantly lower than those reported by Inaba and colleagues. They detected about 
16 ng/ml of HGF when HL60s were stimulated by TPA alone and 7 ng/ml when 
stimulated with dbcAMP. In contrast, our results were 0.227± 0.059 ng/ml for 
stimulation with TPA and 0.036± 0.65 ng/ml for stimulation with dbcAMP, using the 
same conditions reported in the work by Inaba et al. Following correspondence with 
the author of the paper, we had confirmation that no other group could reproduce the 
secretion of HGF by HL60s published in that paper, a reply which led us to reflect 
about the reliability of those experiments.  
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Heparin appeared not to have any effect on stimulation of HGF secretion, but, on the 
contrary it seemed to inhibit the release of the protein, since the levels of HGF 
detected after treatment of the cells with heparin were null, lower than controls in 
contrast with the findings of Matsumoto et al, who reported 15.9 ng/ml of HGF 
secreted by HL60s when stimulated by 1 µg/ml of heparin. Furthermore, no HGF 
was detected when heparin was combined to TPA and dbcAMP, suggesting that 
heparin had an inhibitory effect on the release of HGF from HL60s. It is worthy of 
note that the size of the error bars in this experiment are significantly higher than the 
average values of concentrations detected. This is an indication that the ELISA kit 
used for the measurement of HGF concentration is not sufficiently sensitive at such 
lower protein concentrations. 
 
It can be concluded that the treatment of HL60s with dbcAMP, TPA, heparin or the 
combination of the three of them did not lead to HGF secretion by HL60s. After 
investigating whether another suspension culture secreting HGF was reported in the 
literature, no other suspension cell line was found. The initial plan of realising a co-
culture system which consisted of a suspension cell line which circulated inside the 
lumen of the hollow fibre and continuously secreted HGF for the differentiation of 
the adherent stem cells, was therefore abandoned. 
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Fig. 5.5: HGF released by HL60s when stimulated by DMSO, TPA, dbcAMP, heparin and a 
combination of TPA, heparin and dbcAMP. Data represent the mean ± SD (n= 4). The 
concentration of HGF released by HL60 cells was measured by ELISA. 
 
 
5.4    Secretion of HGF by the MG63 human osteosarcoma cell line 
 
Given the lack of secretion of HGF from HL60s, another cell line capable of 
releasing HGF in cell culture medium was investigated. It has been reported that the 
human osteosarcoma cell line MG63 is able to spontaneously secrete HGF into cell 
culture medium without any external stimulation [295]. Therefore MG63s were 
seeded at a concentration of 10,000 cells/ml and incubated for three days at 37º C in 
order to check whether they were capable of releasing HGF into the cell culture 
medium. 
 
In this project 8.3 ng/ml of HGF released in the supernatant were measured by 
ELISA after culturing the cells for three days at a density of 10,000 cells/ml, 
confirming the data shown in the work of Taichman and colleagues, that reported 
15.5 ng/ml of HGF secreted following a twofold concentration of the culture 
medium. This result is promising, as MG63s could be used a cell factory for HGF 
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production without the need of expensive commercial HGF. In order to achieve the 
maximum level of HGF secreted into cell culture media, MG63s were seeded at 
different densities to see whether the HGF released was increased at increasing cell 
densities. From fig. 5.6 it can be observed that the concentration of HGF increased at 
increasing cell density, but at densities higher than 100,000 cells/ml it plateaued. This 
might be explained by the loss of metabolic activity of the cells at such high seeding 
densities due to the higher uptake of nutrients by the increased number of cells, and 
the less metabolically active cells probably secreted lower levels of HGF. Therefore 
from this graph it can be understood that cell densities between 75,000 and 100,000 
cells/ml gave the highest possible concentration of HGF released. MG63 cells, thanks 
to their ability to secrete HGF at the concentration required for the differentiation of 
stem cells into hepatocytes, were chosen as the “HGF factory cells” instead of 
HL60s. It is worth of note that another advantage in using MG63 cells instead of 
HL60s is given by the fact that MG63s do not require any stimulation with an 
external chemical compound to release HGF, such as TPA, dbcAMP or heparin in 
the case of HL60s, but on the contrary they release it spontaneously. 
 
Fig. 5.6: HGF released by MG63s cells seeded at different concentrations after three days 
from seeding. Data represent the mean ± standard deviation (n= 4) and were fitted with non-
linear regression (polynomial of third order) using GraphPad Prism software.  
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5.5 Comparison of commercial and cell-released HGF behaviour in 
static and dynamic environment 
 
Mechanical forces generated by the fluid flow inside the bioreactor, i.e. shear stress, 
can cause protein denaturation which would lead to loss of product in the system 
[301]. Therefore commercial HGF and HGF released by MG63 cells were both tested 
in static condition or circulated for three hours to analyse whether there was any 
difference between the natural and commercial growth factor and whether the 
dynamic forces caused by the flow might affect the stability and integrity of the 
protein. The concentration of biologically active HGF was then determined by 
ELISA as described in section 2.9.3 and expressed as a percentage of the initial 
concentration. 
 
In fig. 5.7 A, the concentration of commercial HGF in static conditions can be 
observed. The concentration of HGF remained roughly 100% (allowing for 
experimental error) for the first two hours and then decreased slightly to 93%. This 
slight decrease in concentration might be due either to degradation of the protein over 
time, or more likely, to experimental error as, for example, in some previous time 
points the concentrations measured were slightly higher than the initial 2 ng/ml. One 
explanation for the decrease in concentration could be that many globular proteins 
are not very stable in aqueous solutions and are easily subjected to denaturation, 
which can lead to protein aggregation and thereby loss of product [301]. An 
experiment considering a longer time span would be useful in order to understand 
whether the protein started degrading after two hours. In fig. 5.7 B the concentration 
of commercial HGF circulated continuously for three hours was measured. In 
contrast to static environment, the concentration of HGF dropped down exponentially 
with time and after only three hours its concentration was reduced to 35.65% from 
that at time zero. This might be due to a combination of factors: there might be 
spontaneous degradation of the protein over time, or the growth factor might have 
bound to the tubing, which could explain the continuous drop of concentration with 
the continuous recycling of the solution. However, the most probable cause that 
might have affected the stability of the protein is represented by the shear forces 
caused by the flow. It is known that shear stress can have negative effects on protein 
stability, as proteins exposed to flow might undergo irreversible unfolding [302] 
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which can result in protein aggregation and loss of product [303-306]. This result 
indicates that the HGF might be very sensitive to shear stress even at physiological 
values; 0.1-1.2 Pa is the physiological range of shear stress experienced by vascular 
cells while 1.5 Pa can be considered the threeshold value for physiological shear 
stress because arteries exposed to chronic increased blood flow change their diameter 
to maintain the mean shear stress magnitude at approximately 1.5–2.0 Pa [296-298]. 
This might explain the rapid loss of 65% of protein in only 3 hours. These results 
indicate that the commercial HGF purchased from R&D for the project is not suitable 
for use in dynamic environments, like in bioreactors, and therefore not suitable to be 
used for this project. 
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Fig. 5.7: Concentration of commercial HGF (expressed as % of the initial concentration of 
HGF: 2 ng/ml) over time in static conditions (A) and when circulated continuously inside 
plastic tubings at a rate of 2.5 ml/min (B). Data represent the mean ± SD of three samples 
(n=3). Data in graph A were fitted with linear regression, and data in graph B were fitted 
with non-linear regression (one phase exponential decay) using GraphPad Prism software.  
 
 
 
 
B) 
A) 
139 
 
When the same experiment was performed with HGF released by MG63 cells, the 
result was surprisingly different (fig. 5.8). In fact, under static conditions, the 
concentration of the protein remained stable for the whole three hours with very few 
variations among the different samples (indicated by the small error bars) (fig. 5.8 
A), and, in contrast to the commercial HGF, it remained stable even in dynamic 
conditions, with no loss of active protein after three hours (fig. 5.8 B). An 
explanation for the different behaviour between the native and commercial protein 
could be that human HGF purchased from R&D is a recombinant protein generated 
by alternative splicing in spodoptera frugiperda by baculovirus infection and lacks 
some domains of the native protein. In fact it consists of a 60 kDa α and of a 30 kDa 
β chain, while the native HGF has a 69 kDa α and a 34 kDa β chain. Therefore the 
commercial protein might be unstable compared to the native HGF secreted by 
MG63s because some post-translational modifications normally occurring in 
eukaryotes after native protein synthesis might not have occurred in the recombinant 
protein. In fact, the use of insect cells as an expression system, although has been 
shown to express higher protein levels and to be safer compared to mammalian cell 
systems,  presents some disadvantages, e.g. the inability of properly processing 
proteins that are initially synthesised as larger inactive precursor proteins (e.g. 
hormones, growth factors, metalloproteases) [301].  When considering the proteolytic 
cleavage of different protein precursors, it has been found that although mammalian 
secretion signals are accurately processed in insect cells, other proteolytic cleavage 
sites are insufficiently or not at all recognised in insect cell cultures [307]. More 
specifically, the pro-HGF was cleaved non specifically when produced by Sf-9 cells 
[308]. Furthermore, although the N-linked glycosylation sites are the same in 
mammalian and insect cells, insect cells are not capable of processing the mature 
oligosaccharides to the forms found in mammalian cells [307, 309, 310]. Finally, the 
commercial protein during purification is deprived of its natural environment such as 
stabilizing lipids, lipoproteins and/or proteins, and that might also affect its stability 
[301]. All these reasons might explain the instability and rapid degradation of 
commercial HGF when exposed to fluid flow. This result is very important, as HGF 
secreted by MG63, thanks to its stability in a dynamic environment, could be used in 
a bioreactor system and, given the high proliferation rate of MG63 cells, large 
amount of the protein could be continuously available for the stem cells in the 
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bioreactor in order to differentiate them into hepatocytes or, subsequently, to 
maintain their state differentiated. 
 
 
 
 
 
 
Fig. 5.8: Concentration of HGF secreted by MG63s (expressed as % of the initial 
concentration of HGF: 2.5 ng/ml) over time in static conditions (A) and when circulated 
continuously inside plastic tubings at a rate of 2 ml/min (B). Data represent the mean ± SD of 
three samples (n= 3). Data were fitted with linear regression, using GraphPad Prism 
software.  
 
 
 
 
 
A) 
B) 
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5.6   Permeation of HGF secreted by MG63 across 5% PVA-PLGA 
blended hollow fibres 
 
Mass transfer is one of the fundamental parameters to be considered in tissue and 
organ engineering strategies. Without an appropriate transfer of nutrients to the cells 
the in vitro tissue/organ reconstruction would fail. Therefore a membrane that allows 
an appropriate transfer of nutrients to the cells must be employed. In Section 3.2.5 it 
was shown that 5% PVA-PLGA hollow fibre membranes, thanks to their increased 
hydrophilicity, allowed a higher hydraulic and BSA permeability with no protein 
adsorption, when inserted in a single fibre hollow fibre bioreactor. However, several 
proteins should be analysed in order to prove that the 5% PVA-PLGA hollow fibre 
bioreactor is a suitable system for organ/tissue engineering. Among these, HGF (80 
kDa compared to 66 kDa for BSA) is the first candidate that needs to be tested in this 
project since it must be continuously available to mesenchymal stem cells in order to 
differentiate them into hepatocytes and to maintain their state differentiated. 
Therefore HGF must not only be stable when exposed to the flow generated by the 
pump, but must also permeate through the pores of the membrane without being 
absorbed. HGF was therefore circulated inside the lumen of the hollow fibre within 
the single fibre bioreactor system and the permeability of PVA-PLGA blended 
membranes to the growth factor was tested. Given the rapid loss of protein during 
circulation, it was impossible to detect a reasonable amount of commercial HGF after 
permeation through the hollow fibre membrane. Therefore, only the data obtained 
from the permeation of HGF released by MG63 are shown. 
 
Fig. 5.9 A- C represent the concentration of HGF from MG63 (expressed as a w/v % 
of the initial concentration of HGF) in the feed, permeate and retentate respectively, 
when 8 ng/ml of HGF were circulated for 3 hours through a hollow fibre bioreactor 
with a 5% PVA-PLGA hollow fibre membrane. From fig. 5.9 A it can be seen that 
the concentration of HGF in the feed solution was stable over time, as expected, and 
variations from 100% were only due to experimental error. In fig. 5.9 B it can be 
observed that the concentration of HGF in the permeate decreased in the first hour 
and then remained stable for another hour and started decreasing again in the third 
hour. This decrease in concentration could be caused by several different reasons: 
denaturation of the protein while permeating through the pores of the fibre, partial 
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rejection of the protein from the pores or fouling, which can be caused either by 
internal deposition of protein molecules, by blocking of pores by protein aggregates, 
or by formation of protein deposits on the membrane surface (concentration 
polarisation) [253]. From fig. 5.9 C it can be seen that the concentration of the 
retentate did not remain stable over time but decreased after two hours. Therefore in 
the first hour, a decrease in the concentration in the permeate, but not in the retentate 
was observed, which suggests that fouling might have occurred. However, in the 
third hour a decrease both in permeate and in retentate occurred, which might suggest 
that HGF underwent denaturation/degradation. However, despite a decrease in HGF 
concentration in the permeate, 81% of the initial concentration was still present after 
three hours, which is a promising result for an application of the MG63-secreted 
HGF to bioreactor technology, as this native HGF not only appeared to be stable in a 
dynamic environment and not sensitive to shear forces caused by the flow, but also 
could permeate across the pores of the 5% PVA-PLGA hollow fibre membranes 
without significant loss of protein in the first three hours. Further studies should be 
performed in order to understand the mechanism of fouling occurring in the first hour 
of permeation, and to investigate which is the cause that has led to a further decrease 
in concentration during the third hour of experiment. 
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Fig. 5.9: Concentration of HGF (expressed as a % of the initial concentration [8 ng/ml] of 
HGF in the feed solution at time 0) in the feed solution (A), permeate (B) and retentate (C) 
solutions over 3 hours circulation at a flow rate of 2.5 ml/min. Data represent the mean ± SD 
of three samples (n= 3). 
A) 
B) 
C) 
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5.7  Conclusions 
 
The initial aim of this project was to realise a co-culture system consisting of a 
suspension cell line which circulated inside the lumen of the hollow fibre and 
continuously secreted HGF for the differentiation of the stem cells seeded on the 
outer surface of the membrane. Among cell lines secreting HGF, HL60 cells were 
chosen in first place for their characteristic of growing in suspension, which was 
appropriate for achieving the realisation of the system. 
 
The single fibre hollow fibre bioreactor has been shown to be suitable for the culture 
of the HL60 cell line since the shear stress induced by the laminar flow did not affect 
cell viability and, on the contrary, stimulated HL60 metabolic activity compared to 
static culture systems. However, treatment of HL60s with dbcAMP, TPA, heparin or 
the combination of the three of them did not lead to HGF secretion, so this cell line 
was abandoned. Another cell line, adherent MG63 cells, thanks to their ability to 
spontaneously secrete HGF with no need of any external stimulation, and at a 
concentration required for the differentiation of stem cells into hepatocytes, were 
chosen as the “HGF factory cells” instead of HL60s.  
MG63-derived HGF, has been shown to be stable in a dynamic environment, as 
opposed to commercial HGF which degraded rapidly when exposed to the flow of 
the bioreactor. Furthermore, it permeated across the pores of the 5% PVA-PLGA 
hollow fibre membranes without significant loss of protein in the first three hours. 
Therefore, MG63-secreted HGF appears to be suitable for use in a bioreactor system 
and in particular, in the system employed in this project to differentiate stem cells 
into hepatocytes. In particular, when considering the fact that stem cells need to be 
exposed to the growth factors for several days or weeks in order to differentiate, a 
system where MG63 cells, thanks to their high proliferation rate, can continuously 
release large amounts of the protein would be very advantageous over traditional 
systems that employ commercial HGF. In this novel system, not only would HGF be 
continuously available for the stem cells, thus allowing higher differentiation 
efficiency and the maintenance of their differentiated state, but also the cost of the 
process would be greatly reduced: this system would allow in fact for the cost-free 
production of a protein for the whole time required for the differentiation, thus 
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circumventing the high costs associated with the prolonged treatment of cells with 
commercial HGF. Finally, it is worth noting that this system where MG63 cell line 
secretes HGF is only one example of a system that could be used for the production 
of many other growth factors: if a cell line is found to secrete the protein of interest, 
it could be used as a cell factory producing the protein for the differentiation of stem 
cells in lineages other than liver, thus making this system suitable for regeneration of 
many different tissues. 
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6 Differentiation of stem cells towards 
the hepatic lineage with MG63-
secreted HGF 
 
6.1     Cell sources for liver regeneration 
 
Table 6.1 gives a summary of the characteristics of various cell sources available for 
liver regeneration. At present it is clear that the ideal hepatic cell for liver 
regeneration is still not available, although progress has been made in understanding 
liver cell proliferation and differentiation [311]. As a consequence of a lack of donor 
organs for liver transplantation, the supply of primary human hepatocytes (which 
would be the ideal hepatocellular source) is limited. On the contrary, there is an 
unlimited availability of primary mammalian hepatocytes, especially porcine 
hepatocytes. However, porcine xenografts elicit a severe humoral and cellular 
immunologic response in humans [312, 313]. Another possible risk is the 
transmission of viral pathogens from the xenograft donor to the recipient [7, 314]. In 
addition to these risks, it must be taken into consideration that the proteins released 
by porcine hepatocytes do not carry out the same functions of human hepatocytes, 
and that, irrespectively of their source, primary hepatocytes are difficult to maintain 
in culture as they rapidly lose their differentiated function in vitro [7]. 
Due to their potential for unlimited expansion, several human hepatocyte cell lines 
such as HepG2 (human hepatoblastoma) [315], the HepG2 derived C3A [316], 
HepLiu (SV40 immortalised) [317], and immortalised human fetal human 
hepatocytes [318] have been developed via different systems, e.g. via spontaneous 
transformation [319] or via retroviral transfection of SV40 large-T antigen gene 
[320] as alternative to human primary hepatocytes.  However, it has been shown that 
these cell lines tend to lose critical functions, e.g. drug and ammonia metabolism, in 
vitro, compared to primary hepatocytes [7, 321]. Furthermore, a risk correlated with 
the use of immortalized cell lines is the potential risk of transmission of tumorigenic 
products from the bioartificial liver system into the patient’s circulation [286]. 
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Therefore, alternative cell sources for liver cell-based therapies have been 
investigated. Among them, stem cells are receiving a considerable interest from 
researchers for liver regeneration strategies, thanks to their differentiation capacity 
and to their self-renewal capacity, which would allow for the production of a large 
amount of cells, in contrast to the scarce availability of hepatocytes. Human 
embryonic stem cells might be an attractive source for human hepatocytes because of 
their indefinite proliferation in vitro and their capacity to differentiate into almost all 
cell types. Embryonic stem cells have been shown to differentiate into functional 
hepatocytes upon stimulation with FGF-4 and HGF [291] and to improve liver 
function in mice when employed in bioartificial liver assist devices [322] However, 
the differentiation efficiency was found to be rather low [323]; furthermore, the 
transplantation of these cells into the patient presents safety issues related to their 
potential of forming tumours and to their immunogenicity in allogenic setting. 
Finally, the ethical concerns surrounding the use of embryonic stem cells make 
difficult at present a possible clinical application. New immunocompatible 
pluripotent cells like induced pluripotent stem cells (iPSCs) could be an alternative to 
ethical problems associated with the use of human embryos, but long-term studies 
must still be carried out in order to fully characterise them and eliminate any 
potential safety concern about their use [324]. 
Adult stem cells are at present a valid alternative to embryonic stem cells as they do 
not imply the destruction of a human embryo and they are not tumorigenic and not 
immunogenic. Nevertheless, the existence of adult liver stem cells is still debated, 
although there is evidence of the presence of such stem/progenitor cells in adult liver 
[325-327].  
Tissues other than liver are also being considered as they contain adult stem cells 
which were found to have the capacity to differentiate into hepatocytes. In the past, 
the developmental paradigm was that adult stem cells were, in contrast to embryonic 
ones, committed to a specific cell fate. At present, new discoveries on stem cell 
plasticity have challenged the canonical developmental hierarchy [40]. 
Hematopoietic stem cells, for example, are adult stem cells found in the bone marrow 
which give raise mainly to blood cells, but they also can contribute to completely 
different tissues such as liver [45]. There is also evidence that human foetal pancreas 
cells can differentiate into hepatocytes when treated with FGF-2 and dexamethasone 
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[328]. Mesenchymal stem cells are another population of adult stem cells abundant in 
the bone marrow and adipose tissue, that can differentiate into bone, cartilage and 
adipose cells, but have also been found to differentiate into hepatocytes under 
specific induction with cytokines or growth factors [213, 241, 292, 293] or when co-
cultured with foetal liver cells [183]. More recent protocols of differentiation of 
mesenchymal stem cells into the hepatic lineage with growth factors try to mimic 
nature and the cells are exposed to liver specific factors in time sequence that 
resembles that occurring during liver development. Snykers et al. for example, 
reported that mesenchymal stem cells differentiated toward the hepatic lineage with a 
higher efficiency when cells were exposed to liver-specific factors in a time-sequence 
that mimicked the in vivo liver embryogenesis (FGF-4 to induce endoderm, followed 
by HGF, insulin-transferrin-selenium, dexamethason and trichostatin A to induce 
liver specification), compared to those treated with a “cocktail” of the all factors at 
the same time-points [213, 241].  Mesenchymal stem cells therefore seem to be an 
attractive stem cell type to be used for liver tissue engineering, and for their potential 
clinical applications, and for these reasons they were employed in the present work.  
However, although stem cells have a great potential for liver regeneration strategies, 
many challenges remain. In fact, although hepatocytes are the only cell type secreting 
albumin, it should be demonstrated that the stem cell derived hepatocyte expresses 
also the other hepatocyte-specific genes and also that their expression levels are 
comparable to those of primary hepatocytes [329]. Other challenges include the 
ability of triggering and enhancing differentiation and also the stabilisation of the 
hepatocytes functions [3]. A qualitative as well as quantitative analysis of hepatocyte 
marker expression is then needed in order to prove the effective differentiation of 
stem cells into functional hepatocytes. 
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Table 6.1: Characteristics of various cell sources available for liver regeneration. From [330] 
Cell source Supply Liver-specific 
function 
Host 
compatibility 
Other risks to 
patients 
 
Primary Human 
Hepatocytes 
 
 
Scarce 
 
Generally 
unstable 
 
Excellent 
 
Small 
 
Stem-cell derived 
human hepatocytes 
 
 
Unlimited 
 
Low efficiency 
of 
differentiation 
to hepatocytes 
 
 
Excellent 
 
Small 
 
Immortalised 
human hepatocytes 
 
 
Unlimited 
 
Function poorly 
characterised 
 
Excellent 
 
Transmission 
of tumorigenic 
products 
 
 
Human hepatoma 
cell line 
 
 
Unlimited 
 
Reduced level 
compared to 
primary cells 
 
 
Excellent 
 
Transmission 
of tumorigenic 
products 
 
 
Primary xenogenic 
(porcine) 
hepatocytes 
 
Unlimited 
 
Can express 
high levels but 
generally 
decreases over 
time  
 
Metabolic 
mismatch, 
potential 
severe 
immune 
complications 
 
 
Transmission 
of zoonoses 
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6.2     Introduction to the experimental work 
 
In this project, rat mesenchymal stem cells were chosen as the cell source for liver 
regeneration. The many advantages in the use of mesenchymal stem cells include 
their plasticity (i.e. their ability to differentiate into lineages other than their tissue of 
origin), their non-tumourigenicity and non-immunogenicity, and also their ethical 
approval. The strategy used to differentiate MSCs consisted in exposing the cells to a 
sequence of liver-specific growth factors that mimic that occurring during liver 
development. This strategy, if combined to the culture of cells within the hollow fibre 
bioreactor, was supposed to mimic more closely nature, thus possibly leading to an 
improvement of the efficiency of differentiation. 
Before describing the experimental work, it is worth mentioning that the system used 
for the differentiation of mesenchymal stem cells assumes that the cells are 100% 
confluent, and, when they will be seeded on the outer surface of hollow fibre 
membranes, they will evenly adhere to the membrane which presents pores of 1.1 µm 
average size and an overall porosity of 0.77.  
 
Once verified by flow cytometry the identity of mesenchymal stem cells, the culture 
was treated with a sequential exposure of liver-specific factors that mimicked the in 
vivo liver embryogenesis, as shown by Snykers et al [213]. Although the protocol 
from Snykers et al was followed with regard to which specific liver factors were 
added to the cell culture and the time sequence in which they were provided to the 
cells, the novelty of this experiment consists of the use of HGF released by a cell line 
instead of commercial HGF. MSC differentiation into the hepatic lineage was 
analysed either by tracking the morphological changes occurring in cell cultures 
every three days, and by immunofluorescence to see whether the cells expressed 
three specific hepatic markers: albumin, UGT and transferrin. Cells treated with cell-
secreted HGF were compared to those treated with commercial HGF in order to 
check whether there was any difference in the differentiation efficiency between the 
two treatments. 
 
In sections 5.4- 5.6 it was demonstrated that the MG63 cell line has the ability to 
secrete human HGF in the cell culture medium without need of specific inducers, and 
that the growth factor secreted is stable when exposed to the flow created inside a 
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hollow fibre bioreactor and can permeate across 5% PVA-PLGA hollow fibre 
membranes without significant loss of protein after three hour experiment.  
Therefore MG63 secreted-HGF was tested to see whether the native protein was able 
to induce differentiation of mesenchymal stem cells into hepatocytes. It is known that 
mesenchymal stem cells can differentiate into hepatocytes upon induction with 
specific cytokines and growth factors [213, 241, 292, 293]. Mesenchymal stem cells 
treated with MG63 released HGF were compared with MSCs treated with 
commercial HGF to see whether any difference in morphology and/or hepatic marker 
expression had occurred. 
 
6.3    Confirmation of mesenchymal stem cells markers  
 
Prior to differentiation into the hepatic lineage, mesenchymal stem cells extracted 
from Wistar rats were analysed by flow cytometry to check whether they expressed 
some of the mesenchymal stem cell markers. More specifically, one negative  
(CD45) and two positive (CD44 and CD90) MSC markers were analysed. 
The anti-rat CD45 marker is a monoclonal antibody to the rat CD45 antigen that 
recognizes a monomorphic determinant of the rat leukocyte common antigen (L-CA). 
The CD45 antigen is expressed on leukocytes: T-cells, B-cells, monocytes, 
macrophages, and granulocytes [331]. CD45 is not expressed on mesenchymal stem 
cells and therefore is commonly tested as negative marker for MSCs [332]. The anti-
rat CD44 marker is a monoclonal antibody that recognises an epitope on the cell 
surface antigen CD44. It is an adhesion molecule expressed on most leukocytes 
(except a sub population of B cells), endothelial cells, hepatocytes, and MSCs [333-
335]. Furthermore, many cancer cells express high levels of CD44. [336, 337]. Anti-
rat CD90 monoclonal antibody recognizes the Thy 1.1 antigenic determinant, 
designated CD90 on rat as well as mouse cells. This particular determinant has been 
defined to be monomorphic within rats but polymorphic in the mouse. The Thy-1 
antigen is found on a variety of cell types including thymocytes, neuronal cells, 
mesenchymal stem cells, hematopoietic stem cells, T and immature B cells, 
endothelial cells and connective tissue [338-341]. Mouse IgG1 and IgG2 isotype 
control antibodies were used as negative controls in order to estimate non-specific 
binding of the antibodies to the cells, and therefore to assess the level of background 
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staining in flow cytometric analysis. In the scatter plots of the cells, a gate was used 
to select the live MSC population based on cellular size (forward scatter, FSC) and 
granularity (side scatter, SSC) (see appendix). 
 
Fig. 6.1 and 6.2 show the expression of CD44 and CD45 antigens respectively on the 
surface of rat MSCs. IgG2a isotype mouse anti-rat control antibody conjugated with 
fluorescein isothiocyanate (FITC) was used as a negative control for these antigens. 
The red histograms represent the fluorescence emission of cells expressing the 
marker, while the white ones that of the IgG2 controls. Data were subsequently 
normalised to the number of events in order to compare the pairs of histograms. It 
can be observed that the populations of live cells labelled with IgG2a control 
antibody emitted minimal fluorescence, as shown by the white histograms located at 
the left of the diagram, with mean fluorescence emission of 81, while the red 
histogram representing the fluorescence emission of the population labelled with 
CD44 mouse anti-rat antibody (fig. 6.1) was slightly shifted to the right compared to 
the controls, with a mean fluorescence emission of 213, suggesting these cells were 
weakly positive for CD44. In contrast, the histogram representing the population of 
cells labelled with CD45 FITC conjugated antibody (fig. 6.2) overlapped with that of 
IgG2 controls, which also emitted a minimal fluorescence value of 81. This result 
suggested that these cells were negative for CD45. 
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Fig. 6.1: Flow cytometry analysis of the CD44 cell surface marker (red histogram), 
compared to negative control IgG2 (white histogram). Data are expressed as FITC 
fluorescence intensity emission. Fluorescence values were normalised to the number of 
events in order to compare the two histograms. 
 
 
Fig. 6.2: Flow cytometry analysis of the CD45 cell marker (red histogram), compared to 
negative control (white histogram) IgG2. Data are expressed as FITC fluorescence intensity 
emission. Fluorescence values were normalised to the number of events in order to compare 
the two histograms. 
 
Fig. 6.3 shows the expression of the CD90 antigen on the surface of rat MSCs.  The 
IgG1 isotype mouse anti-rat control antibody conjugated to phycoerythrin (PE) was 
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used as negative control for CD90. Data were subsequently normalised to the number 
of events in order to compare the two histograms. It can be observed that the 
populations of live cells labelled with IgG1 control antibody emitted minimal 
fluorescent signal with mean value of 143, as shown by the histogram located at the 
left of the diagram, while the population labelled with PE-conjugated CD90 mouse 
anti-rat antibody emitted a strong fluorescent signal with a mean value of 30,227 and 
the histogram was shifted to the right compared to the controls, suggesting that the 
cells were positive for CD90. 
 
 
Fig. 6.3: Flow cytometry analysis of the CD90 cell surface marker (red histogram), 
compared to negative control (white histogram) IgG1. Data are expressed as PE fluorescence 
intensity emission. Fluorescence values were normalised to the number of events in order to 
compare the two histograms. 
 
 
The flow cytometry analysis conducted on these three markers suggests that the 
technique used to isolate MSCs from rat bone marrow was successful, as cells were 
positive for CD44 and CD90 and negative for CD45, as indicated in the literature. 
However, more markers should be analysed in order to confirm the mesenchymal 
stem cell identity of the population.  
Although rat MSCs resulted positive for both CD44 and CD90 surface markers, as 
expected, the difference in expression between the two markers is probably due to the 
different fluorochrome conjugated to the two antibodies: PE in fact usually has a 
stronger signal than FITC, because it has a maximum emission peak at 575 nm 
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against 518 nm of FITC, and it is more photostable than FITC [342], thus probably 
for this reason cells labelled with CD90 antibody conjugated to PE emitted a stronger 
fluorescent signal than those labelled with CD44 antibody conjugated to FITC, that 
resulted only weakly positive to CD44. 
. 
6.4     MSC differentiation 
 
Once confirmed the identity of MSCs, the culture was exposed to liver-specific 
factors in a sequential manner, as shown by Snykers et al [213, 241]. According to 
the authors, the hepatic differentiation of MSCs was more effective when cells were 
exposed to liver-specific factors in a time-sequence that mimicked the in vivo liver 
embryogenesis, compared to those treated with a “cocktail” of the all factors at the 
same time-points. Following the protocol of Snykers et al, (fig.6.4) cells were  
expanded and when confluent, they were treated for 3 days with fibroblast growth 
factor 4 (FGF-4), a growth factor that stimulates the endoderm specification. On the 
third day, medium was changed and replaced with fresh medium containing 
hepatocyte growth factor (HGF). Two experiments were carried out in parallel: cells 
were treated with commercial HGF or with MG63-derived HGF, in order to check 
any potential difference in morphology and hepatic marker expression between the 
two treatments. From the 6
th
 to 18
th
 day cells were treated with a cocktail of HGF, 
insulin-transferrin-sodium selenite (which contains three important growth factors to 
stimulate cell growth: insulin, transferrin, selenium), dexamethasone (an anti-
infammatory gluticorticoid which regulates cell survival, proliferation and 
differentiation, [182, 343, 344]) and trichostatin A (a Streptomyces metabolite which 
was shown to increase MSCs differentiation into the hepatic lineage [241]). 
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Fig. 6.4: Schematic representation of the protocol used to differentiate MSCs into 
hepatocytes. MSCs at 100% confluency were exposed to liver specific factors in a time-
dependent order that reflects their secretion pattern during in vivo liver embryogenesis. 
Adapted from [213]. 
 
MSC differentiation into the hepatic lineage was analysed by tracking the 
morphological changes occurring in cell cultures every three days, and by 
immunofluorescence to see whether the cells expressed three specific hepatic 
markers: albumin, UGT and transferrin. Oil Red O staining was also performed on 
the cultures in order to detect the potential differentiation of stem cells into the 
adipogenic lineage. 
 
6.4.1 Morphological analysis 
 
Potential morphological changes were observed from the 14
th
 day of cell treatment 
with the differentiation medium. MSCs treated with commercial HGF were almost 
confluent but some dense structures within the culture can be observed (* in fig. 6.5): 
they might be areas of mineralization, of bone formation, indicating that 
differentiation of some MSCs into osteogenic lineage had occurred. However, this 
cannot be confirmed as a specific staining to detect the presence of mineralization, 
such as von Kossa should have been performed. However, the potential 
differentiation of mensenchymal stem cells into bone cells would not be surprising as 
MSCs can spontaneously differentiate into osteoblasts. Therefore, from a first visual 
analysis it can be noticed that a non homogeneous population of cells was observed 
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after 14 days culture consisting of a mixture of mesenchymal stem cells and cells 
potentially differentiating into the osteogenic lineage. 
 
        
Fig. 6.5: Phase contrast microscopy images of MSCs treated with commercial HGF for 14 
days. Scale bars: A) 500 µm; B) 100 µm. *= bone nodules. 
Similarly to MSCs treated with commercial HGF, cells treated with MG63-derived 
HGF exhibited several dark areas that resemble bone nodules formation (* in fig. 6.6) 
which represent the first areas of ossification. An example of a bone nodule is shown 
in fig. 6.7. This differentiation might be due either to the spontaneous differentiation 
of MSCs into osteoblasts or also by the fact that MG63s, being a cell line derived 
from human osteosarcoma, might have released some osteogenic factors in the 
medium. For example, MG63s have the ability to secrete osteocalcin [345], TGF-β 
and prostaglandin E2 [346], which might have induced stem cells to differentiate into 
osteoblasts.  
This suggests that HGF should be purified from the MG63-released supernatant in 
order to discard the other proteins or factors that are not liver tissue-specific and that 
might negatively interfere with the induction of stem cell differentiation into the 
hepatic lineage. A first attempt could be done by filtering the supernatant through a 
membrane with a molecular weight cutoff as close as possible to 80kDa in a 
centrifugal tube. The molecules with MW lower than 80 kDa would pass through the 
filters of the membrane while HGF would be retained. The retained supernatant 
could be then used to differentiate the stem cells into hepatocytes. In case this 
method still results in non-specific differentiation of cells, liquid chromatography 
could be a valid alternative to purify the HGF from the medium. 
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Fig. 6.6: Phase contrast microscopy images of MSCs treated with HGF from MG63s for 14 
days. *= bone nodule. Scale bars: A) 500 µm; B) 200 µm; C) 100 µm. 
 
 
Fig. 6.7: Alizarin red stained osteoblastic cultures showing bone nodules (*) formation. From 
[347]. 
 
At day 17 a significant change in the morphology of the cells was observed. In fig. 
6.8 and 6.9 the cells treated with commercial and MG63-secreted HGF, respectively, 
are displayed. Given the high density of the cells, especially those treated with 
commercial HGF, it is difficult to determine the morphology and the type of cell, 
however, it is very likely that the cell population is not homogeneous, and in fig. 6.9 
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A some structures resembling bone nodules can be observed among the other cells. 
At a first glance, cells exhibit bigger nuclei (arrows in fig. 6.8 B) and a more 
polygonal shape, which might indicate that the cells are losing their stem cell 
properties and might have or be in process of differentiating into the osteoblastic 
lineage: high mesenchymal stem cell densities have in fact been shown to induce 
higher chondrogenic and osteogenic differentiation rates due to soluble factors 
produced by and to signals from the neighbouring cells [180, 181, 185]. 
 
     
Fig. 6.8: Phase contrast microscopy images of MSCs treated with commercial HGF after 17 
day culture. Scale bars: A) 200 µm; B) 100 µm. 
 
    
Fig. 6.9: Phase contrast microscopy images of MSCs treated with HGF released by MG63s 
after 17 day culture. *= bone nodule. Scale bars: A) 200 µm; B) 100 µm. 
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6.4.2 Oil Red O staining 
 
Oil Red O staining was performed at day 18 on mesenchymal stem cells treated with 
commercial and MG63 released HGF to check whether any cells had undergone 
adipogenic differentiation. In fig. 6.10 Oil Red O staining of MG63 cells, which were 
used as negative control, is displayed. In this figure nuclei of MG63s are stained blue 
by haematoxylin staining, and the cytoplasm is weakly stained red/pink, probably 
due to the non-specific background staining with Oil Red O. In MSCs treated with 
commercial HGF (fig. 6.11 and 6.12) some intensely red stained areas can be 
observed, which might be representing lipidic drops. However, it is not clear whether 
the staining was successful as in cells treated with HGF released by MG63s the red 
areas resemble more a residue of dye remaining after the washing rather than a 
specific staining, as can be noticed from the many randomly distributed  red spots 
(fig. 6.12 A, B, C). Therefore it cannot be concluded whether any differentiation of 
mesenchymal stem cells into adipocytes had occurred. 
 
 
 
Fig. 6.10: Oil Red O staining of MG63s (negative control). Scale bar: 100µm. 
 
 
 
 
 
 
  A 
A 
161 
 
       
 
Fig. 6.11: Oil Red O staining of MSCs treated with commercial HGF after 18 day culture. 
Scale bars: A) 100 µm; B) and C) 50 µm. 
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Fig. 6.12: Oil Red O staining of MSCs treated with MG63-derived HGF after 18 day culture. 
Scale bar: 50µm. 
 
6.4.3 Liver markers 
 
The expression of three liver specific markers, albumin (a plasma protein synthesised 
by the liver), UDP-Glucuronosyltransferase (UGT, an important enzyme expressed in 
liver for drug metabolism and elimination of foreign and endogenous substances) and 
transferrin (a plasma protein synthesised by the liver for iron delivery) was analysed 
by immunofluorescence. MG63 cells were used as negative controls and the HepG2 
cell line as positive controls. From the analysis of positive controls, albumin and 
UGT, but not transferrin, were expressed by the HepG2 cell line. This last result was 
not expected as according to the literature, HepG2 cells express transferrin [348] 
However, from the analysis of the immunofluorescence staining of MG63 cells, the 
negative control, although transferrin was not expressed, albumin and UGT were 
highly expressed in MG63s. Undifferentiated MSCs treated with HGF were also 
positive for UGT and albumin, but negative for transferrin. This result confirms that 
a problem with the antibodies or during one of the steps of the immunostaining had 
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occurred, as transferrin was not even expressed in positive controls and albumin and 
UGT were expressed in all the samples, even in negative controls. This suggests that 
the results of the immunofluorescence staining of MSCs treated with HGF are 
unreliable. However, from UGT immunofluorescence images (fig. 6.13), it is 
possible to notice some morphological features of the cells. Most of the well is 
occupied by cells that have a morphology that resembles that of mesenchymal stem 
cells, as an indication that cells had not differentiated, but among these cells there are 
some clusters of bigger cells that lost the elongated shape to assume a more 
polygonal morphology. These cells exhibit large nuclei, and sometimes two nuclei 
are visible, probably indicating that the cells were undergoing division. Some of the 
cells also exhibit cytoplasmic projections, possibly filopodia (fig. 6.13). These cells 
had also spread extensively on the surface of the well, reaching about 100 µm in 
diameter. These cells might just be undifferentiated mesenchymal stem cells that had 
changed their morphology, as when kept in culture for many passages they usually 
lose their elongated shape and acquire a more polygonal morphology. Given the 
polygonal morphology and the large cytoplasm and nuclei of some of these cells (see 
fig. 6.13 A- D), it could be hypothesized that they might be osteoblasts, which would 
not be surprising as mesenchymal stem cells tend to spontaneously differentiate at 
high cell densities [263]. 
Given their large size and high spreading, these cells cannot be classified as 
hepatocytes as they usually exhibit a more compact morphology and an average 
diameter of about 20 µm [349]. In fig. 6.14 the morphology of hepatocytes can be 
observed. It can be noticed that cells in fig. 6.13 present a more spread morphology 
while hepatocytes possess a more defined, compact polygonal morphology. 
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Fig. 6.13: Immunostaining of MSCs treated with HGF from MG63s after 18 days culture. 
Scale bar: 100 µm. 
 
Fig. 6.14: Morphology of hepatocytes. From [213]. 
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Given the unreliable results obtained with the controls, further repeats should be 
performed in order to clarify the effect of MG63-released HGF on the stem cells. 
Currently it can only be concluded that a heterogeneous population of cells was 
observed, and that their morphology did not resemble that of hepatocytes.  
 
If this prediction is correct, then the treatment of MSCs with HGF released by 
MG63s did not lead to the differentiation of stem cells into hepatocytes. Also, the 
morphology of the cells treated with commercial and MG63-secreted HGF is very 
similar, thus suggesting that the treatment of MSCs with hepatogenic growth factors 
and cytokines in a sequential manner that resembled embryonic liver development 
did not stimulate the cells to differentiate into hepatocytes, in contrast with the 
findings of Snykers et al., that reported a homogenous populations of hepatocytes 
after 18 days sequential exposure of rat bone marrow mesenchymal stem cells to 
specific hepatogenic factors. More hepatogenic growth factors and cytokines might 
be required in order to achieve mesenchymal stem cell differentiation, such as 
nicotinamide  [350], oncostatin, EGF [351].  
 
In contrast, the problem might arise from the intrinsic nature of mesenchymal stem 
cells, as being adult stem cells, they might be already committed to a more specific 
lineage and therefore it would be more difficult to successfully differentiate them into 
hepatocytes only by addition of hepatogenic growth factors. The fact that the several 
successful examples of hepatic differentiation of MSCs arise from protocols where 
stem cells where co-cultured with primary hepatocytes [183, 352-354], might suggest 
that mesenchymal stem cells would require further signals provided by primary 
hepatocytes other than the artificial addition of growth factors in order to become 
committed to the hepatic lineage. 
 
6.5   Conclusions 
 
In this chapter, HGF secreted by MG63 cells was employed to differentiate rat 
mesenchymal stem cells into the hepatic lineage. The flow cytometry analysis 
conducted on the cells extracted from rat bone marrow suggests that the technique 
used to isolate MSCs was successful, as cells were positive for CD44 and CD90 and 
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negative for CD45, as indicated in the literature. However, more markers should be 
analysed in order to confirm the mesenchymal stem cell identity of the population. 
Treatment of MSCs with HGF released by MG63s seemed not to lead to the 
differentiation of these cells into hepatocytes when liver specific growth factors were 
added in a sequence-dependent manner that reflected liver development. Further liver 
specific growth factors or co-culture with primary hepatocytes might be needed in 
order to achieve an efficient differentiation of mesenchymal stem cells towards the 
hepatic lineage. Since commercial HGF was also unsuccessful in inducing hepatic 
differentiation of mesenchymal stem cells, this suggests that MG63-derived HGF 
could potentially be used for stem cell differentiation but a deeper understanding of 
the signals involved in stem cell differentiation and in liver development is required 
in order to improve the differentiation protocol. 
However, given the unreliable results obtained with the controls, the experiment 
should be repeated in order to confirm this prediction. 
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7.     Conclusions and future work 
 
The present work has contributed to the field of tissue engineering with two major 
novelties: the development of more hydrophilic PVA-PLGA blended hollow fibre 
membranes for higher transfer of nutrients to the cells, and the realisation of a system 
where a growth factor continuously secreted by a cell line is more stable in dynamic 
environment than the commercial protein. 
In section 7.1 a summary of the main findings of this work is presented with final 
conclusions, while section 7.2 outlines the future work that could lead to further 
advances in tissue engineering and regenerative medicine. 
7.1   Conclusions 
 
The addition of PVA to PLGA polymer solution has been shown to improve the 
porosity, pore size and hydrophilicity of PLGA hollow fibre membranes. These 
characteristics were believed to facilitate the transfer of nutrients across the 
membrane. Among the three different fibres compositions, only 5% PVA–PLGA 
fibres showed to be permeable to water, and this suggested that they are the only 
suitable fibres to be employed in bioreactor devices. These fibres were also shown to 
be permeable to the model protein BSA, with no solute rejection, reduced flux or 
pore size due to fouling, thus confirming their permeability to large molecules and 
suitability for bioreactor devices applications. 
Subsequent treatment of PVA-PLGA hollow fibres with NaOCl caused the removal 
of the skin from the inner and outer surface of the fibre, and an increase of pore size, 
which could potentially lead to an increase in the scaffold surface area and mass 
transport through the membrane. However, this treatment negatively affected the 
mechanical integrity of the fibres, making them unsuitable for tissue engineering 
applications.  
Since increasing membrane hydrophilicity should also increase wettability by cell 
culture medium, it was expected that the novel 5% PVA-PLGA membranes would 
facilitate cell attachment in comparison to pure PLGA membranes. Two cell types 
were analysed for their ability to adhere and proliferate on polymer flat sheets: 
mesenchymal stem cells (MSCs) and osteosarcoma cell line MG63. The results 
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obtained from the qualitative and quantitative analysis of cell adhesion and 
proliferation indicated a different affinity of the two cell types to the different 
materials and were in contrast to our expectations. The analysis conducted on rat 
mesenchymal stem cell attachment and proliferation indicated that MSCs adhered, 
spread and proliferated more on hydrophobic PLGA membranes compared to 
hydrophilic blended PVA-PLGA membranes and to tissue culture plastic, used as 
control. In contrast, MG63s adhered, spread and proliferated better on tissue culture 
plastic than on the two membrane types. The unexpected results obtained indicated 
that the addition of 5% PVA to PLGA did not improve cell attachment and, therefore, 
other strategies should be attempted in order to obtain a membrane that allows the 
mass transfer of nutrients but at the same time facilitates cell attachment.  
The second part of the project focused on a novel system for the inexpensive and 
continuous production of hepatocyte growth factor to be used in the bioreactor for the 
differentiation of stem cells toward the hepatic lineage. The novel strategy pursued in 
this project consisted of the production of HGF by a cell line. Two cell lines, the 
HL60 suspension cell line and the MG63 adherent cell line, were tested for their 
ability to secrete hepatocyte growth factor into cell culture medium. HL60 cells were 
chosen in first place for their characteristic of growing in suspension, which would 
have allowed their continuous circulation inside the lumen of the hollow fibre. The 
single fibre hollow fibre bioreactor has been shown to be suitable for the culture of 
HL60 cell line since the shear stress induced by the laminar flow did not affect cell 
viability and, on the contrary, stimulated HL60s metabolic activity compared to static 
culture systems. However, in contrast with the literature, treatment of HL60s with 
dbcAMP, TPA, heparin or the combination of the three of them did not lead to HGF 
secretion by these cells. In contrast, MG63 cells spontaneously secreted HGF without 
external stimulation as indicated by the literature and, furthermore, showed the 
ability to secrete the growth factors at different concentrations according to the cell 
seeding density. Furthermore, MG63-derived HGF has been shown to be stable in a 
dynamic environment, as opposed to commercial HGF which degraded rapidly when 
exposed to the flow of the bioreactor. MG63-derived HGF also permeated across the 
pores of the 5% PVA-PLGA hollow fibre membranes without significant loss of 
protein in the first three hours of circulation. These promising results would possibly 
allow the realisation of the system described in section 1.10 (Aims and objectives), 
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where a growth factor would be continuously available for the stem cells in order to 
promote their differentiation and for the maintenance of their differentiated state.  
Hence, with these positive results utilising MG63-secreted HGF, the growth factor 
was selected for the subsequent studies on the differentiation of MSCs into the 
hepatic lineage via liver specific factors. After confirmation by flow cytometric 
analysis of the identity of mesenchymal stem cells extracted from rat bone marrow, 
liver specific growth factors were added to the cells in a sequence resembling liver 
development. Results showed that treatment of MSCs with HGF released by MG63s 
did not lead to the differentiation of the stem cells into hepatocytes. Additionally, 
MSCs treated with commercial HGF failed to differentiate, suggesting that the 
unsuccessful outcome might not be due to the growth factor itself but to the 
differentiation protocol used which might not be efficient for the differentiation of 
the stem cells. Further liver specific growth factors or co-culture with primary 
hepatocytes might be needed in order to achieve an efficient differentiation of 
mesenchymal stem cells towards the hepatic lineage.  
 
In conclusion, the present work has succeeded in developing a hollow fibre 
bioreactor system that allows an appropriate mass transfer of proteins across the 
scaffold for an adequate provision of nutrients to the cells and therefore for improved 
in vitro tissue formation. The novel PVA-PLGA hollow fibre membranes represent 
an advance over pure PLGA fibres for their improved permeability to water and 
proteins.  
The other important success of this project is represented by the “cell-factory” 
strategy to produce large amounts of proteins for the differentiation of stem cells, but 
also for other purposes. The successful production of HGF by MG63 cell line 
represents an example of cell factory that can be applied to other proteins thus 
expanding the applicability of the system for the reconstruction of different tissues. 
However, the project failed in developing a suitable scaffold for the stem cells and in 
the differentiation of stem cells into hepatocytes. Therefore future work should focus 
on improving stem cell attachment and differentiation. The next section describes the 
short- and long-term work that is required in order to achieve all the goals of the 
project. 
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7.2    Future work 
 
7.2.1 Short-term work 
 
 Hollow fibres membranes 
PVA-PLGA hollow fibres have been characterised for their morphology, pore size, 
porosity, mechanical properties and hydrophilicity. However, further studies need to 
be carried out to characterise the membranes. Firstly, degradation studies of the 
blended membranes should be performed. The study should investigate the 
degradation of the fibres by assessing the changes in mass, volume, porosity, pore 
size and intrinsic viscosity at different times, temperatures, pH. 
PVA-PLGA hollow fibres have also been shown to be permeable to BSA without 
adsorption of the protein, and to HGF, without significant loss of protein 
concentration in the first three hours of experiment. Further studies should be carried 
out in order to investigate the mechanism by which loss of protein occurred, for 
example whether the protein had been adsorbed by the membrane or degraded by 
means of a very sensitive protein assay. Also the experiments should be performed 
for a longer period of time in order to verify the permeability of the membrane over a 
longer timeframe for a potential clinical application. Furthermore, the permeation of 
other proteins and molecules of different molecular sizes across the blended 
membranes need to be tested in order to obtain a more complete characterisation of 
the membrane in terms of permeability and for the determination of the molecular 
weight cut-off. 
Treatment of PVA-PLGA hollow fibres with 5% NaOCl has been shown to cause 
significant loss of mechanical strength of the fibres. However, since the treatment 
caused the removal of the outer skin of the fibre, which would potentially increase 
the mass transfer across the membrane, it could be performed at a lower 
concentration of NaOCl in order to see whether it could improve the porosity with no 
significant decrease in the mechanical strength. 
 
 Cell attachment  
In chapter 4, mesenchymal stem cells and MG63 cells were seeded on 5% PVA-
PLGA flat sheet in order to verify whether the improved hydrophilicity of the 
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membrane lead to higher cell attachment to the scaffold. Since PVA-PLGA scaffold 
did not show good cell attachment, strategies such as immobilising adhesive proteins 
e.g. fibronectin, collagen, vitronectin, or bioactive peptide ligands (e.g. the RGD 
sequence) on the surface of PVA-PLGA blended membranes could be investigated. 
Additionally, the polymer solution could be blended with ECM proteins prior to 
scaffold fabrication in order to improve cell adhesion, as these strategies have been 
shown to increase cell adhesion onto PLGA scaffolds [355-358]. 
Since the project aims towards the differentiation of mesenchymal stem cells into the 
hepatic lineage, hepatocytes should also be seeded as well on the membranes to 
determine their suitability as a scaffold for this cell type. 
 
 HGF and stem cell differentiation 
 
In chapter 5, HGF released by MG63 was shown to be stable in a dynamic 
environment when circulated for 3 hours. The experiment should be repeated for a 
longer time in order to verify for how long the protein is stable in dynamic culture. 
The analysis of three stem cells markers in chapter 6 showed that the cells extracted 
from rat bone marrow were mesenchymal stem cells. However, further markers 
should be tested, and more specifically, CD14, CD31 and CD34 [359] as negative 
markers, and CD29, CD73, CD105, CD 166 as positive mesenchymal stem cells 
markers [241, 359]. 
The differentiation protocol used in this research was unable to induce differentiation 
of mesenchymal stem cells into hepatocytes. Therefore a new protocol that employs 
further liver specific factors, e.g. oncostatin and EGF [178, 182, 207, 208], in 
addition to those already attempted, should be investigated. 
 
7.2.2 Long term work 
 
The single fibre hollow fibre bioreactor is a novel design that represents a simplified 
model of a multiple hollow fibre bioreactor. The aim of the design is to investigate 
the main components and parameters of the hollow fibre bioreactor, i.e. the 
membrane, the mechanical forces acting within the system, the cell behaviour in 
dynamic culture systems, and the mass transfer across the membrane. The ultimate 
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goal is to obtain a complete characterisation of the system for the development of a 
functional hollow fibre bioreactor to be employed in the clinic. 
The main studies that need to be performed on the single fibre bioreactor and that 
would provide a step forward towards the development of a functional multiple fibre 
bioreactor are described below. 
 Bioreactor design  
The first aspect that has to be considered is the recreation of a suitable environment 
for the cells, therefore key parameters like temperature, oxygen concentration, pH 
and media flow rates need to be measured and controlled in order to be maintained at 
values that mimic the in vivo conditions. Since different tissues have different 
metabolic requirements, the parameters should be modulated according to the tissue 
or organ that will be reconstructed in vitro. Furthermore, since it is known that 
mechanical forces, e.g. shear stress and hydrostatic pressure, can improve or 
accelerate tissue regeneration in vitro [360-362], studies should be carried out in 
order to understand the contributions that these mechanical forces could make 
towards tissue regeneration. Mathematical modelling studies might be helpful in 
order to study these parameters prior to the experiments. Finally, the biomaterial used 
for the fabrication of the hollow fibres could be selected according to the cell type 
that will be seeded on it, thus adapting the system to the in vitro reconstruction of 
different tissues. 
 Cell factory system 
This thesis has shown that a cell line capable of releasing a growth factor can be used 
as a cell factory for the continuous and inexpensive production of hepatocyte growth 
factor that could potentially be used to direct stem cell differentiation toward the 
hepatic lineage. The most important aspect of this system is that it can be used for the 
production of different proteins: a cell line can be engineered to produce the growth 
factor of choice which can be used for the differentiation of stem cells toward 
different lineages, and therefore for the in vitro reconstruction of different tissues.  
 Stem cell cultures in the hollow fibre bioreactor  
Stem cell biology is a relatively new field of research that has a great potential for the 
advance in the field of tissue engineering. However, intensive investigation is still 
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needed for a complete understanding of the mechanisms of their differentiation into a 
specific lineage, and of their behaviour in dynamic culture systems. Further studies 
need to be carried out to investigate whether mechanical forces e.g. shear stress 
might have any negative effect on stem cell attachment to the biomaterial or on stem 
cell viability and metabolic activity. Furthermore, the bioreactor should be tested for 
its ability to expand the number of stem cells as this parameter is very important 
when considering future clinical applications. 
Other studies should focus on the effect of specific mechanical forces that could 
direct the differentiation of stem cells into specific lineages, and on whether the 
differentiation protocols used for static cultures will be still efficient when the cells 
will be cultured in dynamic systems. Moreover, further studies should investigate 
whether the cells would maintain the differentiated state in the long term as it would 
be important for a future clinical application. 
 Clinical application 
Once a complete understanding of the key bioreactor parameters and an efficient 
differentiation of the stem cells have been achieved, it will be possible to develop a 
multiple fibre bioreactor for the in vitro reconstruction of tissues or organs. In order 
to translate these findings to clinical applications, large-scale robust and totally 
controlled culture systems capable of expanding and differentiating stem cells, as fast 
and pure as possible, are needed. The first issue to be considered is the number of 
cells that need to be cultured in the system in order to obtain the minimum mass 
required to regenerate a functional tissue if implanted into the patient. The issue of 
the number of cells needed is related to the surface area of the fibres that will support 
the growth of the cells, and to the size of the bioreactor that will need to contain a 
specific volume of culture medium required by the cells to be kept viable and 
metabolically active.  
Once the system has been set up and the cells within the bioreactor exhibit all the 
specific functions of a given tissue, the system will be suitable for being tested in an 
in vivo setting. Several in vivo studies will be needed before a clinical application 
will effectively be attempted. First, the in vivo degradation of the biomaterial with the 
cells should be analysed in order to study the relationship between the degradation 
rate of the scaffold and the generation of a functional tissue. Furthermore, the ability 
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of the cells to repopulate the damaged tissue once implanted in vivo should be 
investigated. Alternatively, the system could be used to differentiate stem cells that 
could then be used for cell-based therapies. 
Finally, in the case of stem cell-derived tissues, it will be necessary to investigate 
whether the newly differentiated cells maintain their differentiated state once 
implanted in vivo, as their potential dedifferentiation might cause several safety 
concerns as the cells might develop into tumours within the body of the patient. Also, 
since the current systems to differentiate stem cells do not produce a completely 
homogeneous population of differentiated cells, monitoring the differentiation state 
of the cells during the scale-up process and selecting the differentiated cells from the 
immature ones is another challenge that researchers have to face in the near future. 
As can be seen from this section, the research presented in this thesis is only the 
beginning of many years of studies aiming to understand all the mechanisms for 
tissue regeneration in order to realise a perfectly functional and safe tissue that can be 
clinically effective. 
 
 
In conclusion, this research has succeeded in developing a hollow fibre bioreactor 
system which allows an improved transfer of nutrients to cells and that, therefore, 
would be suitable for tissue engineering applications, especially for the in vitro 
reconstruction of highly metabolic tissues. This work also succeeded in developing a 
cell factory system for the continuous and inexpensive production of proteins that 
could be used for the differentiation of stem cells for tissue engineering, regenerative 
medicine or cell therapy applications. These two main developments have the 
potential to bring significant contribution the fields of tissue engineering and 
regenerative medicine. 
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Appendix  
Flow cytometry dot plots 
 
FSC: forward scatter, provides information on cell size 
SSC: side scatter, provides information on cell granularity 
P1:  population of live cells 
 
 
 
Dot plot for IgG2 control FITC conjugated 
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Dot plot for CD44 marker, FITC conjugated 
 
 
 
 
Dot plot for CD45 marker, FITC conjugated 
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Dot plot for IgG1 control PE conjugated 
 
 
 
 
Dot plot for CD90 marker, PE conjugated 
 
 
 
